Document:

Document

Exhibit 10.1

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED

																																																			
	AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT
	1. CONTRACT ID CODE
	PAGE OF PAGES

	1
	29

	2. AMENDMENT/MODIFICATION NO.
P00004
	3. EFFECTIVE DATE
11-Feb-2021
	4. REQUISITION/PURCHASE REQ. NO.
SEE SCHEDULE
	5. PROJECT NO.(If applicable)
	6. ISSUED BY
W6QK ACC-APG NATICK DIVISION
BLDG 1 GENERAL GREENE AVENUE
NATICK MA 01760-5011
	CODE	W911QY	7. ADMINISTERED BY (If other than item 6)    
DEFENSE CONTRACT MANAGEMENT AGENCY
DCMA BOSTON
495 SUMMER STREET
BOSTON MA 02210-2138
	CODE	S2206A
			
	8. NAME AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code)
MODERNA US, INC.
[***]
200 TECHNOLOGY SQ
CAMBRIDGE MA 02139-3578
		9A. AMENDMENT OF SOLICITATION NO.
		9B. DATED (SEE ITEM 11)
	X	10A. MOD. OF CONTRACT/ORDER NO.
W911QY20C0100

	X	10B. DATED (SEE ITEM 13)
09-Aug-2020

	CODE    8PTM0
			FACILITY CODE
	11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS

		The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offer     is extended,     is not extended.
Offer mist acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended by one of the following methods: 
(a) By completing Items 8 and 15, and returning    copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted;
or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE
RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION
OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

	12. ACCOUNTING AND APPROPRIATION DATA (If required)
See Schedule

	13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS.
IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

		A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.

		B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B).

	X	C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:
See Block 14 Continuation Page

		D. OTHER (Specify type of modification and authority)

	E. IMPORTANT: Contractor      is not,     is required to sign this document and return     1     copies to the issuing office.

	14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)
Modification Control Number: [***]
See Block 14 Continuation Page
Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in foil force and effect.

	15A. NAME AND TITLE OF SIGNER (Type or print) 
Stephane Bancel, CEO
	16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)
[***]
TEL: [***]    EMAIL: [***]

	15B. CONTRACTOR/OFFEROR
/s/ Stephane Bancel
        
(Signature of person authorized to sign)
	15C. DATE SIGNED	16B. UNITED STATES OF AMERICA
BY        
(Signature of Contracting Officer)
	16C. DATE SIGNED
11 Feb 2021

SECTION SF 30 BLOCK 14 CONTINUATION PAGE
SUMMARY OF CHANGES
SECTION SF 30 - BLOCK 14 CONTINUATION PAGE
The following have been added by full text:
OBLIGATION AMOUNT: $1,650,000,000
a.    The purpose of this modification (P00004) is to:
-    Exercise, fund Option 2 CLINs 2001AA, 2001AB, 2001AC for a total of $1,650,000,000 (Authority FAR 52.217-7)
-    Add clauses H. 16 & H. 17, and revise the delivery schedule for the Base period, Option 1, and Option 2 LAW the table contained within H. 16 (Authority FAR 43.103(a)(3), Mutual Agreement of the Parties)
-    Revise the table in Section G back to previous amounts, due to an administrative error on modification no. P00003, where the amounts were revised (Authority FAR 52.232-16)
-    Update Contract Data Requirement List (CDRL) no.’s A003, A008, A009, A011, A014, A021, and the corresponding information to the CDRLs in Section C, Statement of Work. (Authority FAR 43.103(a)(3), Mutual Agreement of the Parties)
b.    This modification was requested by the program office to meet the Government’s mission requirements.
c.    The total contract value and total funded amount has increased by $1,650,000,000 from $3,191,598,000 to $4,841,598,000.
All other terms and conditions remain unchanged.  Please see below for details.
SECTION A -SOLICITATION/CONTRACT FORM
The total cost of this contract was increased by $1,650,000,000.00 from $3,191,598,000.00 to $4,841,598,000.00.
SECTION B -SUPPLIES OR SERVICES AND PRICES
CLIN 0001
The CLIN extended description has changed from:
The contractor shall produce and deliver 100M doses of the SARS-CoV-2 mRNA-1273 Vaccine filled drug product (FDP), LAW Section C, Statement of Work (SOW) and CDRLs (Exhibit A) on this contract.
To:
The contractor shall produce and deliver 100M doses of the SARS-CoV-2 mRNA-1273 Vaccine filled drug product (FDP) IAW clause H.16 Delivery Schedule, Section C Statement of Work (SOW), and CDRLs (Exhibit A) on this contract.

W911QY20C0100
[***]
Page 3 of 29

CLIN 1001 
The CLIN extended description has changed from:
The contractor shall produce and deliver 100M doses of the SARS-CoV-2 mRNA-1273 Vaccine filled drug product (FDP), IAW Section C, Statement of Work (SOW) and CDRLs (Exhibit A) on this contract.
To:
The contractor shall produce and deliver 100M doses of the SARS-CoV-2 mRNA-1273 Vaccine filled drug product (FDP) IAW clause H.16 Delivery Schedule, Section C Statement of Work (SOW), and CDRLs (Exhibit A) on this contract.
CLIN 2001
The CLIN extended description has changed from:
The contractor shall produce and deliver 100M doses of the SARS-CoV-2 mRNA-1273 Vaccine filled drug product (FDP), IAW Section C, Statement of Work (SOW) and CDRLs (Exhibit A) on this contract.
To:
The contractor shall produce and deliver 100M doses of the SARS-CoV-2 mRNA-1273 Vaccine filled drug product (FDP) IAW clause H.16 Delivery Schedule, Section C Statement of Work (SOW), and CDRLs (Exhibit A) on this contract.
The option status has changed from Option to Option Exercised.
SUBCLIN 2001AA
The option status has changed from Option to Option Exercised.
SUBCLIN 2001 AB
The option status has changed from Option to Option Exercised.
SUBCLIN 2001AC
The option status has changed from Option to Option Exercised.
SECTION C -DESCRIPTIONS AND SPECIFICATIONS

W911QY20C0100
[***]
Page 4 of 29

The following have been modified:
STATEMENT OF WORK
LARGE SCALE PRODUCTION OF SARS-CoV-2 VACCINE
C.1SCOPE.  The Department of Defense and Health and Human Services (HHS) require large scale manufacturing of vaccine doses in support of the national emergency response to the Coronavirus Disease 2019 (COVID-19) for the United States Government (USG) and the US population.
C.1.1Background.  In December 2019, a novel coronavirus now known as SARS-CoV-2 was first detected in Wuhan, Hubei Province, People’s Republic of China, causing outbreaks of the coronavirus disease COVID-19 that has now spread globally.  The Secretary of Health and Human Service declared a public health emergency on January 31,2020, under section 319 of the Public Health Service Act (42 U.S.C. 247d), in response to COVID-19.  On March 1, 2020, the President of the United States, pursuant to sections 01 and 301 of the National Emergencies Act (50 U.S.C. 1601 et seq.) and consistent with section 1135 of the Social Security Act (SSA), as amended (42 U.S.C. 1320b-5), proclaimed that the COVID-19 outbreak in the United States constitutes a national emergency.
C.1.1.1Under Operation Warp Speed (OWS), the Department of Defense and HHS are leading a whole of nation effort to ensure development of promising vaccine, diagnostic and therapeutic candidates and ensure that these medical countermeasures are available in the quantities required to reduce SARS-CoV-2 transmission, identify prior and/or current infection, and improve patient care, thereby mitigating the impact of COVID-19 on the nation and its people.  The DoD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRD) is providing expertise and contracting support to HHS, in compliance with PL 115-92 Authorization Letter for DoD Medical Priorities, through an Interagency Agreement, signed April 23, 2020.  As OWS products progress to clinical trials to evaluate the safety and efficacy of vaccines and therapeutics, it is critical that, in parallel, the USG supports large scale manufacturing so that vaccine doses or therapeutic treatment courses are immediately available for nationwide access as soon as a positive efficacy signal is obtained and the medical countermeasures are authorized for widespread use.
C.1.2Objective: The objective of this effort is to obtain the following:
(a)Base Period: Large scale manufacturing of 100 million vaccine doses
(b)Option Period 1: Large scale manufacturing of 100 million vaccine doses
(c)Option Period 2: Large scale manufacturing of 100 million vaccine doses
(d)Option Period 3: Large scale manufacturing of 100 million vaccine doses
(e)Option Period 4: Large scale manufacturing of 100 million vaccine doses
The Base Period is [***], with overlapping options for a total of [***] if all options are exercised.
C.2APPLICABLE DOCUMENTS.
C.2.1Federal Documents:
C.2.1.1.Title 21 Code of Federal Regulations (CFR), Food and Drugs: Part 210, Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs; General; and, Part 211, Current Good Manufacturing Practice In Manufacturing, Processing, Packing, or Holding of Drugs; General.
(https://www.ecfr.gov/cgi‐bin/text‐idx?SID=a95cab20f443897a400bb7e44a27cf4c&mc=true&tpl=/ecfrbrowse/Title21/21cfiv4_02.tpl#0)

C.3REQUIREMENTS.  Independently, and not as an agent of the USG, in accordance with the Proposal submitted by Moderna US, Inc. in response to Solicitation Number W911QY20R0043, Titled, “Advanced Procurement of mRNA-1273 Vaccine for Prevention of SARS-CoV-2 Coronavirus (COVID-19)”), dated July 10, 2020 (and any subsequent USG-approved revisions thereto), the contractor shall provide all necessary services, 

W911QY20C0100
[***]
Page 5 of 29

qualified personnel, material, equipment and facilities (not otherwise provided by the USG under the terms of this contract) to perform the specific tasks set forth below.
C.3.1Contract Line Item Number (CLIN) 0001 - Base Period: Large Scale Manufacturing of 100 Million Vaccine Doses.
C.3.1.1The contractor shall complete all scope required for the production, release and delivery use of 100 million Final Drug Product (FDP) doses of a SARS-CoV-2 mRNA-1273 vaccine.  This shall include, the following tasks and other activities reasonably contemplated by such task:
C.3.1.1.1Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of [***].  (Based on FDP stability data that supports a [***] shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC.  Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.
C.3.1.1.2cGMP manufacturing of 100 million doses fully compliant with 21 CFR 210 and 211.
C.3.1.1.3Ensuring that vial labeling and packaging is consistent with FDA guidance for use in target populations and that labeling is updated as appropriate.
C.3.1.1.4Coordinating with FDA to establish an approved commercial vial label, carton and packaging insert (printed or electronic).
C.3.1.1.5Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27,2013), including product verification, serialization, traceability and detection and response requirements, subject to any exceptions established by or the enforcement discretion of the FDA, including “Exemption from Certain Product Tracing and Product Identification Requirements Under Section 582 of the FD&C Act” (April 2020).
C.3.1.1.6[***]. Moderna shall provide specifications and details associated with the shipping process and containers (IAW CDRL A005) to enable the USG to adequately plan and prepare for potential distribution of the vaccine.
C.3.1.1.7Following release of product the contractor shall, promptly deliver product to the designated delivery site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below.  In the unforeseen event that a designated delivery site cannot receive product and the contractor provides storage beyond [***] of product release, the contract will be subject to modification for acceptance purposes.
C.3.1.2Site Visits and Audits.  The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.
C.3.1.2.1BARDA Audits.  If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.
C.3.1.2.2FDA Audits.  The Contractor shall notify the Contracting Officer and Contracting Officer’s Representative (COR) within [***] of a scheduled FDA audit or within [***] of an ad hoc site visit or audit if the FDA does not provide advance notice.  The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within [***] of receiving correspondence from the FDA or third party in accordance with CDRL A002.  The Contractor shall provide the Contracting Officer 

W911QY20C0100
[***]
Page 6 of 29

with a plan for addressing areas of nonconformance, if any are identified, within [***] of submittal of the audit report in accordance with CDRL A002.
C.3.1.2.3FDA Interactions.  The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologies for the following, but not limited to: FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.
C.3.2CLIN 1001 - Option Period 1: Large Scale Manufacturing of 100 Million Vaccine Doses.
C.3.2.1The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine.  This shall include the following tasks and other activities reasonably contemplated by such tasks:
C.3.2.1.1Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of [***].  (Based on FDP stability data that supports a [***] shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC.  Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.
C.3.2.1.2cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA.
C.3.2.1.3Ensuring that vial labeling and packaging is consistent with FDA guidance for use in target populations and that labeling is updated.
C.3.2.1.4Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27,2013), including product verification, serialization, traceability and detection and response requirements subject to any exceptions established by or the enforcement discretion of the FDA.
C.3.2.1.5Following release of the product the contractor shall deliver the produetto the designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below.  [***].
C.3.2.2Site Visits and Audits.  The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.
C.3.2.2.1BARDA Audits.  If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.
C.3.2.2.2FDA Audits.  The Contractor shall notify the Contracting Officer and COR within [***] of a scheduled FDA audit or within [***] of an ad hoc site visit or audit if the FDA does not provide advance notice.  The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within [***] of receiving correspondence from the FDA or third party in accordance with CDRL A015.  The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within [***] of submittal of the audit report in accordance with CDRL A002.
C.3.2.2.3FDA Interactions.  The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologies for the following, but not limited to: FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.

W911QY20C0100
[***]
Page 7 of 29

C.3.3CLIN 2001 - Option Period 2: Large Scale Manufacturing of 100 Million Vaccine Doses.
C.3.3.1The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine.  This shall include the following tasks and other activities reasonably contemplated by such tasks:
C.3.3.1.1Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of [***].  (Based on FDP stability data that supports a [***] shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC.  Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.
C.3.3.1.2cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA.
C.3.3.1.3Ensuring that vial labeling and packaging is consistent with FDA guidance for use in target populations and that labeling is updated as appropriate.
C.3.3.1.4Ensuring that the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581- 585 of PL 113-54 (Nov. 27,2013), including product verification, serialization, traceability and detection and response requirements, subject to any exceptions established by or the enforcement discretion of the FDA.
C.3.3.1.5Following release the contractor shall deliver product to the nearest designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below.  [***].
C.3.3.2Site Visits and Audits.  The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.
C.3.3.2.1BARDA Audits.  If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.
C.3.3.2.2FDA Audits.  The Contractor shall notify the Contracting Officer and COR within [***] of a scheduled FDA audit or within [***] of an ad hoc site visit or audit if the FDA does not provide advance notice.  The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within [***] of receiving correspondence from the FDA or third party in accordance with CDRL A002.  The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within [***] of submittal of the audit report in accordance with CDRL A002.
C.3.3.2.3FDA Interactions.  The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologies for the following, but not limited to: FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.
C.3.4CLIN 3001 - Option Period 3: Large Scale Manufacturing of 100 Million Vaccine Doses.
C.3.4.1The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine.  This shall include the following tasks and other activities reasonably contemplated by such tasks:
C.3.4.1.1Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  Storage and maintenance of the vaccine prior to delivery 

W911QY20C0100
[***]
Page 8 of 29

shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of [***].  (Based on FDP stability data that supports a [***] shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC.  Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.
C.3.4.1.2cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA.
C.3.4.1.3Ensuring that vial labeling and packaging is consistent with FDA guidance for use in target populations and that labeling is updated.
C.3.4.1.4Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27,2013), including product verification, serialization, traceability and detection and response requirements subject to any exceptions established by or the enforcement discretion of the FDA.
C.3.4.1.5Following release of the product the contractor shall deliver the product to the designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below.  [***].
C.3.4.2Site Visits and Audits.  The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.
C.3.4.2.1BARDA Audits.  If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.
C.3.4.2.2FDA Audits.  The Contractor shall notify the Contracting Officer and COR within [***] of a scheduled FDA audit or within [***] of an ad hoc site visit or audit if the FDA does not provide advance notice.  The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within [***] of receiving correspondence from the FDA or third party in accordance with CDRL A015.  The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within [***] of submittal of the audit report in accordance with CDRL A002.
C.3.4.2.3FDA Interactions.  The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding mRNA-1273 for the following, but not limited to: FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.
C.3.5CLIN 4001 - Option Period 4; Large Scale Manufacturing of 100 Million Vaccine Doses.
C.3.5.1The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine.  This shall include the following tasks and other activities reasonably contemplated by such tasks:
C.3.5.1.1Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of [***].  (Based on FDP stability data that supports a [***] shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC.  Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.
C.3.5.1.2cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA.

W911QY20C0100
[***]
Page 9 of 29

C.3.5.1.3Ensuring that vial labeling and packaging is consistent with FDA guidance for use in target populations and that labeling is updated.
C.3.5.1.4Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27,2013), including product verification, serialization, traceability and detection and response requirements subject to any exceptions established by or the enforcement discretion of the FDA.
C.3.5.1.5Following release of the product the contractor shall deliver the product to the designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below.  [***].
C.3.5.2Site Visits and Audits.  The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.
C.3.5.2.1BARDA Audits.  If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.
C.3.5.2.2FDA Audits.  The Contractor shall notify the Contracting Officer and COR within [***] of a scheduled FDA audit or within [***] of an ad hoc site visit or audit if the FDA does not provide advance notice.  The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within [***] of receiving correspondence from the FDA or third party in accordance with CDRL AO 15.  The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within [***] of submittal of the audit report in accordance with CDRL A002.
C.3.5.2.3FDA Interactions.  The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologies for the following, but not limited to: FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.
C.4CLIN 0002: Data Deliverables.  The contractor shall provide the following in accordance with the Contract Data Requirements List (CDRL), DD Forms 1423, provided at Appendix A.
C.4.1Monthly Inventory Report (CDRL A003), detailing at a minimum, raw materials, Built tnRNA, formulated LNPs, and the fill, finish, and released product.
C.4.2Quality Management Plan.  The contractor shall provide a Quality Management Plan, in accordance with CDRL A004, describing the quality policy and objectives, management review, competencies and training, process document control, feedback, evaluation, corrective action and preventive action, process improvement, measurement, and data analysis processes.  The framework is normally divided into infrastructure, senior management responsibility, resource management, lifecycle management, and quality management system evaluation.
C.4.3Shipping Documentation (CDRL A005) for all Finished Drug Product (FDP) transferring from the contractor’s fill/finish facility to a USG facility.  The contractor shall obtain concurrence on planned shipment protocols prior to transport.
C.4.4[***].
C.4.5Key Personnel Listing (CDRL A007).
C.4.6Monthly Technical Progress Report (CDRL A008), to include an Integrated Master Schedule, identifying key activities and contract status.

W911QY20C0100
[***]
Page 10 of 29

C.4.7Final Technical Report (CDRL A009), documenting the work performed and results obtained for the entire contract period of performance.
C.4.8Supply Chain Resiliency Plan (SCRP).  The contractor shall provide, in accordance with CDRL A010 and CDRL Attachment 0001, a comprehensive SCRP that provides for identification and reporting of critical components associated with the secure supply of drug substance, drug product, and work-in-process through to finished goods, and key equipment suppliers and their locations, including addresses, points of contact, and work performed per location, to include subcontractors.
C.4.9[***].
C.4.10Manufacturing Reports and Dose Tracking.  The Contractor shall provide, in accordance with CDRL A013, manufacturing reports and manufacturing dose tracking projections and actuals utilizing the USG-provided “COVID-19 Dose Tracking Template” (CDRL Attachment 0003).
C.4.11[***].
C.4.12Incident Report.  The contractor shall communicate to BARDA and document all critical programmatic concerns, issues, or probable risks that have or are likely to significantly impact project schedule and/or cost and/or performance in accordance with CDRL A016.  “Significant” is frequently defined as a [***] or greater cost or schedule variance within a control account, but should be confirmed in consultation with the COR.  Incidents that present liability to the project even without cost/schedule impact, such as breach of GCP during a clinical study, shall also be reported.
C.4.13FDA Correspondence.  The contractor shall provide any correspondence between Contractor and FDA relevant to the scope of this contract and submit in accordance with CDRL A017.
C.4.14Press Releases.  The contractor shall accurately and factually represent the work conducted under this contract in all press releases.  The contractor shall provide an advance copy of any press release in accordance with CDRL AOI 8.
C.4.15Manufacturing Development Plan.  The contractor shall provide a Manufacturing Development Plan, in accordance with CDRL A025, describing the manufacturing process for the drug/biologic product to ensure conformity with §501(a)(2)(B) of the Food, Drug, and Cosmetics Act (FD&C Act, Title 21 United States Code (USC) §351 (a)(2)(B)), regarding good manufacturing practices (GMP).
C.5Administration.
C.5.1Post Award Teleconference.  The contractor shall host a Post Award Teleconference within [***] calendar days after contract award.
C.5.1.1The contractor shall provide an Agenda, IAW CDRL A020, detailing the planned activities for the subsequent 30 calendar days and shall discuss agenda items for the Post Award Kickoff Meeting.
C.5.1.2The contractor shall provide Meeting Minutes IAW CDRL A021.
C.5.2Post Award Kickoff Meeting.  The contracting officer may request the contractor host a contract Kick-Off Meeting within [***] calendar days after contract award via teleconference.  The contracting officer shall establish the date and time of the conference and prepare the agenda to include discussion on contract activities and schedule.
C.5.3Bi-Weekly Teleconference.  The contractor shall participate in bi-weekly teleconferences (or more frequent meetings required by the USG if warranted based on contract activities) to discuss performance on the contract.

W911QY20C0100
[***]
Page 11 of 29

C.5.4The contractor shall provide an Agenda, IAW CDRL A020; Meeting Minutes in accordance with CDRL A021; and, Presentation Material in accordance with CDRL A022 for each of the aforementioned teleconferences or meetings throughout the contract period of performance.
C.5.5Daily “Check-In”.  The contractor shall participate in a daily “check-in” (via teleconference or email) to address key cost, schedule and technical updates.  Daily updates may be shared with senior USG leaders during the CO VID-19 response and should be provided on a non-confidential basis, unless the update includes confidential information in which case, the contractor shall provide the update in both confidential and non-confidential formats.  Daily check-ins may occur on weekdays, excluding federal holidays.  Upon request of the USG, check-ins may also occur on weekends and on federal holidays, provided at least 24 hours’ notice.
C.6Security.
C.6.1Access and General Protection/Security Policy and Procedures.  The contractor shall provide all information required for background checks necessary to access critical information related to OWS, and to meet USG installation access requirements to be accomplished by the installation Director of Emergency Services or Security Office.  The contractor employees shall comply with all personnel identity verification requirements as directed by the USG and/or local policy.  In addition to the changes otherwise authorized by the changes clause of this contract, should the security status of OWS change the USG may require changes in the contractor’s security matters or processes.  In addition to the industry standards for employment background checks, the contractor shall be willing to have key individuals, in exceptionally sensitive positions, identified for additional vetting by the United States USG.
C.6.2Security Program and Plan.  The contractor shall implement a comprehensive security program that provides overall protection of personnel, information, data, and facilities associated with fulfilling the USG’s requirement.  The contractor’s security practices and procedures shall be detailed in a Security Plan, in accordance with CDRL AO 19, and shall demonstrate how the contractor shall meet and adhere to the security requirements outlined in CDRL Attachment 0002.  This plan shall be delivered to the USG within 45 days of award, and the USG will review in detail and submit comments within ten (10) business days to the Contracting Officer (CO) to be forwarded to the Contractor.  The Contractor shall review the Security Plan comments, and, submit a final Security Plan to the U.S. USG within thirty (30) calendar days after receipt of the comments.  The Security Plan shall include a timeline for compliance of all the required security measures outlined in CDRL Attachment 0002.
C.6.3Operational Security (OPSEC).  The contractor shall develop and submit an OPSEC Standard Operating Procedure (SOP)/Plan IAW CDRL A024.  The contractor shall identify in the SOP/Plan critical information related to this contract, why it needs to be protected, where it is located, who is responsible for it, and how to protect it.
C.7CLIN 0002 Vendor Managed Inventory (VMI).  The Contractor shall provide the capability to store the vaccine for up to [***], up to 100M doses of mRNA-1273 vaccine, in accordance with product labeling.  The contractor shall, in accordance with paragraph C.3.1.1.6, ensure the product storage of FDP doses for up to [***] prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations .  [***].  The contractor shall store the product to insure product quality with audible alarms and contacting.  The contractor shall notify the USG within [***] of detection of an incident with the potential to impact product quality, and implement corrective actions to mitigate the incident..  BARDA/JPEO- CBRND personnel may conduct Quality Audits of the storage facility, when deemed necessary.  The contractor shall notify the USG of Corrective/Preventive actions within [***] of detection of an incident with potential to impacts product quality.  BARDA/JPEO-CBRND personnel may conduct Quality Audits of the storage facility, when deemed necessary.
C.7.1The USG will provide the contractor advance notice of the required delivery locations for the vaccine.  The contractor shall ship mRNA-1273 vaccines to designated locations [***] in the United States.  The contractor shall be responsible for shipment of all vaccine product [***].  
C.7.2The vaccine product shall be shipped and tracked by the distribution vendor’s shipping tracking number, to the USG-designated sites within the continental United States.

W911QY20C0100
[***]
Page 12 of 29

C.7.3[***]  Notwithstanding either of the foregoing sentences, the contractor shall not be liable for loss of or damage to supplies caused by the negligence of officers, agents, or employees of the USG acting within the scope of their employment.
SECTION E -INSPECTION AND ACCEPTANCE
The following have been modified:
E.1Inspection:
Vaccine CLINs:
Quality inspection of Filled Drug Product (FDP) shall occur when the Contractor performs release testing to confirm that products complies with Contractor’s release specifications and criteria.  Contractor will submit the Certificate of Analysis for quality inspection of all drug product lots in BARDA Data Infrastructure (BDI) system.  Initial Inspection under this contract will be performed at the Contractor’s facility, or the subcontractor facility, by the BARDA Contracting Officer Technical Representative (COTR).
The Government shall inspect each shipment of product delivered to it hereunder for visible damage and quantity [***] of final delivery.  In the event Contractor supplies any product to the Government and it is established that such Product was damaged or does not include the required quantities at the time of final delivery, the Government shall promptly notify Contractor in writing [***].  A BDI extract of the inspection documentation shall also be submitted in Wide Area Workflow (WAWF) as supporting documentation for invoice submittals.
Storage CLIN:
In the event the USG requires storage of the FDP to a Vendor Managed Inventory (VMI) location, quantity inspection shall be conducted by submission of shipping or other documentation into WAWF confirming quantity to VMI location.  Physical inspection of the FDP shall be conducted upon receipt of product to USG CDC location.
Data CLIN:
Inspection of all reports and Contract Data Requirement List (CDRL) under this contract will be performed at Destination by duly authorized representative of the Government.
E.2Acceptance
(a)Acceptance [***].  Acceptance [***].  Regardless of where acceptance occurs, the contractor is responsible for final delivery of Filled Drug Product (FDP) to a government designated CDC location.
(b)Acceptance of vaccines under this agreement will be performed by the COTR in the BDI system, which constitutes government acceptance [***].  Documentation of acceptance shall be submitted in accordance with WAWF instructions.
(c)Acceptance of storage services under VMI CLIN No. 0002 shall occur upon [***].  Acceptance of Data CLIN No. 0004 shall occur in WAWF by the KO.
(d)The parties acknowledge that acceptance may depend on the compliance with the Contractor’s product specifications.  The KO and COR may prior to acceptance consult with FDA under its authority under Public Law 115-92 to determine whether the material to be delivered meets the Contractor’s product specifications.  To this end.  Contractor agrees to provide a letter to FDA authorizing the Government to engage in dialog with FDA about the ultimate compliance of this product with the Contractor’s product specifications prior to acceptance.  BARDA/COR will accept product according to the approved Product Acceptance Procedure.

W911QY20C0100
[***]
Page 13 of 29

SECTION F -DELIVERIES OR PERFORMANCE
The following Delivery Schedule item for SUBCLIN 1001 AB has been changed from:
												
	DELIVERY DATE	QUANTITY	SHIP TO ADDRESS	DODAAC /
CAGE
	[***]	[***]	[***]
FOB: Destination 
	[***]

To:
												
	DELIVERY DATE	QUANTITY	SHIP TO ADDRESS	DODAAC /
CAGE
	[***]	[***]	[***]
FOB: Destination 
	[***]

The following Delivery Schedule item for SUBCLIN 1001 AC has been changed from:
												
	DELIVERY DATE	QUANTITY	SHIP TO ADDRESS	DODAAC /
CAGE
	[***]	[***]	[***]
FOB: Destination 
	[***]

To:
												
	DELIVERY DATE	QUANTITY	SHIP TO ADDRESS	DODAAC /
CAGE
	[***]	[***]	[***]
FOB: Destination 
	[***]

The following Delivery Schedule item for SUBCLIN 2001AA has been changed from:
												
	DELIVERY DATE	QUANTITY	SHIP TO ADDRESS	DODAAC /
CAGE
	[***]	[***]	[***]
FOB: Destination 
	[***]

To:
												
	DELIVERY DATE	QUANTITY	SHIP TO ADDRESS	DODAAC /
CAGE
	[***]	[***]	[***]
FOB: Destination 
	[***]

W911QY20C0100
[***]
Page 14 of 29

The following Delivery Schedule item for SUBCLIN 2001AB has been changed from:
												
	DELIVERY DATE	QUANTITY	SHIP TO ADDRESS	DODAAC /
CAGE
	[***]	[***]	[***]
FOB: Destination 
	[***]

To:
												
	DELIVERY DATE	QUANTITY	SHIP TO ADDRESS	DODAAC /
CAGE
	[***]	[***]	[***]
FOB: Destination 
	[***]

The following Delivery Schedule item for SUBCLIN 2001AC has been changed from:
												
	DELIVERY DATE	QUANTITY	SHIP TO ADDRESS	DODAAC /
CAGE
	[***]	[***]	[***]
FOB: Destination 
	[***]

To:
												
	DELIVERY DATE	QUANTITY	SHIP TO ADDRESS	DODAAC /
CAGE
	[***]	[***]	[***]
FOB: Destination 
	[***]

The following have been modified:
F.1The contractor shall ship mRNA-1273 vaccines to the designated locations listed below.  The contractor shall be responsible for secure shipment of all vaccine product whether acceptance is conducted [***].
Delivery Locations:
Location 1
[***]
Location 2
[***]
SECTION G -CONTRACT ADMINISTRATION DATA
Accounting and Appropriation

W911QY20C0100
[***]
Page 15 of 29

Summary for the Payment Office
As a result of this modification, the total funded amount for this document was increased by $ 1,650,000,000.00 from $3,191,598,000.00 to $4,841,598,000.00.
SUBCLIN 2001AA:
AF: [***] increased by $551,100,000.00 from $0.00 to $551,100,000.00
The contract ACRN AF has been added.
The CIN [***] has been added.
The Cost Code [***] has been added.
SUBCLIN 2001AB:
AG: [***] was increased by $551,100,000.00 from $0.00 to $551,100,000.00
The contract ACRN AG has been added.
The CIN [***] has been added.
The Cost Code [***] has been added.
SUBCLIN 2001AC:
AH: [***] was increased by $547,800,000.00 from $0.00 to $547,800,000.00
The contract ACRN AH has been added.
The CIN [***] has been added.
The Cost Code [***] has been added.
The following have been modified:
G.1GOVERNMENT CONTRACT ADMINISTRATION
In no event shall any understanding or agreement, contract modification, change order, or other matter in deviation from the terms of this contract between the Contractor and a person other than the Contracting Officer be effective or binding upon the Government.  All such actions must be formalized by a proper contractual document executed by the Contracting Officer.
Procuring Contracting Officer:
[***]
Bldg. 1, General Greene Avenue
Natick, MA 01760-5011
Contract Specialist:
[***]
Bldg. 1, General Greene Avenue
Natick, MA 01760-5011
G.2GOVERNMENT TECHNICAL POINT OF CONTACT
[***]
Biologist/Project Officer
200 C Street, SW
Washington, DC 20201

W911QY20C0100
[***]
Page 16 of 29

G.3CONTRACTOR’S CONTRACT ADMINISTRATION
[***]
Moderna US, Inc.
200 Technology SQ.
Cambridge, MA 02139-3578
G.4PLACES OF PERFORMANCE
Moderna US, Inc.
200 Technology SQ.
Cambridge, MA 02139-3578
G.5NOTIFICATION OF REVISIONS AND CHANGE
Notification of revision or changes to names or email addresses will be provided by official correspondence from the PCO/ACO or office of the PCO/ACO in lieu of a contract modification.  This does not apply to any such revisions or changes in the event this contract includes a key personnel clause.
G.6PERFORMANCE BASED PAYMENT
Performance-based payments (PBP) are authorized under this contract in accordance with FAR 52.232-32.  The contractor shall bill for the PBP upon achievement of the completion criteria identified in Attachment 0007, Performance-based Payment Milestone Table.  Upon achievement of the completion criteria, the contractor shall bill for the PBP for the base and each option IAW the following schedule:

									
	CLIN	PERIOD	AMOUNT
	0001AA	BASE	$    90,210,000
	0001AB	BASE	$    132,308,000
	0001AC	BASE	$    180,420,000
	0001AD	BASE	$    198,462,000
	TOTAL		$    601,400,000
			
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]		[***]
			
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]		[***]

Delivery Invoicing: PBPs are a type of contract financing and are recouped by the Government through deductions of payments otherwise due to the contractor for the partial or complete delivery of contract items.  The deductions are made by applying a liquidation rate to the price of delivered contract items.  Attachment 0008, Performance-based Payment Milestone Billing Plan, identifies the contractor invoicing schedule for liquidation.  The contractor shall submit all invoices IAW Attachment 0008 dated 4 December 2020.
252.232-    7006 WIDE AREA WORKFLOW PAYMENT INSTRUCTIONS (DEC 2018)
(a)Definitions.  As used in this clause—

W911QY20C0100
[***]
Page 17 of 29

“Department of Defense Activity Address Code (DoDAAC)” is a six position code that uniquely identifies a unit, activity, or organization.
“Document type” means the type of payment request or receiving report available for creation in Wide Area WorkFlow (WAWF).
“Local processing office (LPO)” is the office responsible for payment certification when payment certification is done external to the entitlement system.
“Payment request” and “receiving report” are defined in the clause at 252.232-7003, Electronic Submission of Payment Requests and Receiving Reports.
(b)Electronic invoicing.  The WAWF system provides the method to electronically process vendor payment request and receiving reports, as authorized by Defense Federal Acquisition Regulation Supplement (DFARS) 252.232- 7003, Electronic Submission of Payment Requests and Receiving Reports.
(c)WAWF access.  To access WAWF, the Contractor shall—
(1)Have a designated electronic business point of contact in the System for Award Management at https://www.sam.gov; and
(2)Be registered to use WAWF at https://wawf.eb.mil/ following the step-by-step procedures for self-registration available at this web site.
(d)WAWF training.  The Contractor should follow the training instructions of the WAWF Web-Based Training Course and use the Practice Training Site before submitting payment requests through WAWF.  Both can be accessed by selecting the “Web Based Training” link on the WAWF home page at https://wawf.eb.mil/.
(e)WAWF methods of document submission.  Document submissions may be via web entry, Electronic Data Interchange, or File Transfer Protocol.
(f)WAWF payment instructions.  The Contractor shall use the following information when submitting payment requests and receiving reports in WAWF for this contract or task or delivery order:
(i)Document type.  The Contractor shall submit payment requests using the following document type(s):
COMBO
(ii)For fixed price line items—
(A)    That require shipment of a deliverable, submit the invoice and receiving report specified by the Contracting Officer.
Invoice and receiving report document type
(B)    For services that do not require shipment of a deliverable, submit either the Invoice 2-in-l, which meets the requirements for the invoice and receiving report, or the applicable invoice and receiving report, as specified by the Contracting Officer.
N/A

W911QY20C0100
[***]
Page 18 of 29

(iii)For customary progress payments based on costs incurred, submit a progress payment request.
(iv)For performance based payments, submit a performance based payment request.
(v)For commercial item financing, submit a commercial item financing request.
(2)Fast Pay requests are only permitted when Federal Acquisition Regulation (FAR) 52.213-1 is included in the contract.
(3)Document routing.  The Contractor shall use the information in the Routing Data Table below only to fill in applicable fields in WAWF when creating payment requests and receiving reports in the system.
Routing Data Table
						
	Field Name in WAWF	Data to be entered in WA WF
	Pay Official DoDAAC	HQ0337
	Issue By DoDAAC	W911QY
	Admin DoDAAC	S2206A
	Inspect By DoDAAC	W56XNH
	Acceptor	W911QY
	Ship To	TDB

(4)Payment request.  The Contractor shall ensure a payment request includes documentation appropriate to the type of payment request in accordance with the payment clause, contract financing clause, or Federal Acquisition Regulation 52.216-7, Allowable Cost and Payment, as applicable.
(5)Receiving report.  The Contractor shall ensure a receiving report meets the requirements of DFARS Appendix F.
(g)WAWF point of contact.
(1)The Contractor may obtain clarification regarding invoicing in WAWF from the following contracting activity’s WAWF point of contact.
[***] / DCMA Boston-AFAW, Administrative Contracting Officer / [***]
(2)Contact the WAWF helpdesk at [***], if assistance is needed.
(End of clause)
FOR REFERENCE:
DEARS PGI 204.7108 Payment Instructions Table
https://www.acq.osd.mi1/dpap/dars/pgi/pgi_htm/current/PGI204_71.htm#payment_instructions

W911QY20C0100
[***]
Page 19 of 29

SECTION H -SPECIAL CONTRACT REQUIREMENTS
The following have been modified:
H.1Key Personnel
Any key personnel specified in this contract are considered to be essential to work performance.  At least thirty (30) calendar days prior to the Contractor voluntarily diverting any of the specified individuals to other programs or contracts the Contractor shall notify the Contracting Officer and shall submit a justification for the diversion or replacement and a request to replace the individual.  The request must identify the proposed replacement and provide an explanation of how the replacement’s skills, experience, and credentials meet or exceed the requirements of the contract (including, when applicable, Human Subjects Testing requirements).  If the employee of the Contractor is terminated for cause or separates from the Contractor voluntarily with less than thirty (30) calendar-day notice, the Contractor shall provide the maximum notice practicable under the circumstances.  The Contractor shall not divert, replace, or announce any such change to key personnel without the written consent of the Contracting Officer.  The contract will be modified to add or delete key personnel as necessary to reflect the agreement of the parties.  The following individuals are determined to be key personnel:
						
	Name	Title
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]

H.2Substitution of Key Personnel
The Contractor agrees to assign to the contract those persons whose resumes/CVs were submitted with the proposal who are necessary to fill the requirements of the contract.  No substitutions shall be made except in accordance with this clause.
All requests for substitution must provide a detailed explanation of the circumstance necessitating the proposed substitution, a complete resume for the proposed substitute and any other information requested by the contracting officer to approve or disapprove the proposed substitution.  All proposed substitutes must have qualifications that are equal to or higher than the qualifications of the person to be replaced.  The contracting officer or authorized representative will evaluate such requests and promptly notify the contractor of his approval or disapproval thereof.
H.3Disclosure of Information:
Performance under this contract may require the Contractor to access non-public data and information proprietary to a Government agency, another Government Contractor or of such nature that its dissemination or use other than as specified in the work statement would be adverse to the interests of the Government or others.  Neither the Contractor, nor Contractor personnel, shall divulge nor release data nor information developed or obtained under performance of this contract, except authorized by Government personnel or upon written approval of the CO which the KO will provide in accordance with OWS or other Government policies and/or guidance.  The Contractor shall not use, disclose, or reproduce proprietary data that bears a restrictive legend, other than as specified in this contract, or any information at all regarding this agency.

W911QY20C0100
[***]
Page 20 of 29

The Contractor shall comply with all applicable Government requirements for protection of non-public information.  Unauthorized disclosure of nonpublic information is prohibited by the Government’s rules.  Unauthorized disclosure may result in termination of the contract, replacement of a Contractor employee, or other appropriate redress.  Neither the Contractor nor the Contractor’s employees shall disclose or cause to be disseminated, any information concerning the operations of the activity, which could result in, or increase the likelihood of, the possibility of a breach of the activity’s security or interrupt the continuity of its operations.
No information related to data obtained under this contract shall be released or publicized without the prior written consent of the COR, whose approval shall not be unreasonably withheld, conditioned, or delayed, provided that no such consent is required to comply with any law, rule, regulation, court ruling or similar order; for submission to any government entity’ for submission to any securities exchange on which the Contractor’s (or its parent corporation’s) securities may be listed for trading; or to third parties relating to securing, seeking, establishing or maintaining regulatory or other legal approvals or compliance, financing and capital raising activities, or mergers, acquisitions, or other business transactions.  The exceptions identified in this paragraph apply to all disclosures under this Section H.3 except to the extent that a disclosure is otherwise prohibited by law.
H.4Publication and Publicity
The contractor shall not release any reports, manuscripts, press releases, or abstracts about the work being performed under this contract without written notice in advance to the Government.
(a) Unless otherwise specified in this contract, the contractor may publish the results of its work under this contract.  The contractor shall promptly send a copy of each submission to the COR for security review prior to submission.  The contractor shall also inform the COR when the abstract article or other publication is published, and furnish a copy of it as finally published.
(b) Unless authorized in writing by the CO, the contractor shall not display the DoD logo including Operating Division or Staff Division logos on any publications.
(c) The contractor shall not reference the products(s) or services(s) awarded under this contract in commercial advertising, as defined in FAR 31.205-1, in any manner which states or implies DoD approval or endorsement of the product(s) or service(s) provided.
(d) The contractor shall include this clause, including this section (d) in all subcontracts where the subcontractor may propose publishing the results of its work under the subcontract.  The contractor shall acknowledge the support of the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority whenever publicizing the work under this contract in any media by including an acknowledgement substantially as follows:
“This project has been funded in whole or in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract Number W911QY-20-C-0100.”
H.5Confidentiality of Information
a.  Confidential information, as used in this article, means non-public information or data of a personal nature about an individual, or proprietary information or data submitted by or pertaining to an institution or organization.
b.  The Contracting Officer and the Contractor may, by mutual consent, identify elsewhere in this contract specific information and/or categories of information which the Government will furnish to the Contractor or that the Contractor is expected to generate which is confidential.  Similarly, the Contracting Officer and the Contractor may, by mutual consent, identify such confidential information from time to time during the performance of the contract.  Failure to agree will be settled pursuant to the “Disputes” clause.

W911QY20C0100
[***]
Page 21 of 29

c.  If it is established elsewhere in this contract that information to be utilized under this contract, or a portion thereof, is subject to the Privacy Act, the Contractor will follow the rules and procedures of disclosure set forth in the Privacy Act of 1974, 5 U.S.C. 552a, and implementing regulations and policies, with respect to systems of records determined to be subject to the Privacy Act.
d.  Confidential information, as defined in paragraph (a) of this article, shall not be disclosed without the prior written consent of the individual, institution, or organization.
e.  Whenever the Contractor is uncertain with regard to the proper handling of material under the contract, or if the material in question is subject to the Privacy Act or is confidential information subject to the provisions of this article, the Contractor shall obtain a written determination from the Contracting Officer prior to any release, disclosure, dissemination, or publication.
f.  Contracting Officer Determinations will reflect the result of internal coordination with appropriate program and legal officials.
g.  The provisions of paragraph (d) of this article shall not apply to conflicting or overlapping provisions in other Federal, State or local laws.
ALL REQUIREMENTS OF THIS SECTION H.5 MUST BE PASSED TO ALL SUB-CONTRACTOR.
H.6Regulatory Rights
This contract involves supply of a product that requires FDA pre-market approval or clearance before commercial authorization.  Contractor is seeking FDA authorization or clearance for the commercialization of mRNA-1273, Moderna vaccine for SARS-CoV-2 Coronavirus (the “Technology”).  The Contractor is the Sponsor of the Regulatory Application (an investigational new drug application (IND), investigational device exemption (IDE), emergency use authorization (EUA), new drug application (NDA), biologies license application (BLA), premarket approval application (PMA), or 510(k) pre-market notification filing (510(k)) or another regulatory filing submitted to FDA) for the technology.  As the Sponsor of the Regulatory Application to FDA (as the terms “sponsor” and “applicant” are defined or used in at 21 CFR §§3.2(c), 312.5, 600.3(f), 812.2(b), 812 Subpart C, or 814.20), the Contractor has certain standing before the FDA that entitles it to exclusive communications related to the Regulatory Application.
Accordingly, the Contractor and the Government agree to the following:
a.  DoD Medical Product Priority.  PL 115-92 allows the DoD to request, and FDA to provide, assistance to expedite development of products to diagnose, treat, or prevent serious or life-threatening diseases or conditions facing American military personnel.  The contractor recognizes that only the DoD can utilize PL 115-92.  As such, the contractor will work proactively with the Government to leverage this law to its maximum potential under this contract.  The contractor shall submit Public Law 115-92 Sponsor Authorization Letter that will be delivered to the designated OWS POC(s) within [***] of award.
b.  [***].
H.7Performance Based Payment Liquidated under Termination
Performance Based Payments (PBPs) have been authorized as a method of financing under this contract.  In the event the Moderna’s mRNA-1273 COVID Vaccine is unsuccessful in its bid to obtain EUA or FDA approval, the Government may issue a Termination for Convenience (T4C) in whole or in part, on this contract.  Upon notice of a T4C, the contractor shall submit a termination settlement proposal, IAW FAR 52.249-2, Termination for Convenience of the Government (Fixed-Price).
H.8Public Readiness and Emergency Preparedness (PREP) Act:

W911QY20C0100
[***]
Page 22 of 29

In accordance with the Public Readiness and Emergency Preparedness Act (“PREP Act”), Pub. L. No. 109-148, Division C, Section 2, as amended (codified at 42 U.S.C. § 247d-6d and 42 U.S.C. § 247d-6e), as well as the Secretary of HHS’s Declaration Under the Public Readiness and Emergency Preparedness Act for Medical Countermeasures Against COVID-19, 85 Fed. Reg. 15198 (Mar. 17, 2020, effective Feb. 4,2020), and amended on April 15, 2020, 85 Fed. Reg. 21012 (together, the “Prep Act Declaration”):
(i) This Agreement is being entered into for purposes of facilitating the manufacture, testing, development, distribution, administration, and use of “Covered Countermeasures” for responding to the COVID-19 public health emergency, in accordance with Section VI of the PREP Act Declaration;
(ii) Contractor’s performance of this Agreement falls within the scope of the “Recommended Activities” for responding to the COVID-19 public health emergency, to the extent it is in accordance with Section III of the PREP Act Declaration; and
(iii) Contractor is a “Covered Person” to the extent it is a person defined in Section V of the PREP Act Declaration.
Therefore, in accordance with Sections IV and VII of the PREP Act Declaration as well as the PREP Act (42 U.S.C. § 247d-6d), the Department of Defense contracting via assisted acquisition on behalf of the HHS, expressly acknowledges and agrees that the HHS Declaration cited above, specifically its language providing immunity from suit and liability is applicable to this acquisition as long as Contractors activities fall within the terms and conditions of the PREP Act and the PREP Act Declaration.
The Government may not use, or authorize the use of, any products or materials provided under this contract, unless such use occurs in the United States (or a U.S. territory where U.S. law applies such as embassies, military and NATO installations) and is protected from liability under a declaration issued under the PREP Act, or a successor CO VID-19 PREP Act Declaration of equal or greater scope.  Any use where the application of the PREP Act is in question will be discussed with Moderna prior to use and, if the parties disagree on such use, the dispute will be resolved according to the “Disputes Clause” (52.233-1)
The items and technology covered by this Contract are being developed for both civil and military applications.
H.9[***].
H.10[***].
H.11[***].
H.12Transportation to Final Destination
During the course of performance under this contract, the Government may require storage of the filled drug product (FDP) before delivery to the final government location.  In these circumstances, the Government will accept FDP at the contractor facility (Origin).  The contractor; however, shall continue to be responsible for secure delivery of the vaccine to its final destination as identified on this contract.  [***].
H.13Validation of IP/Data
The Parties acknowledge that background intellectual property and technical data assertions have been made and evaluated by the parties.  The parties agree that, should additional information relevant to these assertions become available, the parties will reevaluate said assertions as necessary in the future.
H.14Novation
Upon Moderna, US, Inc.’s registration in the System for Award Management, the Government will, at the Contractor’s request, complete a novation of this Contract to recognize Moderna US, Inc. as a counterparty instead 

W911QY20C0100
[***]
Page 23 of 29

of Moderna TX, Inc.  This novation will be completed through a modification executed by the Government that identifies Moderna US, Inc. as the contracting party for all purposes as if it had originally executed the Contract.
H.15Base & Option 1 Delivery Acceleration
In an effort to accelerate production of the mRNA-1273 vaccine, [***] within the Option 1 period via a Modification to the contract.  If these manufacturing slots are successfully utilized, [***] above what was projected by Moderna and assumed within the price per dose for the doses of tnRNA-1273 vaccine delivered in the Base Period and Option 1.  However, because the Government is funding the additional slots within the Base and Option 1 periods in order to accelerate production, the Government is entitled to an adjustment under the conditions outlined.  The Government and Moderna agree to the following:
1.  If the Government exercises Option 2 (NLT 15 May):
a [***].
2.  If the Government does not exercise Option 2 (NLT 15 May):
a.  In the event Moderna timely cancels the manufacturing slots and/or is able to otherwise fully utilize the slots originally reserved for production in the Option 2 period, Moderna agrees to [***] for [***] and [***] for [***].  In no case shall the number of drug product manufacturing slots credited exceed the number of successfully accelerated drug product manufacturing fills under the Base Period and Option 1.  It is understood that Moderna will make all good-faith efforts to fill reserved slots or cancel reservations in a timely manner (i.e. within the time period required by the subcontractor).
b.  In the event that Moderna is unable to fill those reserved slots (i.e. due to lack of demand) and cancels slots, Moderna shall be entitled to recoup those reservation cancellation costs from the USG.  The process is outlined as follows:
1.) Moderna shall submit documentation to the USG of the following:
i.) Cancellation notice to the subcontractor,
ii.) The basis of the cancellation, and
iii.) Cancellation fees incurred.
2.) [***].
H.16Delivery Schedule, as revised 11 Feb 2021 via modification P00004
[***]

Moderna confirms that it will provide the USG with the first 300M doses manufactured within its US-based supply chain [***], with the exception of doses required for clinical studies.  [***].  Both parties acknowledge that resulting revisions to future accounting, invoicing, acceptance and delivery of doses subject to the revised label will be implemented via a subsequent modification.
H.17Post-Termination Disposition of Undelivered Product
For the avoidance of doubt, if the USG elects to terminate the exercised CLINs prior to acceptance and delivery in full of the required quantities of mRNA-1273, Moderna will be free to direct any unaccepted/undelivered supplies of mRNA-1273 to customers other than the USG, at its discretion, without further obligation of either party with regard to such unaccepted/undelivered supplies of mRNA-1273.  The contract will be bilaterally modified to decrease the quantities by the agreed upon volume.

W911QY20C0100
[***]
Page 24 of 29

SECTION I -CONTRACT CLAUSES
The following have been modified:
252.232-    7007 LIMITATION OF GOVERNMENT’S OBLIGATION (APR 2014)
(a)Contract line item 0003 is incrementally funded.  For this item, the sum of $300,000,000.00 of the total price is presently available for payment and allotted to this contract.  An allotment schedule is set forth in paragraph (j) of this clause.
(b)For items(s) identified in paragraph (a) of this clause, the Contractor agrees to perform up to the point at which the total amount payable by the Government, including reimbursement in the event of termination of those item(s) for the Government’s convenience, approximates the total amount currently allotted to the contract.  The Contractor is not authorized to continue work on those item(s) beyond that point.  The Government will not be obligated in any event to reimburse the Contractor in excess of the amount allotted to the contract for those item(s) regardless of anything to the contrary in the clause entitled “TERMINATION FOR THE CONVENIENCE OF THE GOVERNMENT.” As used in this clause, the total amount payable by the Government in the event of termination of applicable contract line item(s) for convenience includes costs, profit and estimated termination settlement costs for those item(s).
(c)Notwithstanding the dates specified in the allotment schedule in paragraph (j) of this clause, the Contractor will notify the Contracting Officer in writing at least ninety days prior to the date when, in the Contractor’s best judgment, the work will reach the point at which the total amount payable by the Government, including any cost for termination for convenience, will approximate 85 percent of the total amount then allotted to the contract for performance of the applicable item(s).  The notification will state (1) the estimated date when that point will be reached and (2) an estimate of additional funding, if any, needed to continue performance of applicable line items up to the next scheduled date for allotment of funds identified in paragraph (j) of this clause, or to a mutually agreed upon substitute date.  The notification will also advise the Contracting Officer of the estimated amount of additional funds that will be required for the timely performance of the item(s) funded pursuant to this clause, for subsequent period as may be specified in the allotment schedule in paragraph (j) of this clause, or otherwise agreed to by the parties.  If after such notification additional funds are not allotted by the date identified in the Contractor’s notification, or by an agreed substitute date, the Contracting Officer will terminate any item(s) for which additional funds have not been allotted, pursuant to the clause of this contract entitled “TERMINATION FOR THE CONVENIENCE OF THE GOVERNMENT”.
(d)When additional funds are allotted for continued performance of the contract line item(s) identified in paragraph (a) of this clause, the parties will agree as to the period of contract performance which will be covered by the funds.  The provisions of paragraph (b) through (d) of this clause will apply in like manner to the additional allotted funds and agreed substitute date, and the contract will be modified accordingly.
(e)If, solely by reason of failure of the Government to allot additional funds, by the dates indicated below, in amounts sufficient for timely performance of the contract line item(s) identified in paragraph (a) of this clause, the Contractor incurs additional costs or is delayed in the performance of the work under this contract and if additional funds are allotted, an equitable adjustment will be made in the price or prices (including appropriate target, billing, and ceiling prices where applicable) of the item(s), or in the time of delivery, or both.  Failure to agree to any such equitable adjustment hereunder will be a dispute concerning a question of fact within the meaning of the clause entitled “disputes.”
(f)The Government may at any time prior to termination allot additional funds for the performance of the contract line item(s) identified in paragraph (a) of this clause.

W911QY20C0100
[***]
Page 25 of 29

(g)The termination provisions of this clause do not limit the rights of the Government under the clause entitled “DEFAULT.” The provisions of this clause are limited to work and allotment of funds for the contract line item(s) set forth in paragraph (a) of this clause.  This clause no longer applies once the contract if fully funded except with regard to the rights or obligations of the parties concerning equitable adjustments negotiated under paragraphs (d) or (e) of this clause.
(h)Nothing in this clause affects the right of the Government to this contract pursuant to the clause of this contract entitled “TERMINATION FOR CONVENIENCE OF THE GOVERNMENT.”
(i)Nothing in this clause shall be construed as authorization of voluntary services whose acceptance is otherwise prohibited under 31 U.S.C. 1342.
(j)The parties contemplate that the Government will allot funds to this contract in accordance with the following schedule:
On execution of contract $0.00
Modification P00003 dated 11 Dec 2020 - $300,000,000
(End of clause)
SECTION J -LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS
The following have been modified:

												
	Document Type
	Description
	Page #
	Date

	Exhibit A
	CDRLs
	15
	11 Feb 2021

	Attachment 0001
	Supply Chain Resiliency Plan for CDRL A010
	3
	23 July 2020

	Attachment 0002
	Security Plan
	7
	23 July 2020

	Attachment 0003
	Dose Tracking Template Draft Moderna
	Excel
	15 July 2020

	Attachment 0004
	Data Rights
	3
	7 August 2020

	Attachment 0005
	[***]
	2
	7 August 2020

	Attachment 0006
	ModernaTx, Inc. Background Intellectual Property
	3
	6 August 2020

	Attachment 0007
	Performance Base Payment Milestone Schedule
	2
	7 August 2020

	Attachment 0008
	Performance Base Payment Milestone Billing Plan
	17
	4 December 2020

	Attachment 0009
	HRPAS Moderna Letter
	1
	3 September 2020

(End of Summary of Changes)

																																																			
	AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT
	1. CONTRACT ID CODE
	PAGE OF PAGES

	1
	23

	2. AMENDMENT/MODIFICATION NO.
P00005
	3. EFFECTIVE DATE
23-Apr-2021
	4. REQUISITION/PURCHASE REQ. NO.
SEE SCHEDULE
	5. PROJECT NO.(If applicable)
	6. ISSUED BY
W6QK ACC-APG NATICK DIVISION
BLDG 1 GENERAL GREENE AVENUE
NATICK MA 01760-5011
	CODE	W911QY	7. ADMINISTERED BY (If other than item 6)    
DEFENSE CONTRACT MANAGEMENT AGENCY
DCMA BOSTON
495 SUMMER STREET
BOSTON MA 02210-2138
	CODE	S2206A
			
	8. NAME AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code)
MODERNA US, INC.
[***]
200 TECHNOLOGY SQ
CAMBRIDGE MA 02139-3578
		9A. AMENDMENT OF SOLICITATION NO.
		9B. DATED (SEE ITEM 11)
	X	10A. MOD. OF CONTRACT/ORDER NO.
W911QY20C0100

	X	10B. DATED (SEE ITEM 13)
09-Aug-2020

	CODE    8PTM0
			FACILITY CODE
	11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS

		The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offer     is extended,     is not extended.
Offer mist acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended by one of the following methods: 
(a) By completing Items 8 and 15, and returning    copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted;
or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE
RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION
OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

	12. ACCOUNTING AND APPROPRIATION DATA (If required)
See Schedule

	13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS.
IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

		A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.

		B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B).

	X	C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:
See Block 14 Continuation Page

		D. OTHER (Specify type of modification and authority)

	E. IMPORTANT: Contractor      is not,     is required to sign this document and return     1     copies to the issuing office.

	14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)
Modification Control Number: [***]
See Block 14 Continuation Page
Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in foil force and effect.

	15A. NAME AND TITLE OF SIGNER (Type or print) 
Stephen Hoge, President
	16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)
[***]
TEL: [***]    EMAIL: [***]

	15B. CONTRACTOR/OFFEROR 
/s/ Stephen Hoge
        
(Signature of person authorized to sign)
	15C. DATE SIGNED	16B. UNITED STATES OF AMERICA
BY        
(Signature of Contracting Officer)
	16C. DATE SIGNED
23 April 2021

W911QY20C0100
[***]
Page 2 of 23

SECTION SF 30 BLOCK 14 CONTINUATION PAGE
SUMMARY OF CHANGES
SECTION SF 30 - BLOCK 14 CONTINUATION PAGE
The following have been added by full text:
OBLIGATION AMOUNT: $0.00
a.    The purpose of this modification (P00005) is to:
- Revise Section A and Section C to recognize 8.0mL fill volume (1600mcg) [***] along with the 6.3mL fill volume (1260mcg) [***] currently on contract (Authority FAR 43.103(a)(3), Mutual Agreement of the Parties)
- Add H. [***] Invoicing, to Section H (Authority FAR 43.103(a)(3), Mutual Agreement of the Parties)
b.    This modification was requested by the program office to meet the Government’s mission requirements.
c.    The total contract value and total funded amount remain unchanged.
All other terms and conditions remain unchanged.  Please see below for details.
SECTION A -SOLICITATION/CONTRACT FORM
The following have been modified:
A.1The U.S. Army Contracting Command - Aberdeen Proving Ground (ACC-APG), Natick Division has a requirement for up to 500 million SARS-CoV-2 mRNA-1273 Vaccine doses (100 pg) in support of Joint Program Executive Office - Chemical Biological Radiological Nuclear Defense (JPEO-CBRND).  the Assistant Secretary for Preparedness and Response (ASPR), and Biomedical Advanced Research and Development Authority (BARDA).  All doses of mRNA-1273 Vaccine referenced herein are [***].  All doses will be delivered in a multi-dose vial containing either 6.3mL fill volume (1260mcg) [***] (manufactured as described in Moderna’s FDA concurrence letter dated 01 April 2021 or 8.0mL fill volume (1600mcg) [***] (as described in Moderna’s FDA submission dated (01 April 2021).

W911QY20C0100
[***]
Page 3 of 23

SECTION C -DESCRIPTIONS AND SPECIFICATIONS
The following have been modified:
STATEMENT OF WORK
LARGE SCALE PRODUCTION OF SARS-CoV-2 VACCINE
C.1SCOPE.  The Department of Defense and Health and Human Services (HHS) require large scale manufacturing of vaccine doses in support of the national emergency response to the Coronavirus Disease 2019 (COVID-19) for the United States Government (USG) and the US population.
C.1.1Background.  In December 2019, a novel coronavirus now known as SARS-CoV-2 was first detected in Wuhan, Hubei Province, People’s Republic of China, causing outbreaks of the coronavirus disease COVID-19 that has now spread globally.  The Secretary of Health and Human Service declared a public health emergency on January 31, 2020, under section 319 of the Public Health Service Act (42 U.S.C. 247d), in response to COVID-19.  On March 1, 2020, the President of the United States, pursuant to sections 01 and 301 of the National Emergencies Act (50 U.S.C. 1601 et seq.) and consistent with section 1135 of the Social Security Act (SSA), as amended (42 U.S.C. 1320b-5), proclaimed that the COVID-19 outbreak in the United States constitutes a national emergency.
C1.1.1Under Operation Warp Speed (OWS), the Department of Defense and HHS are leading a whole of nation effort to ensure development of promising vaccine, diagnostic and therapeutic candidates and ensure that these medical countermeasures are available in the quantities required to reduce SARS-CoV-2 transmission, identify prior and/or current infection, and improve patient care, thereby mitigating the impact of COVID-19 on the nation and its people.  The DoD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRD) is providing expertise and contracting support to HHS, in compliance with PL 115-92 Authorization Letter for DoD Medical Priorities, through an Interagency Agreement, signed April 23, 2020.  As OWS products progress to clinical trials to evaluate the safety and efficacy of vaccines and therapeutics, it is critical that, in parallel, the USG supports large scale manufacturing so that vaccine doses or therapeutic treatment courses are immediately available for nationwide access as soon as a positive efficacy signal is obtained and the medical countermeasures are authorized for widespread use.
C.1.2Objective: The objective of this effort is to obtain the following:
(a)Base Period: Large scale manufacturing of 100 million vaccine doses
(b)Option Period 1: Large scale manufacturing of 100 million vaccine doses
(c)Option Period 2: Large scale manufacturing of 100 million vaccine doses
(d)Option Period 3: Large scale manufacturing of 100 million vaccine doses
(e)Option Period 4: Large scale manufacturing of 100 million vaccine doses
The Base Period is [***], with overlapping options for a total of [***] if all options are exercised.
C.1.3Consistent with the Updated EUA Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) dated 01 April 2021, up to [***] may be extracted from Moderna’s newly authorized multidose vials with 8.0mL fdl volume (1600mcg).  The Government and Moderna agree that [***] per vial are only attainable using premium low dead volume (LDV) syringes, which are in short supply globally.  Utilizing initial ancillary equipment, vaccine administration personnel can reliably extract [***] from these vials; however, the Government has identified needle/syringe combinations that can be used to extract [***].
C.1.3.1Given the two parties’ shared interest in reducing vaccine waste and accelerating the availability of Moderna’s SARS-CoV-2 vaccine doses, the Government and Moderna intend that the Moderna vaccines doses be administered with needles and syringes compatible with extraction of [***] when possible.  Toward this end, the Government shall maintain a list of syringe and/or needle combinations which will allow extraction of [***] per 8.0mL vial, which list shall be updated jointly by the Government and Moderna as any additional syringe and/or 

W911QY20C0100
[***]
Page 4 of 23

needle combinations compatible with extraction of [***]/vial are identified.  Furthermore, the Government will, to the extent that appropriate needles and syringes are available, assemble and ship kits containing sufficient quantities of syringes and needles compatible with extraction of [***] per vial (Kit Moderna [***]) with Moderna’s SARS-CoV-2 vaccine.  The Government expects that these kits will be available beginning 01 May 2021 for a significant portion of Moderna’s remaining deliveries.  If, however, appropriate syringes and needles are not available, the Government will revert to shipping the Kit Moderna [***] with Moderna’s SARS-CoV-2 vaccine.
C.2APPLICABLE DOCUMENTS
C.2.1Federal Documents:
C.2.1.1Title 21 Code of Federal Regulations (CFR), Food and Drugs: Part 210.  Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs; General; and, Part 211, Current Good Manufacturing Practice In Manufacturing, Processing, Packing, or Holding of Drugs; General.
(https://www.ecfr.gov/cgi-bin/text-idx?SID=a95cab20f443897a400bb7e44a27cf4c&mc=true&tpl=/ecfrbrowse/Title21/21cfrv4_02.tpl#0)
C.3REQUIREMENTS.  Independently, and not as an agent of the USG, in accordance with the Proposal submitted by Moderna US, Inc. in response to Solicitation Number W911QY20R0043, Titled, “Advanced Procurement of mRNA-1273 Vaccine for Prevention of SARS-CoV-2 Coronavirus (COVID-19)”), dated July 10, 2020 (and any subsequent USG-approved revisions thereto), the contractor shall provide all necessary services, qualified personnel, material, equipment and facilities (not otherwise provided by the USG under the terms of this contract) to perform the specific tasks set forth below.
C.3.1Contract Line Item Number (CLIN) 0001 - Base Period: Large Scale Manufacturing of 100 Million Vaccine Doses
C.3.1.1The contractor shall complete all scope required for the production, release and delivery use of 100 million Final Drug Product (FDP) doses of a SARS-CoV-2 mRNA-1273 vaccine.  This shall include, the following tasks and other activities reasonably contemplated by such task:
C.3.1.1.1Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of [***].  (Based on FDP stability data that supports a [***] shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207.  Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC.  Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.
C.3.1.1.2cGMP manufacturing of 100 million doses fully compliant with 21 CFR 210 and 211.
C.3.1.1.3[***].
C.3.1.1.4[***]. 
C.3.1.1.5Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability and detection and response requirements, subject to any exceptions established by or the enforcement discretion of the FDA, including “Exemption from Certain Product Tracing and Product Identification Requirements Under Section 582 of the FD&C Act” (April 2020).
C.3.1.1.6In coordination with the USG, the contractor shall conduct a demonstration of the vaccine shipping process prior to the first delivery of FDP doses at a time mutually agreed to by the contractor and the USG.  

W911QY20C0100
[***]
Page 5 of 23

Moderna shall provide specifications and details associated with the shipping process and containers (IAW CDRL A005) to enable the USG to adequately plan and prepare for potential distribution of the vaccine.
C.3.1.1.7Following release of product the contractor shall, promptly deliver product to the designated delivery site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below.  In the unforeseen event that a designated delivery site cannot receive product and the contractor provides storage beyond [***] days of product release, the contract will be subject to modification for acceptance purposes.
C.3.1.2Site Visits and Audits.  The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.
C.3.1.2.1BARDA Audits.  If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.
C.3.1.2.2FDA Audits.  The Contractor shall notify the Contracting Officer and Contracting Officer’s Representative (COR) within [***] of a scheduled FDA audit or within [***] of an ad hoc site visit or audit if the FDA does not provide advance notice.  The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within [***] of receiving correspondence from the FDA or third party in accordance with CDRL A002.  The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within [***] of submittal of the audit report in accordance with CDRL A002.
C.3.1.2.3FDA Interactions.  The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologies for the following, but not limited to: FDA interactions.  FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.
C.3.2CLIN 1001 - Option Period 1: Large Scale Manufacturing of 100 Million Vaccine Doses.
C.3.2.1The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine.  This shall include the following tasks and other activities reasonably contemplated by such tasks:
C.3.2.1.1Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of [***].  (Based on FDP stability data that supports a [***] shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC.  Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.
C.3.2.1.2cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA.
C.3.2.1.3[***].
C.3.2.1.4Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27. 2013), including product verification, serialization, traceability and detection and response requirements subject to any exceptions established by or the enforcement discretion of the FDA.
C.3.2.1.5Following release of the product the contractor shall deliver the product to the designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below.  To the extent a natural disaster or other emergency affecting a designated delivery site restricts such site’s ability to receive 

W911QY20C0100
[***]
Page 6 of 23

product, the Contractor and the USG will promptly agree on an alternate USG delivery location, or storage as Vendor Managed Inventory (VMI) at the contractor site.
C.3.2.2Site Visits and Audits.  The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.
C.3.2.2.1BARDA Audits.  If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.
C.3.2.2.2FDA Audits.  The Contractor shall notify the Contracting Officer and COR within [***] of a scheduled FDA audit or within [***] of an ad hoc site visit or audit if the FDA does not provide advance notice.  The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within [***] of receiving correspondence from the FDA or third party in accordance with CDRL A015.  The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within [***] of submittal of the audit report in accordance with CDRL A002.
C.3.2.2.3FDA Interactions.  The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drags and biologies for the following, but not limited to: FDA interactions.  FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.
C.3.3CLIN 2001 - Option Period 2: Large Scale Manufacturing of 100 Million Vaccine Doses.
C.3.3.1The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine.  This shall include the following tasks and other activities reasonably contemplated by such tasks:
C.3.3.1.1Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of [***].  (Based on FDP stability data that supports a [***] shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207.  Registration of Producers of Drags and Listing of Drags in Commercial Distribution are met prior to distribution to the CDC.  Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.
C.3.3.1.2cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA.
C.3.3.1.3[***].
C.3.3.1.4Ensuring that the product complies with the Drag Supply Chain Security Act (DSCSA), Sections 581- 585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability and detection and response requirements, subject to any exceptions established by or the enforcement discretion of the FDA.
C.3.3.1.5Following release the contractor shall deliver product to the nearest designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below.  To the extent a natural disaster or other emergency affecting a designated delivery site restricts such site’s ability to receive product, the Contractor and the USG will promptly agree on an alternate USG delivery location, or storage as Vendor Managed Inventory (VMI) at the contractor site.
C.3.3.2Site Visits and Audits.  The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.

W911QY20C0100
[***]
Page 7 of 23

C.3.3.2.1BARDA Audits.  If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.
C.3.3.2.2FDA Audits.  The Contractor shall notify the Contracting Officer and COR within [***] of a scheduled FDA audit or within [***] of an ad hoc site visit or audit if the FDA does not provide advance notice.  The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within [***] of receiving correspondence from the FDA or third party in accordance with CDRL A002.  The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within [***] of submittal of the audit report in accordance with CDRL A002.
C.3.3.2.3FDA Interactions.  The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologies for the following, but not limited to: FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.
C.3.4CLIN 3001 - Option Period 3: Large Scale Manufacturing of 100 Million Vaccine Doses.
C.3.4.1The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine.  This shall include the following tasks and other activities reasonably contemplated by such tasks:
C.3.4.1.1Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of [***].  (Based on FDP stability data that supports a [***] shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207.  Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC.  Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.
C.3.4.1.2cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA.
C.3.4.1.3[***].
C.3.4.1.4Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability and detection and response requirements subject to any exceptions established by or the enforcement discretion of the FDA.
C.3.4.1.5Following release of the product the contractor shall deliver the product to the designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below.  To the extent a natural disaster or other emergency affecting a designated delivery site restricts such site’s ability to receive product, the Contractor and the USG will promptly agree on an alternate USG delivery location, or storage as Vendor Managed Inventory (VMI) at the contractor site.
C.3.4.2Site Visits and Audits.  The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.
C.3.4.2.1BARDA Audits.  If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.
C.3.4.2.2FDA Audits.  The Contractor shall notify the Contracting Officer and COR within [***] of a scheduled FDA audit or within [***] of an ad hoc site visit or audit if the FDA does not provide advance notice.  The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of 

W911QY20C0100
[***]
Page 8 of 23

this contract or for this product within [***] of receiving correspondence from the FDA or third party in accordance with CDRL A015.  The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within [***] of submittal of the audit report in accordance with CDRL A002.
C.3.4.2.3FDA Interactions.  The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding mRNA-1273 for the following, but not limited to: FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.
C.3.5CLIN 4001 - Option Period 4: Large Scale Manufacturing of 100 Million Vaccine Doses.
A.3.5.1The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine.  This shall include the following tasks and other activities reasonably contemplated by such tasks:
C.3.5.1.1Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of [***].  (Based on FDP stability data that supports a [***] shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC.  Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.
C.3.5.1.2cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA.
C.3.5.1.3[***].
C.3.5.1.4Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability and detection and response requirements subject to any exceptions established by or the enforcement discretion of the FDA.
C.3.5.1.5Following release of the product the contractor shall deliver the product to the designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below.  To the extent a natural disaster or other emergency affecting a designated delivery site restricts such site’s ability to receive product, the Contractor and the USG will promptly agree on an alternate USG delivery location, or storage as Vendor Managed Inventory (VMI) at the contractor site.
C.3.5.2Site Visits and Audits.  The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.
C.3.5.2.1BARDA Audits.  If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.
C.3.5.2.2FDA Audits.  The Contractor shall notify the Contracting Officer and COR within [***] of a scheduled FDA audit or within [***] of an ad hoc site visit or audit if the FDA does not provide advance notice.  The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within [***] of receiving correspondence from the FDA or third party in accordance with CDRL A015.  The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within [***] of submittal of the audit report in accordance with CDRL A002.
C.3.5.2.3FDA Interactions.  The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologies for the following, 

W911QY20C0100
[***]
Page 9 of 23

but not limited to: FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.
C.4CLIN 0002: Data Deliverables.  The contractor shall provide the following in accordance with the Contract Data Requirements List (CDRL), DD Forms 14230, provided at Appendix A.
C.4.1Monthly Inventory Report (CDRL A003), detailing at a minimum, raw materials, Bulk-mRNA, formulated LNPs, and the fill, finish, and released product.
C.4.2Quality Management Plan.  The contractor shall provide a Quality Management Plan, in accordance with CDRL A004, describing the quality policy and objectives, management review, competencies and training, process document control, feedback, evaluation, corrective action and preventive action, process improvement, measurement, and data analysis processes.  The framework is normally divided into infrastructure, senior management responsibility, resource management, lifecycle management, and quality management system evaluation.
C.4.3Shipping Documentation (CDRL A005) for all Finished Drug Product (FDP) transferring from the contractor’s fill/finish facility to a USG facility.  The contractor shall obtain concurrence on planned shipment protocols prior to transport.
C.4.4Expiring Items Report (CDRL A006) for all FDP in the USG’s possession.
C.4.5Key Personnel Listing (CDRL A007).
C.4.6Monthly Technical Progress Report (CDRL A008), to include an Integrated Master Schedule, identifying key activities and contract status.
C.4.7Final Technical Report (CDRL A009), documenting the work performed and results obtained for the entire contract period of performance.
C.4.8Supply Chain Resiliency Plan (SCRP).  The contractor shall provide, in accordance with CDRL A010 and CDRL Attachment 0001, a comprehensive SCRP that provides for identification and reporting of critical components associated with the secure supply of drug substance, drug product, and work-in-process through to finished goods, and key equipment suppliers and their locations, including addresses, points of contact, and work performed per location, to include subcontractors.
C.4.9[***].
C.4.10Manufacturing Reports and Dose Tracking.  The Contractor shall provide, in accordance with CDRL A013, manufacturing reports and manufacturing dose tracking projections and actuals utilizing the USG-provided “COVID-19 Dose Tracking Template” (CDRL Attachment 0003).
C.4.11Product Acceptance Report (for each lot of Drug Product).  The contractor shall provide, in accordance with CDRL A014, pictures of the drug product with lot number, drug product lot tree, list of associated deviations (from drug substance and product), and a Certificate of Analysis.
C.4.12Incident Report.  The contractor shall communicate to BARD A and document all critical programmatic concerns, issues, or probable risks that have or are likely to significantly impact project schedule and/or cost and/or performance in accordance with CDRL A016.  “Significant” is frequently defined as a [***] or greater cost or schedule variance within a control account, but should be confirmed in consultation with the COR.  Incidents that present liability to the project even without cost/schedule impact, such as breach of GCP during a clinical study, shall also be reported.

W911QY20C0100
[***]
Page 10 of 23

C.4.13FDA Correspondence.  The contractor shall provide any correspondence between Contractor and FDA relevant to the scope of this contract and submit in accordance with CDRL AO 17.
C.4.14Press Releases.  The contractor shall accurately and factually represent the work conducted under this contract in all press releases.  The contractor shall provide an advance copy of any press release in accordance with CDRL A018.
C.4.15Manufacturing Development Plan.  The contractor shall provide a Manufacturing Development Plan, in accordance with CDRL A025, describing the manufacturing process for the drug/biologic product to ensure conformity with §501(a)(2)(B) of the Food, Drug, and Cosmetics Act (FD&C Act, Title 21 United States Code (USC) §351 (a)(2)(B)), regarding good manufacturing practices (GMP).
C.5Administration.
C.5.1Post Award Teleconference.  The contractor shall host a Post Award Teleconference within 15 calendar days after contract award.
C.5.1.1The contractor shall provide an Agenda, IAW CDRL A020, detailing the planned activities for the subsequent 30 calendar days and shall discuss agenda items for the Post Award Kickoff Meeting.
C.5.1.2The contractor shall provide Meeting Minutes IAW CDRL A021.
C.5.2Post Award Kickoff Meeting.  The contracting officer may request the contractor host a contract Kick-Off Meeting within 30 calendar days after contract award via teleconference.  The contracting officer shall establish the date and time of the conference and prepare the agenda to include discussion on contract activities and schedule.
C.5.3Bi-Weekly Teleconference.  The contractor shall participate in bi-weekly teleconferences (or more frequent meetings required by the USG if warranted based on contract activities) to discuss performance on the contract.
C.5.4The contractor shall provide an Agenda, IAW CDRL A020; Meeting Minutes in accordance with CDRL A021; and, Presentation Material in accordance with CDRL A022 for each of the aforementioned teleconferences or meetings throughout the contract period of performance.
C.5.5Daily “Check-In”.  The contractor shall participate in a daily “check-in” (via teleconference or email) to address key cost, schedule and technical updates.  Daily updates may be shared with senior USG leaders during the CO VID-19 response and should be provided on a non-confidential basis, unless the update includes confidential information in which case, the contractor shall provide the update in both confidential and non-confidential formats.  Daily check-ins may occur on weekdays, excluding federal holidays.  Upon request of the USG, check-ins may also occur on weekends and on federal holidays, provided at least 24 hours’ notice.
C.6Security.
C.6.1Access and General Protection/Security Policy and Procedures.  The contractor shall provide all information required for background checks necessary to access critical information related to OWS, and to meet USG installation access requirements to be accomplished by the installation Director of Emergency Services or Security Office.  The contractor employees shall comply with all personnel identity verification requirements as directed by the USG and/or local policy.  In addition to the changes otherwise authorized by the changes clause of this contract, should the security status of OWS change the USG may require changes in the contractor’s security matters or processes.  In addition to the industry standards for employment background checks, the contractor shall be willing to have key individuals, in exceptionally sensitive positions, identified for additional vetting by the United States USG.
C.6.2Security Program and Plan.  The contractor shall implement a comprehensive security program that provides overall protection of personnel, information, data, and facilities associated with fulfilling the USG’s 

W911QY20C0100
[***]
Page 11 of 23

requirement.  The contractor’s security practices and procedures shall be detailed in a Security Plan, in accordance with CDRL AO 19.  and shall demonstrate how the contractor shall meet and adhere to the security requirements outlined in CDRL Attachment 0002.  Titis plan shall be delivered to the USG within 45 days of award, and the USG will review in detail and submit comments within ten (10) business days to the Contracting Officer (CO) to be forwarded to the Contractor.  The Contractor shall review the Security Plan comments, and, submit a final Security Plan to the U.S. USG within thirty (30) calendar days after receipt of the comments.  The Security Plan shall include a timeline for compliance of all the required security measures outlined in CDRL Attachment 0002.
C.6.3Operational Security (OPSEC).  The contractor shall develop and submit an OPSEC Standard Operating Procedure (SOP)ZPlan IAW CDRL A024.  The contractor shall identify in the SOP/Plan critical information related to this contract, why it needs to be protected, where it is located, who is responsible for it, and how to protect it.
C.7CLIN 0002 Vendor Managed Inventory (VMI).  The Contractor shall provide the capability to store the vaccine for up to [***], up to 100M doses of mRNA-1273 vaccine, in accordance with product labeling.  The contractor shall, in accordance with paragraph C. 3.1.1.6. ensure the product storage of FDP doses for up to [***] prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  [***]  The contractor shall store the product to insure product quality with audible alarms and contacting.  The contractor shall notify the USG within [***] of detection of an incident with the potential to impact product quality, and implement corrective actions to mitigate the incident.  BARDA/JPEO- CBRND personnel may conduct Quality Audits of the storage facility, when deemed necessary.  The contractor shall notify the USG of Corrective/Preventive actions within [***] of detection of an incident with potential to impacts product quality.  BARDA/JPEO-CBRND personnel may conduct Quality Audits of the storage facility, when deemed necessary.
C.7.1The USG will provide the contractor advance notice of the required delivery locations for the vaccine.  The contractor shall ship mRNA-1273 vaccines to designated locations [***] in the United States.  The contractor shall be responsible for shipment of all vaccine product whether acceptance is conducted [***].  [***].
C.7.2The vaccine product shall be shipped and tracked by the distribution vendor’s shipping tracking number, to the USG-designated sites within the continental United States.
C.7.3[***].  Notwithstanding either of the foregoing sentences, the contractor shall not be liable for loss of or damage to supplies caused by the negligence of officers, agents, or employees of the USG acting within the scope of their employment.
SECTION G -CONTRACT ADMINISTRATION DATA
The following have been modified:
G.1GOVERNMENT CONTRACT ADMINISTRATION
In no event shall any understanding or agreement, contract modification, change order, or other matter in deviation from the terms of this contract between the Contractor and a person other than the Contracting Officer be effective or binding upon the Government.  All such actions must be formalized by a proper contractual document executed by the Contracting Officer.
Procuring Contracting Officer:
[***]
Bldg. 1, General Greene Avenue
Natick, MA 01760-5011
Contract Specialist:
[***]

W911QY20C0100
[***]
Page 12 of 23

Bldg. 1, General Greene Avenue
Natick, MA 01760-5011
G.2GOVERNMENT TECHNICAL POINT OF CONTACT
[***]
Biologist/Project Officer
200 C Street. SW
Washington, DC 20201
G.3CONTRACTOR’S CONTRACT ADMINISTRATION
[***]
Moderna US, Inc.
200 Technology SQ.
Cambridge, MA 02139-3578
G.4PLACES OF PERFORMANCE
Moderna US, Inc.
200 Technology SQ.
Cambridge, MA 02139-3578
G.5NOTIFICATION OF REVISIONS AND CHANGE
Notification of revision or changes to names or email addresses will be provided by official correspondence from the PCO/ACO or office of the PCO/ACO in lieu of a contract modification.  This does not apply to any such revisions or changes in the event this contract includes a key personnel clause.
G.6PERFORMANCE BASED PAYMENT
Performance-based payments (PBP) are authorized under this contract in accordance with FAR 52.232-32.  The contractor shall bill for the PBP upon achievement of the completion criteria identified in Attachment 0007, Performance-based Payment Milestone Table.  Upon achievement of the completion criteria, the contractor shall bill for the PBP for the base and each option I AW the following schedule:									
	CLIN	PERIOD	AMOUNT
	0001AA	BASE	$    90,210,000
	0001AB	BASE	$    132,308,000
	0001AC	BASE	$    180,420,000
	0001AD	BASE	$    198,462,000
	TOTAL		$    601,400,000
			
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]		[***]
			
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]		[***]

Delivery Invoicing: PBPs are a type of contract financing and are recouped by the Government through deductions 

W911QY20C0100
[***]
Page 13 of 23

of payments otherwise due to the contractor for the partial or complete delivery of contract items.  The deductions are made by applying a liquidation rate to the price of delivered contract items.  Attachment 0008, Performance-based Payment Milestone Billing Plan, identifies the contractor invoicing schedule for liquidation.  The contractor shall submit all invoices IAW Attachment 0008 dated 4 December 2020.
252.232-    7006 WIDE AREA WORKFLOW PAYMENT INSTRUCTIONS (DEC 2018)
(a)Definitions.  As used in this clause—
“Department of Defense Activity Address Code (DoDAAC)” is a six position code that uniquely identifies a unit, activity, or organization.
“Document type” means the type of payment request or receiving report available for creation in Wide Area WorkFlow (WAWF).
“Local processing office (LPO)” is the office responsible for payment certification when payment certification is done external to the entitlement system.
“Payment request” and “receiving report” are defined in the clause at 252.232-7003, Electronic Submission of Payment Requests and Receiving Reports.
(b)Electronic invoicing.  The WAWF system provides the method to electronically process vendor payment requests and receiving reports, as authorized by Defense Federal Acquisition Regulation Supplement (DFARS) 252.232- 7003, Electronic Submission of Payment Requests and Receiving Reports.
(c)WAWF access.  To access WAWF, the Contractor shall—
(1)Have a designated electronic business point of contact in the System for Award Management at https://www.sam.gov; and
(2)Be registered to use WAWF at https://wawf.eb.mil/ following the step-by-step procedures for self-registration available at this web site.
(d)WAWF training.  The Contractor should follow the training instructions of the WAWF Web-Based Training Course and use the Practice Training Site before submitting payment requests through WAWF.  Both can be accessed by selecting the “Web Based Training” link on the WAWF home page at https://wawf.eb.miF.
(e)WAWF methods of document submission.  Document submissions may be via web entry.  Electronic Data Interchange, or File Transfer Protocol.
(f)WAWF payment instructions.  The Contractor shall use the following information when submitting payment requests and receiving reports in WAWF for this contract or task or delivery order:
(i)Document type.  The Contractor shall submit payment requests using the following document type(s):
COMBO
(ii)For fixed price line items—
(A) That require shipment of a deliverable, submit the invoice and receiving report specified by the Contracting Officer.

W911QY20C0100
[***]
Page 14 of 23

Invoice and receiving report document type
(B) For services that do not require shipment of a deliverable, submit either the Invoice 2-in-1, which meets the requirements for the invoice and receiving report, or the applicable invoice and receiving report, as specified by the Contracting Officer.
N/A
(iii)For customary progress payments based on costs incurred, submit a progress payment request.
(iv)For performance based payments, submit a performance based payment request.
(v)For commercial item financing, submit a commercial item financing request.
(2)Fast Pay requests are only permitted when Federal Acquisition Regulation (FAR) 52.213-1 is included in the contract.
(3)Document routing.  The Contractor shall use the information in the Routing Data Table below only to fill in applicable fields in WAWF when creating payment requests and receiving reports in the system.
Routing Data Table
						
	Field Name in HA IFF
	Data to be entered in WA WF

	Pay Official DoDAAC
	HQ0337

	Issue By DoDAAC
	W911QY

	Admin DoDAAC
	S2206A

	Inspect By DoDAAC
	W56XNH

	Acceptor
	W911QY

	Ship To
	TDB

(4)Payment request.  The Contractor shall ensure a payment request includes documentation appropriate to the type of payment request in accordance with the payment clause, contract financing clause, or Federal Acquisition Regulation 52.216-7, Allowable Cost and Payment, as applicable.
(5)Receiving report.  The Contractor shall ensure a receiving report meets the requirements of DFARS Appendix F.
(g)WAWF point of contact.
(1)The Contractor may obtain clarification regarding invoicing in WAWF from the following contracting activity’s WAWF point of contact.
[***] / DCMA Boston-AFAW, Administrative Contracting Officer / [***]
(2)Contact the WAWF helpdesk at [***], if assistance is needed.
(End of clause)
FOR REFERENCE:
DFARS PGI 204.7108 Payment Instructions Table

W911QY20C0100
[***]
Page 15 of 23

https://www.acq.osd.mi1/dpap/dars/pgi/pgihtm/current/PGI204_71.htm#payment_instructions

SECTION H -SPECIAL CONTRACT REQUIREMENTS
The following have been modified:
H.1Key Personnel
Any key personnel specified in this contract are considered to be essential to work performance.  At least thirty (30) calendar days prior to the Contractor voluntarily diverting any of the specified individuals to other programs or contracts the Contractor shall notify the Contracting Officer and shall submit a justification for the diversion or replacement and a request to replace the individual.  The request must identify the proposed replacement and provide an explanation of how the replacement’s skills, experience, and credentials meet or exceed the requirements of the contract (including, when applicable.  Human Subjects Testing requirements).  If the employee of the Contractor is terminated for cause or separates from the Contractor voluntarily with less than thirty (30) calendar-day notice, the Contractor shall provide the maximum notice practicable under the circumstances.  The Contractor shall not divert, replace, or announce any such change to key personnel without the written consent of the Contracting Officer.  The contract will be modified to add or delete key personnel as necessary to reflect the agreement of the parties.  The following individuals are determined to be key personnel:
						
	Name
	Title

	[***]
	[***]

	[***]
	[***]

	[***]
	[***]

	[***]
	[***]

	[***]
	[***]

	[***]
	[***]

	[***]
	[***]

H.2Substitution of Key Personnel
The Contractor agrees to assign to the contract those persons whose resumes/CVs were submitted with the proposal who are necessary to fill the requirements of the contract.  No substitutions shall be made except in accordance with this clause.
All requests for substitution must provide a detailed explanation of the circumstance necessitating the proposed substitution, a complete resume for the proposed substitute and any other information requested by the contracting officer to approve or disapprove the proposed substitution.  All proposed substitutes must have qualifications that are equal to or higher than the qualifications of the person to be replaced.  The contracting officer or authorized representative will evaluate such requests and promptly notify the contractor of his approval or disapproval thereof.
H.3Disclosure of Information:
Performance under this contract may require the Contractor to access non-public data and information proprietary to a Government agency, another Government Contractor or of such nature that its dissemination or use other than as specified in the work statement would be adverse to the interests of the Government or others.  Neither the Contractor, nor Contractor personnel, shall divulge nor release data nor information developed or obtained under performance of this contract, except authorized by Government personnel or upon written approval of the CO which the KO will provide in accordance with OWS or other Government policies and/or guidance.  The Contractor shall not use, disclose, or reproduce proprietary data that bears a restrictive legend, other than as specified in this contract, or any information at all regarding this agency.

W911QY20C0100
[***]
Page 16 of 23

The Contractor shall comply with all applicable Government requirements for protection of non-public information.  Unauthorized disclosure of nonpublic information is prohibited by the Government’s rules.  Unauthorized disclosure may result in termination of the contract, replacement of a Contractor employee, or other appropriate redress.  Neither the Contractor nor the Contractors employees shall disclose or cause to be disseminated, any information concerning the operations of the activity, which could result in, or increase the likelihood of, the possibility of a breach of the activity’s security or interrupt the continuity of its operations.
No information related to data obtained under this contract shall be released or publicized without the prior written consent of the COR, whose approval shall not be unreasonably withheld, conditioned, or delayed, provided that no such consent is required to comply with any law, rule, regulation, court ruling or similar order; for submission to any government entity’ for submission to any securities exchange on which the Contractor’s (or its parent corporation’s) securities may be listed for trading; or to third parties relating to securing, seeking, establishing or maintaining regulatory or other legal approvals or compliance, financing and capital raising activities, or mergers, acquisitions, or other business transactions.  The exceptions identified in this paragraph apply to all disclosures under this Section H.3 except to the extent that a disclosure is otherwise prohibited by law.
H.4Publication and Publicity
The contractor shall not release any reports, manuscripts, press releases, or abstracts about the work being performed under this contract without written notice in advance to the Government.
(a) Unless otherwise specified in this contract, the contractor may publish the results of its work under this contract.  The contractor shall promptly send a copy of each submission to the COR for security review prior to submission.  The contractor shall also inform the COR when the abstract article or other publication is published, and furnish a copy of it as finally published.
(b) Unless authorized in writing by the CO, the contractor shall not display the DoD logo including Operating Division or Staff Division logos on any publications.
(c) The contractor shall not reference the products(s) or services(s) awarded under this contract in commercial advertising, as defined in FAR 31.205-1, in any manner which states or implies DoD approval or endorsement of the product(s) or service(s) provided.
(d) The contractor shall include this clause, including this section (d) in all subcontracts where the subcontractor may propose publishing the results of its work under the subcontract.  The contractor shall acknowledge the support of the Department of Health and Human Services.  Office of the Assistant Secretary’ for Preparedness and Response.  Biomedical Advanced Research and Development Authority whenever publicizing the work under this contract in any media by including an acknowledgement substantially as follows:
“This project has been funded in whole or in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract Number W911QY-20-C-0100.”
H.5Confidentiality of Information
a.  Confidential information, as used in this article, means non-public information or data of a personal nature about an individual, or proprietary information or data submitted by or pertaining to an institution or organization.
b.  The Contracting Officer and the Contractor may, by mutual consent, identify elsewhere in this contract specific information and/or categories of information which the Government will furnish to the Contractor or that the Contractor is expected to generate which is confidential.  Similarly, the Contracting Officer and the Contractor may, by mutual consent, identify such confidential information from time to time during the performance of the contract.  Failure to agree will be settled pursuant to the “Disputes” clause.

W911QY20C0100
[***]
Page 17 of 23

c.    If it is established elsewhere in this contract that information to be utilized under this contract, or a portion thereof, is subject to the Privacy Act, the Contractor will follow the rules and procedures of disclosure set forth in the Privacy Act of 1974, 5 U.S.C. 552a, and implementing regulations and policies, with respect to systems of records determined to be subject to the Privacy Act.
d.    Confidential information, as defined in paragraph (a) of this article, shall not be disclosed without the prior written consent of the individual, institution, or organization.
e.    Whenever the Contractor is uncertain with regard to the proper handling of material under the contract, or if the material in question is subject to the Privacy Act or is confidential information subject to the provisions of this article, the Contractor shall obtain a written determination from the Contracting Officer prior to any release, disclosure, dissemination, or publication.
f.    Contracting Officer Determinations will reflect the result of internal coordination with appropriate program and legal officials.
g.    The provisions of paragraph (d) of this article shall not apply to conflicting or overlapping provisions in other Federal, State or local laws.
ALL REQUIREMENTS OF THIS SECTION H.5 MUST BE PASSED TO ALL SUB-CONTRACTOR.
H.6Regulatory Rights
This contract involves supply of a product that requires FDA pre-market approval or clearance before commercial authorization.  Contractor is seeking FDA authorization or clearance for the commercialization of mRNA-1273, Moderna vaccine for SARS-CoV-2 Coronavirus (the “Technology”).  The Contractor is the Sponsor of the Regulatory Application (an investigational new drug application (IND), investigational device exemption (IDE), emergency use authorization (EUA), new drug application (NDA), biologies license application (BLA), premarket approval application (PMA), or 510(k) pre-market notification filing (510(k)) or another regulatory filing submitted to FDA) for the technology.  As the Sponsor of the Regulatory Application to FDA (as the terms “sponsor” and “applicant” are defined or used in at 21 CFR §§3.2(c), 312.5, 600.3(t), 812.2(b), 812 Subpart C, or 814.20), the Contractor has certain standing before the FDA that entitles it to exclusive communications related to the Regulatory Application.
Accordingly, the Contractor and the Government agree to the following:
a.  DoD Medical Product Priority.  PL 115-92 allows the DoD to request, and FDA to provide, assistance to expedite development of products to diagnose, treat, or prevent serious or life-threatening diseases or conditions facing American military personnel.  The contractor recognizes that only the DoD can utilize PL 115-92.  As such, the contractor will work proactively with the Government to leverage this law to its maximum potential under this contract.  The contractor shall submit Public Law 115-92 Sponsor Authorization Letter that will be delivered to the designated OWS POC(s) within [***] of award.
b.  [***].
H.7Performance Based Payment Liquidated under Termination
Performance Based Payments (PBPs) have been authorized as a method of financing under this contract.  In the event the Moderna’s mRNA-1273 COVID Vaccine is unsuccessful in its bid to obtain EUA or FDA approval, the Government may issue a Termination for Convenience (T4C) in whole or in part, on this contract.  Upon notice of a T4C, the contractor shall submit a termination settlement proposal, IAW FAR 52.249-2.  Termination for Convenience of the Government (Fixed-Price).
H.8Public Readiness and Emergency Preparedness (PREP) Act:

W911QY20C0100
[***]
Page 18 of 23

In accordance with the Public Readiness and Emergency Preparedness Act (“PREP Act”), Pub. L. No. 109-148, Division C, Section 2, as amended (codified at 42 U.S.C. § 247d-6d and 42 U.S.C. § 247d-6e), as well as the Secretary of HHS’s Declaration Under the Public Readiness and Emergency Preparedness Act for Medical Countermeasures Against COVID-19. 85 Fed. Reg. 15198 (Mar. 17, 2020, effective Feb. 4. 2020), and amended on April 15. 2020. 85 Fed. Reg. 21012 (together, the “Prep Act Declaration”):
(i) This Agreement is being entered into for purposes of facilitating the manufacture, testing, development, distribution, administration, and use of “Covered Countermeasures” for responding to the CO VID-19 public health emergency, in accordance with Section VI of the PREP Act Declaration;
(ii) Contractor’s performance of this Agreement falls within the scope of the “Recommended Activities” for responding to the COVID-19 public health emergency, to the extent it is in accordance with Section III of the PREP Act Declaration; and
(iii) Contractor is a “Covered Person” to the extent it is a person defined in Section V of the PREP Act Declaration.
Therefore, in accordance with Sections IV and VII of the PREP Act Declaration as well as the PREP Act (42 U.S.C. § 247d-6d), the Department of Defense contracting via assisted acquisition on behalf of the HHS, expressly acknowledges and agrees that the HHS Declaration cited above, specifically its language providing immunity from suit and liability is applicable to this acquisition as long as Contractors activities fall within the terms and conditions of the PREP Act and the PREP Act Declaration.
The Government may not use, or authorize the use of, any products or materials provided under this contract, unless such use occurs in the United States (or a U.S. territory where U.S. law applies such as embassies, military and NATO installations) and is protected from liability under a declaration issued under the PREP Act, or a successor CO VID-19 PREP Act Declaration of equal or greater scope.  Any use where the application of the PREP Act is in question will be discussed with Moderna prior to use and, if the parties disagree on such use, the dispute will be resolved according to the “Disputes Clause” (52.233-1)
The items and technology covered by tins Contract are being developed for both civil and military applications.
H.9[***] .
H.10[***].
H.11[***].
H.12Transportation to Final Destination
During the course of performance under this contract, the Government may require storage of the filled drag product (FDP) before delivery to the final government location.  In these circumstances, the Government will accept FDP at the contractor facility (Origin).  The contractor; however, shall continue to be responsible for secure delivery of the vaccine to its final destination as identified on this contract.  [***].
H.13Validation of IP/Data
The Parties acknowledge that background intellectual property and technical data assertions have been made and evaluated by the parties.  The parties agree that, should additional information relevant to these assertions become available, the parties will reevaluate said assertions as necessary in the future.
H.14Novation
Upon Moderna, US, Inc.’s registration in the System for Award Management, the Government will, at the Contractor’s request, complete a novation of this Contract to recognize Moderna US, Inc. as a counterparty instead 

W911QY20C0100
[***]
Page 19 of 23

of Moderna TX, Inc.  This novation will be completed through a modification executed by the Government that identifies Moderna US, Inc. as the contracting party for all purposes as if it had originally executed the Contract.
H.15Base & Option 1 Delivery Acceleration
In an effort to accelerate production of the mRNA-1273 vaccine, [***] within the Option 1 period via a Modification to the contract.  If these manufacturing slots are successfully utilized, [***] above what was projected by Moderna and assumed within the price per dose for the doses of mRNA-1273 vaccine delivered in the Base Period and Option 1.  However, because the Government is funding the additional slots within the Base and Option 1 periods in order to accelerate production, the Government is entitled to an adjustment under the conditions outlined.  The Government and Moderna agree to the following:
1.  If the Government exercises Option 2 (NLT 15 May):
a.  Moderna will reduce the cost of Option 2 by [***] for each successfully accelerated drag product fill under the Base Period [***] and [***] for each successfully accelerated drag product fill under Option 1 [***].
2.  If the Government does not exercise Option 2 (NLT 15 May):
a.  In the event Moderna timely cancels the manufacturing slots and/or is able to otherwise fully utilize the slots originally reserved for production in the Option 2 period, Moderna agrees to credit the Government [***] for [***] and [***] for [***].  In no case shall the number of drug product manufacturing slots credited exceed the number of successfully accelerated drug product manufacturing fills under the Base Period and Option 1.  It is understood that Moderna will make all good-faith efforts to fdl reserved slots or cancel reservations in a timely manner (i.e. within the time period required by the subcontractor).
b.  In the event that Moderna is unable to fill those reserved slots (i.e. due to lack of demand) and cancels slots, Moderna shall be entitled to recoup those reservation cancellation costs from the USG.  The process is outlined as follows:
1.) Moderna shall submit documentation to the USG of the following:
i.)Cancellation notice to the subcontractor,
ii.) The basis of the cancellation, and
iii.) Cancellation fees incurred.
2.) Moderna shall reduce credits to the USG under paragraph 2a) of this clause.  IAW agreed cancellation costs incurred.
3.) Bi-lateral agreement of the final credit shall be included in a modification to the contract.  Net credit shall be deducted from final payments under the contract.
H.16Delivery Schedule, as revised H Feb 2021 via modification P00004
[***]

Moderna confirms that it will provide the USG with the first 300M doses manufactured within its US-based supply chain [***], with the exception of doses required for clinical studies.  The delivery schedule assumes that Moderna will work to further maximize fill/finish capacity by working with the FDA to increase fill volumes, [***].  Both parties acknowledge that resulting revisions to future accounting, invoicing, acceptance and delivery of doses subject to the revised label will be implemented via a subsequent modification.
H.17Post-Termination Disposition of Undelivered Product

W911QY20C0100
[***]
Page 20 of 23

For the avoidance of doubt, if the USG elects to terminate the exercised CLINs prior to acceptance and delivery in full of the required quantities of mRNA-1273, Moderna will be free to direct any unaccepted/undelivered supplies of mRNA-1273 to customers other than the USG, at its discretion, without further obligation of either party with regard to such unaccepted/undelivered supplies of mRNA-1273.  The contract will be bilaterally modified to decrease the quantities by the agreed upon volume.
H.18[***]. 
In order to facilitate projections and invoicing, the Government shall provide or direct a third party (e.g., McKesson) to provide to Moderna (1) actual quantities of Moderna [***] with 8.0mL vials during the reporting period; (2) actual quantities of Moderna [***] with 8.0mL vials during the reporting period; and (3) the number of [***] remaining in inventory and available for upcoming shipments.  This information will be provided to Moderna at a frequency of at least twice monthly.
For each 8.0mL fill volume (1600mcg) vial of vaccine shipped with a [***].
Both parties acknowledge that the delivery schedule is based on [***] 8.0mL fill volume (1600mcg) vial delivered.  In accordance with the agreed approach for invoicing and counting doses toward Moderna’s delivery requirement, [***].  Specifically for purposes of adhering to the scheduled delivery dates set forth in this contract for the Base Period.  Option 1 and Option 2, schedule shall be deemed to have been met once doses are released by Moderna and are available for order.

W911QY20C0100
[***]
Page 21 of 23

SECTION J -LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS
The following have been modified:
												
	Document Type
	Description
	Page #
	Date

	Exhibit A
	CDRLs
	15
	11 Feb 2021

	Attachment 0001
	Supply Chain Resiliency Plan for CDRL A010
	3
	23 July 2020

	Attachment 0002
	Security Plan
	7
	23 July 2020

	Attachment 0003
	Dose Tracking Template Draft Moderna
	Excel
	15 July 2020

	Attachment 0004
	Data Rights
	3
	7 August 2020

	Attachment 0005
	[***]
	2
	7 August 2020

	Attachment 0006
	ModernaTx. Inc. Background Intellectual Property
	3
	6 August 2020

	Attachment 0007
	Performance Base Payment Milestone Schedule
	2
	7 August 2020

	Attachment 0008
	Performance Base Payment Milestone Billing Plan
	17
	4 December 2020

	Attachment 0009
	HRPAS Moderna Letter
	1
	3 September 2020

(End of Summary of Changes)

																																																			
	AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT
	1. CONTRACT ID CODE
	PAGE OF PAGES

	1
	24

	2. AMENDMENT/MODIFICATION NO.
P00006
	3. EFFECTIVE DATE
4-Jun-2021
	4. REQUISITION/PURCHASE REQ. NO.
SEE SCHEDULE
	5. PROJECT NO.(If applicable)
	6. ISSUED BY
W6QK ACC-APG NATICK DIVISION
BLDG 1 GENERAL GREENE AVENUE
NATICK MA 01760-5011
	CODE	W911QY	7. ADMINISTERED BY (If other than item 6)    
DEFENSE CONTRACT MANAGEMENT AGENCY
DCMA BOSTON
495 SUMMER STREET
BOSTON MA 02210-2138
	CODE	S2206A
			
	8. NAME AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code)
MODERNA US, INC.
[***]
200 TECHNOLOGY SQ
CAMBRIDGE MA 02139-3578
		9A. AMENDMENT OF SOLICITATION NO.
		9B. DATED (SEE ITEM 11)
	X	10A. MOD. OF CONTRACT/ORDER NO.
W911QY20C0100

	X	10B. DATED (SEE ITEM 13)
09-Aug-2020

	CODE    8PTM0
			FACILITY CODE
	11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS

		The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offer     is extended,     is not extended.
Offer mist acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended by one of the following methods: 
(a) By completing Items 8 and 15, and returning    copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted;
or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE
RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION
OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

	12. ACCOUNTING AND APPROPRIATION DATA (If required)
See Schedule

	13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS.
IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

		A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.

		B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B).

	X	C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:
See Block 14 Continuation Page

		D. OTHER (Specify type of modification and authority)

	E. IMPORTANT: Contractor      is not,     is required to sign this document and return     1     copies to the issuing office.

	14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)
Modification Control Number: [***]
See Block 14 Continuation Page
Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in foil force and effect.

	15A. NAME AND TITLE OF SIGNER (Type or print) 
Stephane Bancel, CEO
	16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)
[***]
TEL: [***]    EMAIL: [***]

	15B. CONTRACTOR/OFFEROR 
/s/ Stephane Bancel
        
(Signature of person authorized to sign)
	15C. DATE SIGNED	16B. UNITED STATES OF AMERICA
BY        
(Signature of Contracting Officer)
	16C. DATE SIGNED
4 Jun 2021

W911QY20C0100
(P00006)
Page 2 of 24

SECTION SF 30 BLOCK 14 CONTINUATION PAGE
SUMMARY OF CHANGES
SECTION SF 30 - BLOCK 14 CONTINUATION PAGE
The following have been added by full text:
OBLIGATION AMOUNT: $3,993,662.60
a.    The purpose of this modification (P00006) is to:
- Change the Purchasing Office from W911QY (NCD) to W58P05 (JCRD); the new Contracting Officer is [***] and Contract Specialist remains unchanged (Authority FAR 52.243-1)
- Update CLIN 0002 pricing for VMI Storage and obligate funding of $1,355,232.80; revise CLIN structure for 0002 to add 0002AA, 0002AB, 00002AC; void out CLINs 1002, 2002, 3002, 4002 (Authority FAR 52.243-1).
- Add Accelerated Distribution CLINs 0005, 0005AA, 0005AB, 0005AC, and fund in the amount of $2,638,429.80 (Authority FAR 43.103(a)).
- Revise Section E, Inspect and Acceptance (Authority FAR 52.243-1).
- Revise the Acceptor DODAAC from W911QY to W58P05 in FAR Clause 252.232-7006 (Authority FAR 52.243-1)
b.    This modification was requested by the program office to meet the Government’s mission requirements.
c.    The total value of the contract has increased by $3,993,662.60 from $8,141,598,000 to $8,145,591,662.60.  The total funded amount has increased by $3,993,662.60 from $4,841,598,000 to $4,845,591,662.60.
All other terms and conditions remain unchanged.  Please see below for details.
The following have been modified:
OBLIGATION AMOUNT: $1,650,000,000
a.    The purpose of this modification (P00004) is to:
- Exercise, fund Option 2 CLINs 2001AA, 2001AB, 2001AC for a total of $1,650,000,000 (Authority FAR 52.217- 7)
- Add clauses H. 16 & H. 17, and revise the delivery schedule for the Base period, Option 1, and Option 2 IAW the table contained within H. 16 (Authority FAR 43.103(a)(3), Mutual Agreement of the Parties)

W911QY20C0100
(P00006)
Page 3 of 24

- Revise the table in Section G back to previous amounts, due to an administrative error on modification no. P00003, where the amounts were revised (Authority FAR 52.232-16)
- Update Contract Data Requirement List (CDRL) no.’s A003, A008, A009, A011, A014, A021, and the corresponding information to the CDRLs in Section C, Statement of Work, (Authority FAR 43.103(a)(3), Mutual Agreement of the Parties)
b.    This modification was requested by the program office to meet the Government’s mission requirements.
c.    The total contract value and total funded amount has increased by $ 1.650.000.000 from $3.191.598.000 to $4,841,598,000.
All other terms and conditions remain unchanged.  Please see below for details.
SECTION A -SOLICITATION/CONTRACT FORM
The total cost of this contract was increased by $3,993,662.60 from $4,841,598,000.00 to $4,845,591,662.60.
The ‘administered by’ organization has changed from
DEFENSE CONTRACT MANAGEMENT AGENCY
DCMA BOSTON
495 SUMMER STREET
BOSTON MA 02210-2138
to
DEFENSE CONTRACT MANAGEMENT AGENCY
DCMA BOSTON
37 GRENIER STREET, BLDG. 1108
HANSCOM AIR FORCE BASE MA 01731 -1600
SECTION B - SUPPLIES OR SERVICES AND PRICES
CLIN 0002
The pricing detail quantity has increased by 11.00 from 1.00 to 12.00.
The unit price amount has increased by $112,936.07 from $0.00 to $112,936.067.
The unit of issue has changed from Job to Months.
The cost constraint TBN has been deleted.
The total cost of this line item has increased by $1,355,232.80 from $0.00 to $1,355,232.80.
CLIN 1002
The CLIN description has changed from Vendor Managed Inventory to Void - Vendor Managed Inventory.
The CLIN extended description has changed from:
a.    The contractor shall secure, manage and maintain storage for up to 100M doses of mRNA-1273 vaccine and deliver to the designated government facility in accordance with Section F. 
b.    [***].

W911QY20C0100
(P00006)
Page 4 of 24

To:
VMI Storage requirements were consolidated into CLIN 0002 via modification P00006.  All other VMI Storage CLINs are hereby void.
The pricing detail quantity has decreased by 1.00 from 1.00 to 0.00.
The unit of issue Job has been deleted.
The option status has changed from Option to No Status.
The cost constraint TBN has been deleted.
CLIN 2002
The CLIN description has changed from Vendor Managed Inventory to Void - Vendor Managed Inventory.
The CLIN extended description has changed from:
a.  The contractor shall secure, manage and maintain storage for up to 100M doses of mRNA-1273 vaccine and deliver to the designated government facility in accordance with Section F. 
b.  [***].
To:
VMI Storage requirements were consolidated into CLIN 0002 via modification P00006.  All other VMI Storage CLINs are hereby void.
The pricing detail quantity has decreased by 1.00 from 1.00 to 0.00.
The unit of issue Job has been deleted.
The option status has changed from Option to No Status.
The cost constraint TBN has been deleted.
CLIN 3001
The CLIN extended description has changed from:
The contractor shall produce and deliver 100M doses of the SARS-CoV-2 mRNA-1273 Vaccine filled drug product (FDP), IAW Section C, Statement of Work (SOW) and CDRLs (Exhibit A) on this contract.
To:
The contractor shall produce and deliver 100M doses of the SARS-CoV-2 mRNA-1273 Vaccine filled drug product (FDP), IAW Section C, Statement of Work (SOW), and CDRLs (Exhibit A) on this contract.
CLIN 3002
The CLIN description has changed from Vendor Managed Inventory to Void - Vendor Managed Inventory.
The CLIN extended description has changed from:
The contractor shall secure, manage and maintain storage for up to 100M doses of mRNA-1273 vaccine and deliver to the designated government facility in accordance with Section F. 

W911QY20C0100
(P00006)
Page 5 of 24

b.  [***].
To:
VMI Storage requirements were consolidated into CLIN 0002 via modification P00006.  All other VMI Storage CLINs are hereby void.
The pricing detail quantity has decreased by 1.00 from 1.00 to 0.00.
The unit of issue Job has been deleted.
The option status has changed from Option to No Status.
The cost constraint TBN has been deleted.
CLIN 4001
The CLIN extended description has changed from:
The contractor shall produce and deliver 100M doses of the SARS-CoV-2 mRNA-1273 Vaccine filled drug product (FDP), IAW Section C, Statement of Work (SOW) and CDRLs (Exhibit A) on this contract.
To:
The contractor shall produce and deliver 100M doses of the SARS-CoV-2 mRNA-1273 Vaccine filled drug product (FDP), I AW Section C, Statement of Work (SOW), and CDRLs (Exhibit A) on this contract.
CLIN 4002
The CLIN description has changed from Vendor Managed Inventory to Void - Vendor Managed Inventory.
The CLIN extended description has changed from:
The contractor shall secure, manage and maintain storage for up to 100M doses of mRNA-1273 vaccine and deliver to the designated government facility in accordance with Section F. 
b.  [***].
To:
VMI Storage requirements were consolidated into CLIN 0002 via modification P00006.  All other VMI Storage CLINs are hereby void.
The pricing detail quantity has decreased by 1.00 from 1.00 to 0.00.
The unit of issue Job has been deleted.
The option status has changed from Option to No Status.
The cost constraint TBN has been deleted.

W911QY20C0100
(P00006)
Page 6 of 24

CLIN 0005 is added as follows:
																		
	ITEM NO	SUPPLIES/SERVICES	QUANTITY	UNIT	UNIT PRICE	AMOUNT
	0005	Accelerated Distribution
FFP
[***] associated with Base, Option 1, and Option 2 periods (300M doses total) to meet fluctuating CDC allocation requirements [***].	$0.00
					NET AMT	$0.00
		SUBCLIN 005AA is added as follows:				
	ITEM NO	SUPPLIES/SERVICES	QUANTITY	UNIT	UNIT PRICE	AMOUNT
	00055AA		1	Job	$879,476.60	$879,476.60
		Base Period
FFP
[***]
FOB: Destination
PURCHASE REQUEST NUMBER: [***]
PSC CD: 6505	
					NET AMT	$879,476.60
		ACRN AJ
CIN: GFEBS001165492700002				$879,476.60
		SUBCLIN 0005AB is added as follows:				
	ITEM NO	SUPPLIES/SERVICES	QUANTITY	UNIT	UNIT PRICE	AMOUNT
	0005AB		1	Job	$879,476.60	$879,476.60
		Option 1 Period
FFP
[***]
FOB: Destination
PURCHASE REQUEST NUMBER: [***]
PSC CD: 6505	
					NET AMT	$879,476.60
		ACRN AJ
CIN: GFEBS001165492700003				$879,476.60
		SUBCLIN 0005AC is added as follows:				
	ITEM NO	SUPPLIES/SERVICES	QUANTITY	UNIT	UNIT PRICE	AMOUNT
	0005AC		1	Job	$879,476.60	$879,476.60
		[***].  
FOB:  Destination PURCHASE REQUEST NUMBER: [***] 
PSC CD:  6505
	
					NET AMT	$879,476.60
		ACRN AJ
CIN: GFEBS001165492700004				$879,476.60

SECTION C -DESCRIPTIONS AND SPECIFICATIONS
The following have been modified:

W911QY20C0100
(P00006)
Page 7 of 24

STATEMENT OF WORK
LARGE SCALE PRODUCTION OF SARS-CoV-2 VACCINE
C.1SCOPE.  The Department of Defense and Health and Human Services (HHS) require large scale manufacturing of vaccine doses in support of the national emergency response to the Coronavirus Disease 2019 (COVID-19) for the United States Government (USG) and the US population.
C.1.1Background.  In December 2019, a novel coronavirus now known as SARS-CoV-2 was first detected in Wuhan, Hubei Province, People’s Republic of China, causing outbreaks of the coronavirus disease COVID-19 that has now spread globally.  The Secretary’ of Health and Human Service declared a public health emergency on January 31, 2020, under section 319 of the Public Health Service Act (42 U.S.C. 247d), in response to CO VID-19.  On March 1, 2020, the President of the United States, pursuant to sections 01 and 301 of the National Emergencies Act (50 U.S.C. 1601 et seq.) and consistent with section 1135 of the Social Security Act (SSA), as amended (42 U.S.C. 1320b-5), proclaimed that the COVID-19 outbreak in the United States constitutes a national emergency.
C.1.1.1Under Operation Warp Speed (OWS), the Department of Defense and HHS are leading a whole of nation effort to ensure development of promising vaccine, diagnostic and therapeutic candidates and ensure that these medical countermeasures are available in the quantities required to reduce SARS-CoV-2 transmission, identify prior and/or current infection, and improve patient care, thereby mitigating the impact of COVID-19 on the nation and its people.  The DoD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRD) is providing expertise and contracting support to HHS, in compliance with PL 115-92 Authorization Letter for DoD Medical Priorities, through an Interagency Agreement, signed April 23, 2020.  As OWS products progress to clinical trials to evaluate the safety and efficacy of vaccines and therapeutics, it is critical that, in parallel, the USG supports large scale manufacturing so that vaccine doses or therapeutic treatment courses are immediately available for nationwide access as soon as a positive efficacy signal is obtained and the medical countermeasures are authorized for widespread use.
C.1.2Objective: The objective of this effort is to obtain the following:
(a)Base Period: Large scale manufacturing of 100 million vaccine doses
(b)Option Period 1: Large scale manufacturing of 100 million vaccine doses
(c)Option Period 2: Large scale manufacturing of 100 million vaccine doses
(d)Option Period 3: Large scale manufacturing of 100 million vaccine doses
(e)Option Period 4: Large scale manufacturing of 100 million vaccine doses
The Base Period is [***], with overlapping options for a total of [***] if all options are exercised.
C.1.3Consistent with the Updated EUA Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) dated 01 April 2021, up to [***] may be extracted from Moderna’s newly authorized multidose vials with 8.0mL fill volume (1600mcg).  The Government and Moderna agree that [***] per vial are only attainable using premium low dead volume (LDV) syringes, which are in short supply globally.  Utilizing initial ancillary equipment, vaccine administration personnel can reliably extract [***] from these vials: however, the Government has identified needle/syringe combinations that can be used to extract [***].
C.1.3.1Given the two parties’ shared interest in reducing vaccine waste and accelerating the availability of Moderna’s SARS-CoV-2 vaccine doses, the Government and Moderna intend that the Moderna vaccines doses be administered with needles and syringes compatible with extraction of [***] when possible.  Toward this end, the Government shall maintain a list of syringe and/or needle combinations which will allow extraction of [***] per 8.0mL vial, which list shall be updated jointly by the Government and Moderna as any additional syringe and/or needle combinations compatible with extraction of [***]/vial are identified.  Furthermore, the Government will, to the extent that appropriate needles and syringes are available, assemble and ship kits containing sufficient quantities of syringes and needles compatible with extraction of [***] per vial (Kit Moderna [***]) with Moderna’s SARS-CoV-2 vaccine.  The Government expects that these kits will be available beginning 01 May 2021 for a significant 

W911QY20C0100
(P00006)
Page 8 of 24

portion of Moderna’s remaining deliveries.  If, however, appropriate syringes and needles are not available, the Government will revert to shipping the Kit Moderna [***] with Moderna’s SARS-CoV-2 vaccine.
C.2APPLICABLE DOCUMENTS
C.2.1Federal Documents:
C.2.1.1Title 21 Code of Federal Regulations (CFR), Food and Drugs: Part 210, Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs; General; and, Part 211, Current Good Manufacturing Practice In Manufacturing, Processing, Packing, or Holding of Drugs; General.  (https://www.ecfr.gov/cgi-bin/text- idx?SID=a95cab20f443897a400bb7e44a27cf4c&mc=tme&tpl=/ecfrbrowse/Title21/21cfrv4_02.tpl#0)
C.3REQUIREMENTS.  Independently, and not as an agent of the USG, in accordance with the Proposal submitted by Moderna US, Inc. in response to Solicitation Number W911QY20R0043, Titled, “Advanced Procurement of mRNA-1273 Vaccine for Prevention of SARS-CoV-2 Coronavirus (COVID-19)”), dated July 10, 2020 (and any subsequent USG-approved revisions thereto), the contractor shall provide all necessary services, qualified personnel, material, equipment and facilities (not otherwise provided by the USG under the terms of this contract) to perform the specific tasks set forth below.
C.3.1Contract Line Item Number (CLIN) 0001 - Base Period: Large Scale Manufacturing of 100 Million Vaccine Doses.
C.3.1.1The contractor shall complete all scope required for the production, release and delivery use of 100 million Final Drug Product (FDP) doses of a SARS-CoV-2 mRNA-1273 vaccine.  This shall include, the following tasks and other activities reasonably contemplated by such task:
C.3.1.1.1Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of [***].  (Based on FDP stability data that supports a [***] shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC.  Documents shall be provided under CDRL A002.  FDA Interactions and Inspections Documentation.
C.3.1.1.2cGMP manufacturing of 100 million doses fully compliant with 21 CFR 210 and 211.
C.3.1.1.3[***].
C.3.1.1.4[***].
C.3.1.1.5Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability and detection and response requirements, subject to any exceptions established by or the enforcement discretion of the FDA, including “Exemption from Certain Product Tracing and Product Identification Requirements Under Section 582 of the FD&C Act” (April 2020).
C.3.1.1.6In coordination with the USG, the contractor shall conduct a demonstration of the vaccine shipping process prior to the first delivery of FDP doses at a time mutually agreed to by the contractor and the USG.  Moderna shall provide specifications and details associated with the shipping process and containers (IAW CDRL A005) to enable the USG to adequately plan and prepare for potential distribution of the vaccine.
C.3.1.1.7Following release of product the contractor shall, promptly deliver product to the designated delivery site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below.  In the 

W911QY20C0100
(P00006)
Page 9 of 24

unforeseen event that a designated delivery site cannot receive product and the contractor provides storage beyond [***] days of product release, the contract will be subject to modification for acceptance purposes.
C.3.1.2Site Visits and Audits.  The contractor shall accommodate periodic or ad hoc site visits by BARD A and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.
C.3.1.2.1BARDA Audits.  If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.
C.3.1.2.2FDA Audits.  The Contractor shall notify the Contracting Officer and Contracting Officer’s Representative (COR) within [***] of a scheduled FDA audit or within [***] of an ad hoc site visit or audit if the FDA does not provide advance notice.  The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within [***] of receiving correspondence from the FDA or third party in accordance with CDRL A002.  The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within [***] of submittal of the audit report in accordance with CDRL A002.
C.3.1.2.3FDA Interactions. The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologies for the following, but not limited to: FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.
C.3.2CLIN 1001 - Option Period 1: Large Scale Manufacturing of 100 Million Vaccine Doses.
C.3.2.1The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine.  This shall include the following tasks and other activities reasonably contemplated by such tasks:
C.3.2.1.1Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of [***].  (Based on FDP stability data that supports a [***] shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC.  Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.
C.3.2.1.2cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA.
C.3.2.1.3[***].
C.3.2.1.4Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability and detection and response requirements subject to any exceptions established by or the enforcement discretion of the FDA.
C.3.2.1.5Following release of the product the contractor shall deliver the product to the designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below.  To the extent a natural disaster or other emergency affecting a designated delivery site restricts such site’s ability to receive product, the Contractor and the USG will promptly agree on an alternate USG delivery location, or storage as Vendor Managed Inventory (VMI) at the contractor site.

W911QY20C0100
(P00006)
Page 10 of 24

C.3.2.2Site Visits and Audits.  The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.
C.3.2.2.1BARDA Audits.  If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.
C.3.2.2.2FDA Audits.  The Contractor shall notify the Contracting Officer and COR within [***] of a scheduled FDA audit or within [***] of an ad hoc site visit or audit if the FDA does not provide advance notice.  The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within [***] of receiving correspondence from the FDA or third party in accordance with CDRL A015.  The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within [***] of submittal of the audit report in accordance with CDRL A002.
C.3.2.2.3FDA Interactions.  The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologies for the following, but not limited to: FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.
C.3.3CLIN 2001 - Option Period 2: Large Scale Manufacturing of 100 Million Vaccine Doses.
C.3.3.1The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine.  This shall include the following tasks and other activities reasonably contemplated by such tasks:
C.3.3.1.1Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of [***].  (Based on FDP stability data that supports a [***] shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC.  Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.
C.3.3.1.2cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA.
C.3.3.1.3[***].
C.3.3.1.4Ensuring that the product complies with the Drug Supply Chain Security Act (DSCSA).  Sections 581- 585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability’ and detection and response requirements, subject to any exceptions established by or the enforcement discretion of the FDA.
C.3.3.1.5Following release the contractor shall deliver product to the nearest designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below.  To the extent a natural disaster or other emergency affecting a designated delivery site restricts such site’s ability to receive product, the Contractor and the USG will promptly agree on an alternate USG delivery’ location, or storage as Vendor Managed Inventory (VMI) at the contractor site.
C.3.3.2Site Visits and Audits.  The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.
C.3.3.2.1BARDA Audits.  If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL AOOL

W911QY20C0100
(P00006)
Page 11 of 24

C.3.3.2.2FDA Audits.  The Contractor shall notify the Contracting Officer and COR within [***] of a scheduled FDA audit or within [***] of an ad hoc site visit or audit if the FDA does not provide advance notice.  The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within [***] of receiving correspondence from the FDA or third part) in accordance with CDRL A002.  The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if am are identified, within [***] of submittal of the audit report in accordance with CDRL A002.
C.3.3.2.3FDA Interactions.  The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologies for the following, but not limited to: FDA interactions.  FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.
C.3.4CLIN 3001 - Option Period 3: Large Scale Manufacturing of 100 Million Vaccine Doses.
C.3.4.1The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine.  This shall include the following tasks and other activities reasonably contemplated by such tasks:
C.3.4.1.1Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of [***].  (Based on FDP stability data that supports a [***] shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC.  Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.
C.3.4.1.2cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA.
C.3.4.1.3[***].
C.3.4.1.4Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA).  Sections 581-585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability and detection and response requirements subject to any exceptions established by or the enforcement discretion of the FDA.
C.3.4.1.5Following release of the product the contractor shall deliver the product to the designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below.  To the extent a natural disaster or other emergency affecting a designated delivery site restricts such site’s ability to receive product, the Contractor and the USG will promptly agree on an alternate USG delivery location, or storage as Vendor Managed Inventory’ (VMI) at the contractor site.
C.3.4.2Site Visits and Audits.  The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.
C.3.4.2.1BARDA Audits.  If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.
C.3.4.2.2FDA Audits.  The Contractor shall notify the Contracting Officer and COR within [***] of a scheduled FDA audit or within [***] of an ad hoc site visit or audit if the FDA does not provide advance notice.  The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within [***] of receiving correspondence from the FDA or third party in accordance with CDRL A015.  The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within [***] of submittal of the audit report in accordance with CDRL A002.

W911QY20C0100
(P00006)
Page 12 of 24

C.3.4.2.3FDA Interactions.  The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding mRNA-1273 for the following, but not limited to: FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.
C.3.5CLIN 4001 - Option Period 4: Large Scale Manufacturing of 100 Million Vaccine Doses.
C.3.5.1The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine.  This shall include the following tasks and other activities reasonably contemplated by such tasks:
C.3.5.1.1Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of [***].  (Based on FDP stability data that supports a [***] shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC.  Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.
C.3.5.1.2cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA.
C.3.5.1.3[***].
C.3.5.1.4Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability and detection and response requirements subject to any exceptions established by or the enforcement discretion of the FDA.
C.3.5.1.5Following release of the product the contractor shall deliver the product to the designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below.  To the extent a natural disaster or other emergency affecting a designated delivery site restricts such site’s ability to receive product, the Contractor and the USG will promptly agree on an alternate USG delivery location, or storage as Vendor Managed Inventory (VMI) at the contractor site.
C.3.5.2Site Visits and Audits.  The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.
C.3.5.2.1BARDA Audits.  If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.
C.3.5.2.2FDA Audits.  The Contractor shall notify the Contracting Officer and COR within [***] of a scheduled FDA audit or within [***] of an ad hoc site visit or audit if the FDA does not provide advance notice.  The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within [***] of receiving correspondence from the FDA or third party in accordance with CDRL A015.  The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within [***] of submittal of the audit report in accordance with CDRL A002.
C.3.5.2.3FDA Interactions.  The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologies for the following, but not limited to: FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.

W911QY20C0100
(P00006)
Page 13 of 24

C.4CLIN 0002: Data Deliverables.  The contractor shall provide the following in accordance with the Contract Data Requirements List (CDRL), DD Forms 1423, provided at Appendix A.
C.4.1Monthly Inventory Report (CDRL A003), detailing at a minimum, raw materials, formulated LNPs, and the fill, finish, and released product.
C.4.2Quality Management Plan.  The contractor shall provide a Quality Management Plan, in accordance with CDRL A004, describing the quality policy and objectives, management review, competencies and training, process document control, feedback, evaluation, corrective action and preventive action, process improvement, measurement, and data analysis processes.  The framework is normally divided into infrastructure, senior management responsibility, resource management, lifecycle management, and quality management system evaluation.
C.4.3Shipping Documentation (CDRL A005) for all Finished Drug Product (FDP) transferring from the contractor’s fill/finish facility to a USG facility.  The contractor shall obtain concurrence on planned shipment protocols prior to transport.
C.4.4Expiring Items Report (CDRL A006) for all FDP in the USG’s possession.
C.4.5Key Personnel Listing (CDRL A007).
C.4.6Monthly Technical Progress Report (CDRL A008), to include an Integrated Master Schedule, identifying key activities and contract status.
C.4.7Final Technical Report (CDRL A009), documenting the work performed and results obtained for the entire contract period of performance.
C.4.8Supply Chain Resiliency Plan (SCRP).  The contractor shall provide, in accordance with CDRL A010 and CDRL Attachment 0001, a comprehensive SCRP that provides for identification and reporting of critical components associated with the secure supply of drug substance, drug product, and work-in-process through to finished goods, and key equipment suppliers and their locations, including addresses, points of contact, and work performed per location, to include subcontractors.
C.4.9[***].
C.4.10Manufacturing Reports and Dose Tracking.  The Contractor shall provide, in accordance with CDRL A013, manufacturing reports and manufacturing dose tracking projections and actuals utilizing the USG-provided “COVID-19 Dose Tracking Template” (CDRL Attachment 0003).
C.4.11Product Acceptance Report (for each lot of Drug Product).  The contractor shall provide, in accordance with CDRL A014, pictures of the drug product with lot number, drug product lot tree, list of associated deviations (from drug substance and product), and a Certificate of Analysis.
C.4.12Incident Report.  The contractor shall communicate to BARDA and document all critical programmatic concerns, issues, or probable risks that have or are likely to significantly impact project schedule and/or cost and/or performance in accordance with CDRL A016.  “Significant” is frequently defined as a [***] or greater cost or schedule variance within a control account, but should be confirmed in consultation with the COR.  Incidents that present liability to the project even without cost/schedule impact, such as breach of GCP during a clinical study, shall also be reported.
C.4.13FDA Correspondence.  The contractor shall provide any correspondence between Contractor and FDA relevant to the scope of this contract and submit in accordance with CDRL AO 17.

W911QY20C0100
(P00006)
Page 14 of 24

C.4.14Press Releases.  The contractor shall accurately and factually represent the work conducted under this contract in all press releases.  The contractor shall provide an advance copy of any press release in accordance with CDRL AO 18.
C.4.15Manufacturing Development Plan.  The contractor shall provide a Manufacturing Development Plan, in accordance with CDRL A025, describing the manufacturing process for the drug/biologic product to ensure conformity’ with §501(a)(2)(B) of the Food, Drug, and Cosmetics Act (FD&C Act, Title 21 United States Code (USC) §351 (a)(2)(B)), regarding good manufacturing practices (GMP).
C.5Administration.
C.5.1Post Award Teleconference.  The contractor shall host a Post Award Teleconference within 15 calendar days after contract award.
C.5.1.1The contractor shall provide an Agenda, IAW CDRL A020, detailing the planned activities for the subsequent 30 calendar days and shall discuss agenda items for the Post Award Kickoff Meeting.
C.5.1.2The contractor shall provide Meeting Minutes IAW CDRL A021.
C.5.2Post Award Kickoff Meeting.  The contracting officer may request the contractor host a contract Kick-Off Meeting within 30 calendar days after contract award via teleconference.  The contracting officer shall establish the date and time of the conference and prepare the agenda to include discussion on contract activities and schedule.
C.5.3Bi-Weekly Teleconference.  The contractor shall participate in bi-weekly teleconferences (or more frequent meetings required by the USG if warranted based on contract activities) to discuss performance on the contract.
C.5.4The contractor shall provide an Agenda.  IAW CDRL A020; Meeting Minutes in accordance with CDRL A02L and, Presentation Material in accordance with CDRL A022 for each of the aforementioned teleconferences or meetings throughout the contract period of performance.
C.5.5Daily “Check-In”.  The contractor shall participate in a daily “check-in” (via teleconference or email) to address key cost, schedule and technical updates.  Daily updates may be shared with senior USG leaders during the CO VID-19 response and should be provided on a non-confidential basis, unless the update includes confidential information in which case, the contractor shall provide the update in both confidential and non-confidential formats.  Daily check-ins may occur on weekdays, excluding federal holidays.  Upon request of the USG, check-ins may also occur on weekends and on federal holidays, provided at least 24 hours’ notice.
C.6Security.
C.6.1Access and General Protection/Security Policy and Procedures.  The contractor shall provide all information required for background checks necessary’ to access critical information related to OWS, and to meet USG installation access requirements to be accomplished by the installation Director of Emergency Services or Security Office.  The contractor employees shall comply with all personnel identity verification requirements as directed by the USG and/or local policy.  In addition to the changes otherwise authorized by the changes clause of this contract, should the security status of OWS change the USG may require changes in the contractor’s security matters or processes.  In addition to the industry standards for employment background checks, the contractor shall be willing to have key individuals, in exceptionally sensitive positions, identified for additional vetting by the United States USG.
C.6.2Security Program and Plan.  The contractor shall implement a comprehensive security program that provides overall protection of personnel, information, data, and facilities associated with fulfilling the USG’s requirement.  The contractor’s security’ practices and procedures shall be detailed in a Security Plan, in accordance with CDRL A019, and shall demonstrate how the contractor shall meet and adhere to the security requirements outlined in CDRL Attachment 0002.  This plan shall be delivered to the USG within 45 days of award, and the USG 

W911QY20C0100
(P00006)
Page 15 of 24

will review in detail and submit comments within ten (10) business days to the Contracting Officer (CO) to be forwarded to the Contractor.  The Contractor shall review the Security Plan comments, and, submit a final Security Plan to the U.S. USG within thirty (30) calendar days after receipt of the comments.  The Security Plan shall include a timeline for compliance of all the required security measures outlined in CDRL Attachment 0002.
C.6.3Operational Security (OPSEC).  The contractor shall develop and submit an OPSEC Standard Operating Procedure (SOP)ZPlan IAW CDRL A024.  The contractor shall identify in the SOP/Plan critical information related to this contract, why it needs to be protected, where it is located, who is responsible for it, and how to protect it.
C.7CLIN 0002 Vendor Managed Inventory (VMI).  The Contractor shall provide the capability to store the vaccine for up to [***], up to 100M doses of mRNA-1273 vaccine, in accordance with product labeling.  The contractor shall, in accordance with paragraph C.3.1.1.6, ensure the product storage of FDP doses for up to [***] prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  [***].  The contractor shall store the product to insure product quality with audible alarms and contacting.  The contractor shall notify the USG within [***] of detection of an incident with the potential to impact product quality, and implement corrective actions to mitigate the incident.  B ARDA/JPEO- CBRND personnel may conduct Quality Audits of the storage facility, when deemed necessary.  The contractor shall notify the USG of Corrective/Preventive actions within [***] of detection of an incident with potential to impacts product qualify, BARDA/JPEO-CBRND personnel may conduct Quality Audits of the storage facility, when deemed necessary.
C.7.1The USG will provide the contractor advance notice of the required delivery locations for the vaccine.  The contractor shall ship mRNA-1273 vaccines to designated locations [***] in the United States.  The contractor shall be responsible for shipment of all vaccine product whether acceptance is conducted [***].  
C.7.2The vaccine product shall be shipped and tracked by the distribution vendor’s shipping tracking number, to the USG-designated sites within the continental United States.
C.7.3[***].  Notwithstanding either of the foregoing sentences, the contractor shall not be liable for loss of or damage to supplies caused by the negligence of officers, agents, or employees of the USG acting within the scope of their employment.
SECTION E -INSPECTION AND ACCEPTANCE
												
	The following Acceptance/Inspection Schedule was added for CLIN 0005:
	INSPECT AT	INSPECT BY	ACCEPT AT	ACCEPT BY
	N/A	N/A	N/A	N/A

												
	The following Acceptance/Inspection Schedule was added for SUBCLIN 0005AA:
	INSPECT AT	INSPECT BY	ACCEPT AT	ACCEPT BY
	Origin	Government	Origin	Government

												
	The following Acceptance/Inspection Schedule was added for SUBCLIN 0005AB:
	INSPECT AT	INSPECT BY	ACCEPT AT	ACCEPT BY
	Origin	Government	Origin	Government

W911QY20C0100
(P00006)
Page 16 of 24

												
	The following Acceptance/Inspection Schedule was added for SUBCLIN 0005AC:
	INSPECT AT	INSPECT BY	ACCEPT AT	ACCEPT BY
	Origin	Government	Origin	Government

The following have been modified:
E.1Inspection:
Vaccine CLINs:
Quality inspection of Filled Drug Product (FDP) shall occur when the Contractor performs release testing to confirm that products complies with Contractor’s release specifications and criteria.  Contractor will submit the Certificate of Analysis for quality inspection of all drug product lots in BARDA Data Infrastructure (BDI) system.  Initial Inspection under this contract will be performed at the Contractor’s facility, or the subcontractor facility, by the BARDA Contracting Officer Technical Representative (COTR).
The Government shall inspect each shipment of product delivered to it hereunder for visible damage and quantity [***] of final delivery.  In the event Contractor supplies any product to the Government and it is established that such Product was damaged or does not include the required quantities at the time of final delivery, the Government shall promptly notify Contractor in writing [***].  A BDI extract of the inspection documentation shall also be submitted in Wide Area Workflow (WAWF) as supporting documentation for invoice submittals.
Storage CLIN:
Inspection of storage under this contract will be performed at destination by a duly authorized representative of the Government.  Contractor shall submit an invoice into WAWF at the end of each month during the period of performance specified.
Accelerated Distribution CLIN:
Inspection of Accelerated Distribution shall occur at origin when the Contractor completes deliveries for each ordering period: a).  Base Period, b).  Option 1 Period, and c).  Option 2 Period.  Contractor shall submit an invoice against the appropriate subCLIN under CLIN 0005 in WAWF, accordingly.  Inspection will be conducted by the BARDA Contracting Officer’s Technical Representative (COTR) to ensure all vaccines doses have been delivered.
Data CLIN:
Inspection of all reports and Contract Data Requirement List (CDRL) under this contract will be performed at Destination by a duly authorized representative of the Government.
E.2Acceptance
a.  Acceptance [***].  Acceptance [***].  Regardless of where acceptance occurs, the contractor is responsible for final delivery of Filled Drug Product (FDP) to a government designated CDC location.
b.  Acceptance of vaccines under this agreement will be performed by the COTR in the BDI system, which constitutes government acceptance at origin.  Documentation of acceptance shall be submitted in accordance with WAWF instructions.
c.  Acceptance of storage & accelerated distribution shall occur in WAWF by the KO.

W911QY20C0100
(P00006)
Page 17 of 24

d.  The parties acknowledge that acceptance may depend on the compliance with the Contractor’s product specifications.  The KO and COR may prior to acceptance consult with FDA under its authority under Public Law 115-92 to determine whether the material to be delivered meets the Contractor’s product specifications.  To this end, Contractor agrees to provide a letter to FDA authorizing the Government to engage in dialog with FDA about the ultimate compliance of this product with the Contractor’s product specifications prior to acceptance.  BARDA/COR will accept product according to the approved Product Acceptance Procedure.
SECTION F -DELIVERIES OR PERFORMANCE
The following Delivery Schedule Item has been deleted from CLIN 0002:
												
	DELIVERY DATE	QUANTITY	SHIP TO ADDRESS	DODAAC /
CAGE
	[***]	[***]	N/A
FOB: Destination	

The following Delivery Schedule item has been added to CLIN 0002:
												
	DELIVERY DATE	QUANTITY	SHIP TO ADDRESS	DODAAC /
CAGE
	[***]	[***]	[***]
FOB: Destination 
	[***]

The following Delivery’ Schedule for SUBCLIN 0005AA has been added:
												
	DELIVERY DATE	QUANTITY	SHIP TO ADDRESS	DODAAC /
CAGE
	[***]	[***]	[***]
FOB: Destination 
	[***]

The following Delivery Schedule for SUBCLIN 0005AB has been added:
												
	DELIVERY DATE	QUANTITY	SHIP TO ADDRESS	DODAAC /
CAGE
	[***]	[***]	[***]
FOB: Destination 
	[***]

The following Delivery Schedule for SUBCLIN 0005AC has been added:
												
	DELIVERY DATE	QUANTITY	SHIP TO ADDRESS	DODAAC /
CAGE
	[***]	[***]	[***]
FOB: Destination 
	[***]

W911QY20C0100
(P00006)
Page 18 of 24

The following Delivery’ Schedule for CLIN 1002 has been deleted:
												
	DELIVERY DATE	QUANTITY	SHIP TO ADDRESS	DODAAC /
CAGE
	[***]	[***]	N/A
FOB: Destination 
	

The following Delivery Schedule for CLIN 2002 has been deleted:
												
	DELIVERY DATE	QUANTITY	SHIP TO ADDRESS	DODAAC /
CAGE
	[***]	[***]	N/A
FOB: Destination 
	

The following Delivery Schedule for CLIN 3002 has been deleted:
												
	DELIVERY DATE	QUANTITY	SHIP TO ADDRESS	DODAAC /
CAGE
	[***]	[***]	N/A
FOB: Destination	

The following Delivery Schedule for CLIN 4002 has been deleted:
												
	DELIVERY DATE	QUANTITY	SHIP TO ADDRESS	DODAAC /
CAGE
	[***]	[***]	N/A
FOB: Destination	

SECTION G -CONTRACT ADMINISTRATION DATA
Accounting and Appropriation
Summary for the Payment Office
As a result of this modification, the total funded amount for this document was increased by $3,993,662.60 from $4,841,598,000.00 to $4,845,591,662.60.
CLIN 0002:
AJ: [***] was increased by $1,355,232.80 from $0.00 to $1,355,232.80
The contract ACRN AJ has been added.
The CIN [***] has been added.
SUBCLIN 0005AA:
Funding on SUBCLIN 0005AA is initiated as follows:
ACRN: AJ

W911QY20C0100
(P00006)
Page 19 of 24

CIN: [***]
Acctng Data: [***]
Increase: $879,476.60
Total: $879,476.60
SUBCLIN 0005AB:
Funding on SUBCLIN 0005AB is initiated as follows:
ACRN: AJ
CIN: [***]
Acctng Data: [***]
Increase: $879,476.60
Total: $879,476.60
SUBCLIN 0005AC:
Funding on SUBCLIN 0005AC is initiated as follows:
ACRN: AJ
CIN: [***]
Acctng Data: [***]
Increase: $879,476.60
Total: $879,476.60
The following have been modified:
G.1GOVERNMENT CONTRACT ADMINISTRATION
In no event shall any understanding or agreement, contract modification, change order, or other matter in deviation from the terms of this contract between the Contractor and a person other than the Contracting Officer be effective or binding upon the Government.  All such actions must be formalized by a proper contractual document executed by the Contracting Officer.
Procuring Contracting Officer:
[***]
Joint COVID-19 Response Division
US Army Contracting Command
6472 Integrity Court (Building 4401)
Aberdeen Proving Ground, MD 21005-3013
Contract Specialist:
[***]
Joint COVID-19 Response Division

W911QY20C0100
(P00006)
Page 20 of 24

US Army Contracting Command
6472 Integrity Court (Building 4401)
Aberdeen Proving Ground, MD 21005-3013
G.2GOVERNMENT TECHNICAL POINT OF CONTACT
[***]
Biologist/Project Officer
200 C Street, SW
Washington, DC 20201
G.3CONTRACTOR’S CONTRACT ADMINISTRATION
[***]
Moderna US, Inc.
200 Technology SQ.
Cambridge, MA 02139-3578
G.4PLACES OF PERFORMANCE
Moderna US. Inc.
200 Technology SQ.
Cambridge, MA 02139-3578
G.5NOTIFICATION OF REVISIONS AND CHANGE
Notification of revision or changes to names or email addresses will be provided by official correspondence from the PCO/ACO or office of the PCO/ACO in lieu of a contract modification.  This does not apply to any such revisions or changes in the event this contract includes a key personnel clause.
G.6PERFORMANCE BASED PAYMENT
Performance-based payments (PBP) are authorized under this contract in accordance with FAR 52.232-32.  The contractor shall bill for the PBP upon achievement of the completion criteria identified in Attachment 0007, Performance-based Payment Milestone Table dated 4 May 2021.  Upon achievement of the completion criteria, the contractor shall bill for the PBP for the base and each option I AW the following schedule:									
	CLIN	PERIOD	AMOUNT
	0001AA	BASE	$    90,210,000
	0001AB	BASE	$    132,308,000
	0001AC	BASE	$    180,420,000
	0001AD	BASE	$    198,462,000
	TOTAL		$    601,400,000
			
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]		[***]
			
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]		[***]

W911QY20C0100
(P00006)
Page 21 of 24

Delivery Invoicing: PBPs are a type of contract financing and are recouped by the Government through deductions of payments otherwise due to the contractor for the partial or complete delivery of contract items.  The deductions are made by applying a liquidation rate to the price of delivered contract items. Attachment 0008.  Performance-based Payment Milestone Billing Plan, identifies the contractor invoicing schedule for liquidation.  The contractor shall submit all invoices IAW Attachment 0008.
252.232-    7006 WIDE AREA WORKFLOW PAYMENT INSTRUCTIONS (DEC 2018)
(a)Definitions.  As used in this clause—
“Department of Defense Activity Address Code (DoDAAC)” is a six position code that uniquely identifies a unit, activity, or organization.
“Document type” means the type of payment request or receiving report available for creation in Wide Area WorkFlow (WAWF).
“Local processing office (LPO)” is the office responsible for payment certification when payment certification is done external to the entitlement system.
“Payment request” and “receiving report” are defined in the clause at 252.232-7003, Electronic Submission of Payment Requests and Receiving Reports.
(b)Electronic invoicing.  The WAWF system provides the method to electronically process vendor payment requests and receiving reports, as authorized by Defense Federal Acquisition Regulation Supplement (DFARS) 252.232- 7003, Electronic Submission of Payment Requests and Receiving Reports.
(c)WAWF access.  To access WAWF.  the Contractor shall—
(1)Have a designated electronic business point of contact in the System for Award Management at https://www.sam.gov; and
(2)Be registered to use WAWF at https://wawf.eb.mil/ following the step-by-step procedures for self-registration available at this web site.
(d)WAWF training.  The Contractor should follow the training instructions of the WAWF Web-Based Training Course and use the Practice Training Site before submitting payment requests through WAWF.  Both can be accessed by selecting the “Web Based Training” link on the WAWF home page at https://wawf.eb.miF.
(e)WAWF methods of document submission.  Document submissions may be via web entry.  Electronic Data Interchange, or File Transfer Protocol.
(f)WAWF payment instructions.  The Contractor shall use the following information when submitting payment requests and receiving reports in WAWF for this contract or task or delivery order:
(i)Document type.  The Contractor shall submit payment requests using the following document type(s):
COMBO

W911QY20C0100
(P00006)
Page 22 of 24

(ii)For fixed price line items—
(A) That require shipment of a deliverable, submit the invoice and receiving report specified by the Contracting Officer.
Invoice and receiving report document type
(B) For services that do not require shipment of a deliverable, submit either the Invoice 2-in-1, which meets the requirements for the invoice and receiving report, or the applicable invoice and receiving report, as specified by the Contracting Officer.
N/A
(iii)For customary progress payments based on costs incurred, submit a progress payment request.
(iv)For performance based payments, submit a performance based payment request.
(v)For commercial item financing, submit a commercial item financing request.
(2)Fast Pay requests are only permitted when Federal Acquisition Regulation (FAR) 52.213-1 is included in the contract.
(3)Document routing.  The Contractor shall use the information in the Routing Data Table below only to fill in applicable fields in WAWF when creating payment requests and receiving reports in the system.
Routing Data Table
						
	Field Name in HA IFF
	Data to be entered in WA WF

	Pay Official DoDAAC
	HQ0337

	Issue By DoDAAC
	W911QY

	Admin DoDAAC
	S2206A

	Inspect By DoDAAC
	W56XNH

	Acceptor
	W911QY

	Ship To
	TDB

(4)Payment request.  The Contractor shall ensure a payment request includes documentation appropriate to the type of payment request in accordance with the payment clause, contract financing clause, or Federal Acquisition Regulation 52.216-7, Allowable Cost and Payment, as applicable.
(5)Receiving report.  The Contractor shall ensure a receiving report meets the requirements of DFARS Appendix F.
(g)WAWF point of contact.
(1)The Contractor may obtain clarification regarding invoicing in WAWF from the following contracting activity’s WAWF point of contact.
[***] / DCMA Boston-AFAW.  Administrative Contracting Officer / [***]
(2)Contact the WAWF helpdesk at [***], if assistance is needed.
(End of clause)

W911QY20C0100
(P00006)
Page 23 of 24

FOR REFERENCE:
DFARS PGI 204.7108 Payment Instructions Table
https://www.acq.osd.mi1/dpap/dars/pgi/pgi_htm/current/PGI204_71.htm#payment_instructions

W911QY20C0100
(P00006)
Page 24 of 24

SECTION J -LIST OF DOCUMENTS; EXHIBITS AND OTHER ATTACHMENTS
The following have been modified:
												
	Document Type	Description	Page #	Date
	Exhibit A	CDRLs	15	11 Feb 2021
	Attachment 0001	Supply Chain Resiliency Plan for CDRL A010	3	23 July 2020
	Attachment 0002	Security Plan	7	23 July 2020
	Attachment 0003	Dose Tracking Template Draft Moderna	Excel	15 July 2020
	Attachment 0004	Data Rights	3	7 August 2020
	Attachment 0005	[***]	2	7 August 2020
	Attachment 0006	ModernaTx, Inc. Background Intellectual Property	3	6 August 2020
	Attachment 0007	Performance Base Payment Milestone Schedule	2	7 August 2020
	Attachment 0008	Performance Base Payment Milestone Billing Plan	17	4 December 2020
	Attachment 0009	HRPAS Moderna Letter	1	3 September 2020

(End of Summary of Changes)

																																																			
	AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT
	1. CONTRACT ID CODE
	PAGE OF PAGES

	1
	29

	2. AMENDMENT/MODIFICATION NO.
P00007
	3. EFFECTIVE DATE
15-Jun-2021
	4. REQUISITION/PURCHASE REQ. NO.
SEE SCHEDULE
	5. PROJECT NO.(If applicable)
	6. ISSUED BY
W6QK ACC-APG NATICK DIVISION
BLDG 1 GENERAL GREENE AVENUE
NATICK MA 01760-5011
	CODE	W58Po5	7. ADMINISTERED BY (If other than item 6)    
DEFENSE CONTRACT MANAGEMENT AGENCY
DCMA BOSTON
495 SUMMER STREET
BOSTON MA 02210-2138
	CODE	S2206A
			
	8. NAME AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code)
MODERNA US, INC.
[***]
200 TECHNOLOGY SQ
CAMBRIDGE MA 02139-3578
		9A. AMENDMENT OF SOLICITATION NO.
		9B. DATED (SEE ITEM 11)
	X	10A. MOD. OF CONTRACT/ORDER NO.
W911QY20C0100

	X	10B. DATED (SEE ITEM 13)
09-Aug-2020

	CODE    8PTM0
			FACILITY CODE
	11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS

		The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offer     is extended,     is not extended.
Offer mist acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended by one of the following methods: 
(a) By completing Items 8 and 15, and returning    copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted;
or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE
RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION
OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

	12. ACCOUNTING AND APPROPRIATION DATA (If required)
See Schedule

	13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS.
IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

		A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.

		B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B).

	X	C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:
See Block 14 Continuation Page

		D. OTHER (Specify type of modification and authority)

	E. IMPORTANT: Contractor      is not,     is required to sign this document and return     1     copies to the issuing office.

	14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)
Modification Control Number: [***]
See Block 14 Continuation Page
Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in foil force and effect.

	15A. NAME AND TITLE OF SIGNER (Type or print) 
Stephane Bancel, CEO
	16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)
[***]
TEL: [***]    EMAIL: [***]

	15B. CONTRACTOR/OFFEROR 
/s/ Stephane Bancel
        
(Signature of person authorized to sign)
	15C. DATE SIGNED
6/15/2021
	16B. UNITED STATES OF AMERICA
BY        
(Signature of Contracting Officer)
	16C. DATE SIGNED
15 June 2021

SECTION SF 30 BLOCK 14 CONTINUATION PAGE
SUMMARY OF CHANGES
SECTION SF 30 - BLOCK 14 CONTINUATION PAGE
The following have been added by full text:
P00007
OBLIGATION AMOUNT: $3,300,000,000.00
a.    The purpose of this modification (P00007) is to:
- Revise Section A (Authority FAR 43.103(a)(3), Mutual Agreement of the Parties)
- Exercise, revise delivery schedule for, and fund Option 3 and 4 CLINs 3001, 3001AA, 3001AB, 3001AC, 3001AD, 4001, 4001AA, 4001AB, 4001AC for a total of $3,300,000,00 (Authority FAR 52.217-7)
- Update Contracting Officer (Authority FAR 43.103(b))
- Add Performance Based Payments for Options 3 and 4; and revise the table in Section G, accordingly (Authority FAR 52.232-16)
- Add clause H.19 Product Variations (Authority FAR 43.103(a)(3), Mutual Agreement of the Parties)
- Revise Attachment 0007, Performance Based Payment (PBP) Milestone Schedule, and Attachment 0008, PBP Milestone Billing Plan (Authority FAR 52.243-1).
b.    This modification was requested by the program office to meet the Government’s mission requirements.
c.    The total funded amount has increased by $3,300,000,000 from $4,845,591,662.60 to $8,145,591,662.60.  The total contract value amount remains unchanged.
All other terms and conditions remain unchanged.  Please see below for details.
SECTION A -SOLICITATION/CONTRACT FORM
The total cost of this contract was increased by $3,300,000,000.00 from $4,845,591,662.60 to $8,145,591,662.60.
The following have been modified:
A.1The U.S. Army Contracting Command - Aberdeen Proving Ground (ACC-APG), Natick Division has a requirement for up to 500 million SARS-CoV-2 mRNA-1273 Vaccine doses ([***]) in support of Joint Program Executive Office - Chemical Biological Radiological Nuclear Defense (JPEO- CBRND), the Assistant Secretary for Preparedness and Response (ASPR), and Biomedical Advanced Research and Development Authority (BARDA).

W911QY20C0100
(P00007)
Page 2 of 29

All doses of mRNA-1273 Vaccine to satisfy the delivery requirements of CLINs 0001, 1001, and 2001 are 100 pg doses which will be delivered in a multi-dose vial containing either 6.3mL fill volume (1260mcg) [***] or 8.0mL fill volume (1600mcg) [***] (as described in Moderna’s COVID-19 Vaccine Authorized Fact Sheet and label).
Specifications of doses of mRNA-1273 Vaccine to satisfy the delivery requirements of CLINs 3001 and 4001 are described in Section H.19.
The delivery schedule for CLINs 3001 and 4001 may be concurrent with Moderna’s Biologics License Application and FDA approval of the SARS-CoV-2 vaccine.  Moderna agrees to continue to perform all regulatory efforts required to ensure that product delivered while the SARS-CoV-2 vaccine was under Emergency Use Authorization will remain available for use in the US.
SECTION B -SUPPLIES OR SERVICES AND PRICES
CLIN 3001
The CLIN extended description has changed from:
The contractor shall produce and deliver 100M doses of the SARS-CoV-2 mRNA-1273 Vaccine filled drug product (FDP), IAW Section C, Statement of Work (SOW), and CDRLs (Exhibit A) on this contract.
To:
The contractor shall produce and deliver 100M doses of the SARS-CoV-2 mRNA-1273 Vaccine filled drug product (FDP), IAW Section C, Statement of Work (SOW), Clause no. H-19, and CDRLs (Exhibit A) on this contract.
The option status has changed from Option to Option Exercised.
SUB CLIN 3001AA
The CLIN description has changed from 33.4M Doses to 25M Doses.
The pricing detail quantity has decreased by 8,400,000.00 from 33,400,000.00 to 25,000,000.00.
The option status has changed from Option to Option Exercised.
The total cost of this line item has decreased by $138,600,000.00 from $551,100,000.00 to $412,500,000.00.
SUBCLIN 3001AB
The CLIN description has changed from 33.4M Doses to 25M Doses.
The pricing detail quantity has decreased by 8,400,000.00 from 33,400,000.00 to 25,000,000.00.
The option status has changed from Option to Option Exercised.
The total cost of this line item has decreased by $138,600,000.00 from $551,100,000.00 to $412,500,000.00.
SUB CLIN 3001 AC
The CLIN description has changed from 33.2M Doses to 30M Doses.
The pricing detail quantity has decreased by 3,200,000.00 from 33.200.000.00 to 30,000,000.00.
The option status has changed from Option to Option Exercised.
The total cost of tins line item has decreased by $52,800,000.00 from $547,800,000.00 to $495,000,000.00.
CLIN 4001
The CLIN extended description has changed from:

W911QY20C0100
(P00007)
Page 3 of 29

The contractor shall produce and deliver 100M doses of the SARS-CoV-2 mRNA-1273 Vaccine filled drug product (FDP), IAW Section C, Statement of Work (SOW), and CDRLs (Exhibit A) on this contract.
To:
The contractor shall produce and deliver 100M doses of the SARS-CoV-2 mRNA-1273 Vaccine filled drug product (FDP), IAW Section C, Statement of Work (SOW), Clause no. 19, and CDRLs (Exhibit A) on this contract.
The option status has changed from Option to Option Exercised.
SUBCLIN 4001AA
The CLIN description has changed from 33.4M Doses to 10M Doses.
The pricing detail quantity has decreased by 23,400.000.00 from 33.400,000.00 to 10,000,000.00.
The option status has changed from Option to Option Exercised.
The total cost of this line item has decreased by $386,100,000.00 from $551,100,000.00 to $165,000,000.00.
SUBCLIN 4001AB
The CLIN description has changed from 33.4M Doses to 28M Doses.
The pricing detail quantity has decreased by 5.400.000.00 from 33.400.000.00 to 28,000,000.00.
The option status has changed from Option to Option Exercised.
The total cost of this line item has decreased by $89,100,000.00 from $551,100,000.00 to $462,000,000.00.
SUBCLIN 4001AC
The CLIN description has changed from 33.2M Doses to 28M Doses.
The pricing detail quantity has decreased by 5,200,000.00 from 33.200.000.00 to 28,000,000.00.
The option status has changed from Option to Option Exercised.
The total cost of this line item has decreased by $85,800,000.00 from $547,800,000.00 to $462,000,000.00.
SUBCLIN 3001AD is added as follows:
																		
	ITEM NO	SUPPLIES/SERVICES	QUANTITY	UNIT	UNIT PRICE	AMOUNT
	3001AD EXERCISED OPTION
	20M Doses
FFP	20,000,000	Each	$16.50	$330,000,000.00
		a.  If executed, the option shall be awarded upon EUA or no later than [***]
b.  The government shall provide [***] notification to exercise the option.
FOB: Destination
PURCHASE REQUEST NUMBER: [***]
PROJECT: Operation Warp Speed
PSC CD: 6505
	
					NET AMT	$330,000,000.00
		ACRN AM	$330,000,000.00
		CIN: GFEBS001166190500004	
						
						

SUBCLIN 4001AD is added as follows:

W911QY20C0100
(P00007)
Page 4 of 29

																		
	ITEM NO	SUPPLIES/SERVICES	QUANTITY	UNIT	UNIT PRICE	AMOUNT
	4001AD EXERCISED OPTION
	34M Doses
FFP	34,000,000	Each	$16.50	$561,000,000.00
		a.  If executed, the option shall be awarded upon EUA or no later than [***]
b.  The government shall provide [***] notification to exercise the option.
FOB: Destination
PURCHASE REQUEST NUMBER: [***]
PROJECT: Operation Warp Speed
PSC CD: 6505
	
					NET AMT	$561,000,000.00
		ACRN AM	$561,000,000.00
		CIN: GFEBS001166190500008	
						
						

SECTION C -DESCRIPTIONS AND SPECIFICATIONS
The following have been modified:
STATEMENT OF WORK
LARGE SCALE PRODUCTION OF SARS-CoV-2 VACCINE
C.1SCOPE.  The Department of Defense and Health and Human Services (HHS) require large scale manufacturing of vaccine doses in support of the national emergency response to the Coronavirus Disease 2019 (COVID-19) for the United States Government (USG) and the US population.
C.1.1Background.  In December 2019, a novel coronavirus now known as SARS-Co V-2 was first detected in Wuhan, Hubei Province, People’s Republic of China, causing outbreaks of the coronavirus disease COVID-19 that has now spread globally.  The Secretary of Health and Human Service declared a public health emergency on January 31, 2020, under section 319 of the Public Health Service Act (42 U.S.C. 247d), in response to CO VID-19.  On March 1, 2020, the President of the United States, pursuant to sections 01 and 301 of the National Emergencies Act (50 U.S.C. 1601 et seq.) and consistent with section 1135 of the Social Security Act (SSA), as amended (42 U.S.C. 1320b-5), proclaimed that the COVID-19 outbreak in the United States constitutes a national emergency.
C.1.1.1Under Operation Warp Speed (OWS), the Department of Defense and HHS are leading a whole of nation effort to ensure development of promising vaccine, diagnostic and therapeutic candidates and ensure that these medical countermeasures are available in the quantities required to reduce SARS-CoV-2 transmission, identify prior and/or current infection, and improve patient care, thereby mitigating the impact of COVID-19 on the nation and its people.  The DoD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRD) is providing expertise and contracting support to HHS, in compliance with PL 115-92 Authorization Letter for DoD Medical Priorities, through an Interagency Agreement, signed April 23, 2020.  As OWS products progress to clinical trials to evaluate the safety and efficacy of vaccines and therapeutics, it is critical that, in parallel, the USG supports large scale manufacturing so that vaccine doses or therapeutic treatment courses are immediately available for nationwide access as soon as a positive efficacy signal is obtained and the medical countermeasures are authorized for widespread use.
C.1.2Objective: The objective of this effort is to obtain the following:
(a)Base Period: Large scale manufacturing of 100 million vaccine doses

W911QY20C0100
(P00007)
Page 5 of 29

(b)Option Period 1: Large scale manufacturing of 100 million vaccine doses
(c)Option Period 2: Large scale manufacturing of 100 million vaccine doses
(d)Option Period 3: Large scale manufacturing of 100 million vaccine doses
(e)Option Period 4: Large scale manufacturing of 100 million vaccine doses
The Base Period is [***], with overlapping options for a total of [***] if all options are exercised.
C.1.3Consistent with the Updated EUA Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) dated 01 April 2021, up to [***] may be extracted from Moderna’s newly authorized multidose vials with 8.0mL fill volume (1600mcg).  The Government and Moderna agree that [***] per vial are only attainable using premium low dead volume (LDV) syringes, which are in short supply globally.  Utilizing initial ancillary equipment, vaccine administration personnel can reliably extract [***] from these vials; however, the Government has identified needle/syringe combinations that can be used to extract [***].
C.1.3.1Given the two parties’ shared interest in reducing vaccine waste and accelerating the availability of Moderna’s SARS-CoV-2 vaccine doses, the Government and Moderna intend that the Moderna vaccines doses be administered with needles and syringes compatible with extraction of [***] when possible.  Toward this end, the Government shall maintain a list of syringe and/or needle combinations which will allow extraction of [***] per 8.0mL vial, which list shall be updated jointly by the Government and Moderna as any additional syringe and/or needle combinations compatible with extraction of [***]/vial are identified.  Furthermore, the Government will, to the extent that appropriate needles and syringes are available, assemble and ship kits containing sufficient quantities of syringes and needles compatible with extraction of [***] per vial (Kit Moderna [***]) with Moderna’s SARS-CoV-2 vaccine.  The Government expects that these kits will be available beginning 01 May 2021 for a significant portion of Moderna’s remaining deliveries.  If, however, appropriate syringes and needles are not available, the Government will revert to shipping the Kit Moderna [***] with Moderna’s SARS-CoV-2 vaccine.
C.2APPLICABLE DOCUMENTS
C.2.1Federal Documents:
C.2.1.1Title 21 Code of Federal Regulations (CFR), Food and Drugs: Part 210, Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs; General; and, Part 211, Current Good Manufacturing Practice In Manufacturing, Processing, Packing, or Holding of Drugs; General.
(https://www.ecfr.gov/cgi-bin/text-idx?SID=a95cab20f443897a400bb7e44a27cf4c&mc=tme&tpl=/ecfrbrowse/Title21/21cfrv4_02.tpl#0)
C.3REQUIREMENTS.  Independently, and not as an agent of the USG, in accordance with the Proposal submitted by Moderna US, Inc. in response to Solicitation Number W911QY20R0043, Titled, “Advanced Procurement of mRNA-1273 Vaccine for Prevention of SARS-CoV-2 Coronavirus (COVID-19)”), dated July 10, 2020 (and any subsequent USG-approved revisions thereto), the contractor shall provide all necessary services, qualified personnel, material, equipment and facilities (not otherwise provided by the USG under the terms of this contract) to perform the specific tasks set forth below.
C.3.1Contract Line Item Number (CLIN) 0001 - Base Period: Large Scale Manufacturing of 100 Million Vaccine Doses.
C.3.1.1The contractor shall complete all scope required for the production, release and delivery use of 100 million Final Drug Product (FDP) doses of a SARS-CoV-2 mRNA-1273 vaccine.  This shall include, the following tasks and other activities reasonably contemplated by such task:
C.3.1.1.1Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of [***].  (Based on FDP stability data that supports a [***] shelf-life, subject to FDA confirmation of the 

W911QY20C0100
(P00007)
Page 6 of 29

assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC.  Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.
C.3.1.1.2cGMP manufacturing of 100 million doses fully compliant with 21 CFR 210 and 211.
C.3.1.1.3[***].
C.3.1.1.4[***].
C.3.1.1.5Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability and detection and response requirements, subject to any exceptions established by or the enforcement discretion of the FDA, including “Exemption from Certain Product Tracing and Product Identification Requirements Under Section 582 of the FD&C Act” (April 2020).
C.3.1.1.6In coordination with the USG, the contractor shall conduct a demonstration of the vaccine shipping process prior to the first delivery of FDP doses at a time mutually agreed to by the contractor and the USG. Moderna shall provide specifications and details associated with the shipping process and containers (IAW CDRL A005) to enable the USG to adequately plan and prepare for potential distribution of the vaccine.
C.3.1.1.7Following release of product the contractor shall, promptly deliver product to the designated delivery site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below.  In the unforeseen event that a designated delivery site cannot receive product and the contractor provides storage beyond [***] of product release, the contract will be subject to modification for acceptance purposes.
C.3.1.2Site Visits and Audits.  The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.
C.3.1.2.1BARDA Audits.  If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.
C.3.1.2.2FDA Audits.  The Contractor shall notify the Contracting Officer and Contracting Officer’s Representative (COR) within [***] of a scheduled FDA audit or within [***] of an ad hoc site visit or audit if the FDA does not provide advance notice.  The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within [***] of receiving correspondence from the FDA or third party in accordance with CDRL A002.  The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within [***] of submittal of the audit report in accordance with CDRL A002.
C.3.1.2.3FDA Interactions.  The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologies for the following, but not limited to: FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.
C.3.2CLIN 1001 - Option Period 1: Large Scale Manufacturing of 100 Million Vaccine Doses.
C.3.2.1The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine.  This shall include the following tasks and other activities reasonably contemplated by such tasks:
C.3.2.1.1Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  Storage and maintenance of the vaccine prior to delivery 

W911QY20C0100
(P00007)
Page 7 of 29

shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of [***].  (Based on FDP stability data that supports a [***] shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC.  Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.
C.3.2.1.2cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA.
C.3.2.1.3[***].
C.3.2.1.4Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability and detection and response requirements subject to any exceptions established by or the enforcement discretion of the FDA.
C.3.2.1.5Following release of the product the contractor shall deliver the product to the designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below.  To the extent a natural disaster or other emergency affecting a designated delivery site restricts such site’s ability to receive product, the Contractor and the USG will promptly agree on an alternate USG delivery location, or storage as Vendor Managed Inventory (VMI) at the contractor site.
C.3.2.2Site Visits and Audits.  The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.
C.3.2.2.1BARDA Audits.  If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.
C.3.2.2.2FDA Audits.  The Contractor shall notify the Contracting Officer and COR within [***] of a scheduled FDA audit or within [***] of an ad hoc site visit or audit if the FDA does not provide advance notice.  The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within [***] of receiving correspondence from the FDA or third party in accordance with CDRL A015.  The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within [***] of submittal of the audit report in accordance with CDRL A002.
C.3.2.2.3FDA Interactions.  The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologies for the following, but not limited to: FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.
C.3.3CLIN 2001 - Option Period 2: Large Scale Manufacturing of 100 Million Vaccine Doses.
C.3.3.1The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine.  This shall include the following tasks and other activities reasonably contemplated by such tasks:
C.3.3.1.1Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of [***].  (Based on FDP stability data that supports a [***] shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC.  Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.

W911QY20C0100
(P00007)
Page 8 of 29

C.3.3.1.2cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA.
C.3.3.1.3[***].
C.3.3.1.4Ensuring that the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581- 585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability’ and detection and response requirements, subject to any exceptions established by or the enforcement discretion of the FDA.
C.3.3.1.5Following release the contractor shall deliver product to the nearest designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below.  To the extent a natural disaster or other emergency affecting a designated delivery site restricts such site’s ability to receive product, the Contractor and the USG will promptly agree on an alternate USG delivery’ location, or storage as Vendor Managed Inventory (VMI) at the contractor site.
C.3.3.2Site Visits and Audits.  The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.
C.3.3.2.1BARDA Audits.  If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL AOOL
C.3.3.2.2FDA Audits.  The Contractor shall notify the Contracting Officer and COR within [***] of a scheduled FDA audit or within [***] of an ad hoc site visit or audit if the FDA does not provide advance notice.  The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within [***] of receiving correspondence from the FDA or third party in accordance with CDRL A002.  The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if am are identified, within [***] of submittal of the audit report in accordance with CDRL A002.
C.3.3.2.3FDA Interactions.  The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologies for the following, but not limited to: FDA interactions.  FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.
C.3.4CLIN 3001 - Option Period 3: Large Scale Manufacturing of 100 Million Vaccine Doses.
C.3.4.1The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine.  This shall include the following tasks and other activities reasonably contemplated by such tasks:
C.3.4.1.1Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of [***].  (Based on FDP stability data that supports a [***] shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC.  Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.
C.3.4.1.2cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA.
C.3.4.1.3[***].

W911QY20C0100
(P00007)
Page 9 of 29

C.3.4.1.4Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA).  Sections 581-585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability and detection and response requirements subject to any exceptions established by or the enforcement discretion of the FDA.
C.3.4.1.5Following release of the product the contractor shall deliver the product to the designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below.  To the extent a natural disaster or other emergency affecting a designated delivery site restricts such site’s ability to receive product, the Contractor and the USG will promptly agree on an alternate USG delivery location, or storage as Vendor Managed Inventory’ (VMI) at the contractor site.
C.3.4.2Site Visits and Audits.  The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.
C.3.4.2.1BARDA Audits.  If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.
C.3.4.2.2FDA Audits.  The Contractor shall notify the Contracting Officer and COR within [***] of a scheduled FDA audit or within [***] of an ad hoc site visit or audit if the FDA does not provide advance notice.  The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within [***] of receiving correspondence from the FDA or third party in accordance with CDRL A015.  The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within [***] of submittal of the audit report in accordance with CDRL A002.
C.3.4.2.3FDA Interactions.  The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding mRNA-1273 for the following, but not limited to: FDA interactions.  FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.
C.3.5CLIN 4001 - Option Period 4: Large Scale Manufacturing of 100 Million Vaccine Doses.
C.3.5.1The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine.  This shall include the following tasks and other activities reasonably contemplated by such tasks:
C.3.5.1.1Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of [***].  (Based on FDP stability data that supports a [***] shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC.  Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.
C.3.5.1.2cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA.
C.3.5.1.3[***].
C.3.5.1.4Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability and detection and response requirements subject to any exceptions established by or the enforcement discretion of the FDA.
C.3.5.1.5Following release of the product the contractor shall deliver the product to the designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below.  To the 

W911QY20C0100
(P00007)
Page 10 of 29

extent a natural disaster or other emergency affecting a designated delivery site restricts such site’s ability to receive product, the Contractor and the USG will promptly agree on an alternate USG delivery location, or storage as Vendor Managed Inventory (VMI) at the contractor site.
C.3.5.2Site Visits and Audits.  The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.
C.3.5.2.1BARDA Audits.  If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.
C.3.5.2.2FDA Audits.  The Contractor shall notify the Contracting Officer and COR within [***] of a scheduled FDA audit or within [***] of an ad hoc site visit or audit if the FDA does not provide advance notice.  The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within [***] of receiving correspondence from the FDA or third party in accordance with CDRL A015.  The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within [***] of submittal of the audit report in accordance with CDRL A002.
C.3.5.2.3FDA Interactions.  The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologies for the following, but not limited to: FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.
C.4CLIN 0002: Data Deliverables.  The contractor shall provide the following in accordance with the Contract Data Requirements List (CDRL), DD Forms 1423, provided at Appendix A.
C.4.1Monthly Inventory Report (CDRL A003), detailing at a minimum, raw materials, formulated LNPs, and the fill, finish, and released product.
C.4.2Quality Management Plan.  The contractor shall provide a Quality Management Plan, in accordance with CDRL A004, describing the quality policy and objectives, management review, competencies and training, process document control, feedback, evaluation, corrective action and preventive action, process improvement, measurement, and data analysis processes.  The framework is normally divided into infrastructure, senior management responsibility, resource management, lifecycle management, and quality management system evaluation.
C.4.3Shipping Documentation (CDRL A005) for all Finished Drug Product (FDP) transferring from the contractor’s fill/finish facility to a USG facility.  The contractor shall obtain concurrence on planned shipment protocols prior to transport.
C.4.4Expiring Items Report (CDRL A006) for all FDP in the USG’s possession.
C.4.5Key Personnel Listing (CDRL A007).
C.4.6Monthly Technical Progress Report (CDRL A008), to include an Integrated Master Schedule, identifying key activities and contract status.
C.4.7Final Technical Report (CDRL A009), documenting the work performed and results obtained for the entire contract period of performance.
C.4.8Supply Chain Resiliency Plan (SCRP).  The contractor shall provide, in accordance with CDRL A010 and CDRL Attachment 0001, a comprehensive SCRP that provides for identification and reporting of critical components associated with the secure supply of drug substance, drug product, and work-in-process through to 

W911QY20C0100
(P00007)
Page 11 of 29

finished goods, and key equipment suppliers and their locations, including addresses, points of contact, and work performed per location, to include subcontractors.
C.4.9[***]. 
C.4.10Manufacturing Reports and Dose Tracking.  The Contractor shall provide, in accordance with CDRL A013, manufacturing reports and manufacturing dose tracking projections and actuals utilizing the USG-provided “COVID-19 Dose Tracking Template” (CDRL Attachment 0003).
C.4.11Product Acceptance Report (for each lot of Drug Product).  The contractor shall provide, in accordance with CDRL A014, pictures of the drug product with lot number, drug product lot tree, list of associated deviations (from drug substance and product), and a Certificate of Analysis.
C.4.12Incident Report.  The contractor shall communicate to BARDA and document all critical programmatic concerns, issues, or probable risks that have or are likely to significantly impact project schedule and/or cost and/or performance in accordance with CDRL A016.  “Significant” is frequently defined as a [***] or greater cost or schedule variance within a control account, but should be confirmed in consultation with the COR.  Incidents that present liability to the project even without cost/schedule impact, such as breach of GCP during a clinical study, shall also be reported.
C.4.13FDA Correspondence.  The contractor shall provide any correspondence between Contractor and FDA relevant to the scope of this contract and submit in accordance with CDRL AO 17.
C.4.14Press Releases.  The contractor shall accurately and factually represent the work conducted under this contract in all press releases.  The contractor shall provide an advance copy of any press release in accordance with CDRL AO 18.
C.4.15Manufacturing Development Plan.  The contractor shall provide a Manufacturing Development Plan, in accordance with CDRL A025, describing the manufacturing process for the drug/biologic product to ensure conformity’ with §501(a)(2)(B) of the Food, Drug, and Cosmetics Act (FD&C Act, Title 21 United States Code (USC) §351 (a)(2)(B)), regarding good manufacturing practices (GMP).
C.5Administration.
C.5.1Post Award Teleconference.  The contractor shall host a Post Award Teleconference within 15 calendar days after contract award.
C.5.1.1The contractor shall provide an Agenda, IAW CDRL A020, detailing the planned activities for the subsequent 30 calendar days and shall discuss agenda items for the Post Award Kickoff Meeting.
C.5.1.2The contractor shall provide Meeting Minutes IAW CDRL A021.
C.5.2Post Award Kickoff Meeting.  The contracting officer may request the contractor host a contract Kick-Off Meeting within 30 calendar days after contract award via teleconference.  The contracting officer shall establish the date and time of the conference and prepare the agenda to include discussion on contract activities and schedule.
C.5.3Bi-Weekly Teleconference.  The contractor shall participate in bi-weekly teleconferences (or more frequent meetings required by the USG if warranted based on contract activities) to discuss performance on the contract.
C.5.4The contractor shall provide an Agenda.  IAW CDRL A020; Meeting Minutes in accordance with CDRL A02L and, Presentation Material in accordance with CDRL A022 for each of the aforementioned teleconferences or meetings throughout the contract period of performance.

W911QY20C0100
(P00007)
Page 12 of 29

C.5.5Daily “Check-In”.  The contractor shall participate in a daily “check-in” (via teleconference or email) to address key cost, schedule and technical updates.  Daily updates may be shared with senior USG leaders during the CO VID-19 response and should be provided on a non-confidential basis, unless the update includes confidential information in which case, the contractor shall provide the update in both confidential and non-confidential formats.  Daily check-ins may occur on weekdays, excluding federal holidays.  Upon request of the USG, check-ins may also occur on weekends and on federal holidays, provided at least 24 hours’ notice.
C.6Security.
C.6.1Access and General Protection/Security Policy and Procedures.  The contractor shall provide all information required for background checks necessary’ to access critical information related to OWS, and to meet USG installation access requirements to be accomplished by the installation Director of Emergency Services or Security Office.  The contractor employees shall comply with all personnel identity verification requirements as directed by the USG and/or local policy.  In addition to the changes otherwise authorized by the changes clause of this contract, should the security status of OWS change the USG may require changes in the contractor’s security matters or processes.  In addition to the industry standards for employment background checks, the contractor shall be willing to have key individuals, in exceptionally sensitive positions, identified for additional vetting by the United States USG.
C.6.2Security Program and Plan.  The contractor shall implement a comprehensive security program that provides overall protection of personnel, information, data, and facilities associated with fulfilling the USG’s requirement.  The contractor’s security’ practices and procedures shall be detailed in a Security Plan, in accordance with CDRL AO 19, and shall demonstrate how the contractor shall meet and adhere to the security requirements outlined in CDRL Attachment 0002.  This plan shall be delivered to the USG within 45 days of award, and the USG will review in detail and submit comments within ten (10) business days to the Contracting Officer (CO) to be forwarded to the Contractor.  The Contractor shall review the Security Plan comments, and, submit a final Security Plan to the U.S. USG within thirty (30) calendar days after receipt of the comments.  The Security Plan shall include a timeline for compliance of all the required security measures outlined in CDRL Attachment 0002.
C.6.3Operational Security (OPSEC).  The contractor shall develop and submit an OPSEC Standard Operating Procedure (SOP)Plan IAW CDRL A024.  The contractor shall identify in the SOP/Plan critical information related to this contract, why it needs to be protected, where it is located, who is responsible for it, and how to protect it.
C.7CLIN 0002 Vendor Managed Inventory (VMI).  The Contractor shall provide the capability to store the vaccine for up to [***], up to 100M doses of mRNA-1273 vaccine, in accordance with product labeling.  The contractor shall, in accordance with paragraph C.3.1.1.6, ensure the product storage of FDP doses for up to [***] prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  [***]  The contractor shall store the product to insure product quality with audible alarms and contacting.  The contractor shall notify the USG within [***] of detection of an incident with the potential to impact product quality, and implement corrective actions to mitigate the incident.  BARDA/JPEO-CBRND personnel may conduct Quality Audits of the storage facility, when deemed necessary.  The contractor shall notify the USG of Corrective/Preventive actions within [***] of detection of an incident with potential to impacts product qualify.  BARDA/JPEO-CBRND personnel may conduct Quality Audits of the storage facility, when deemed necessary.
C.7.1The USG will provide the contractor advance notice of the required delivery locations for the vaccine.  The contractor shall ship mRNA-1273 vaccines to designated locations [***] in the United States.  The contractor shall be responsible for shipment of all vaccine product whether acceptance is conducted [***].
C.7.2The vaccine product shall be shipped and tracked by the distribution vendor’s shipping tracking number, to the USG-designated sites within the continental United States.
C.7.3[***].  Notwithstanding either of the foregoing sentences, the contractor shall not be liable for loss of or damage to supplies caused by the negligence of officers, agents, or employees of the USG acting within the scope of their employment.

W911QY20C0100
(P00007)
Page 13 of 29

SECTION E -INSPECTION AND ACCEPTANCE
The following Acceptance/Inspection Schedule was added for SUBCLIN 3001AD:
												
	INSPECT AT	INSPECT BY	ACCEPT AT	ACCEPT BY
	Origin	Government	Origin	Government

The following Acceptance/Inspection Schedule was added for SUBCLIN 4001AD:
												
	INSPECT AT	INSPECT BY	ACCEPT AT	ACCEPT BY
	Origin	Government	Origin	Government

SECTION F -DELIVERIES OR PERFORMANCE
The following Delivery Schedule item for SUBCLIN 3001AA has been changed from:
												
	DELIVERY DATE	QUANTITY	SHIP TO ADDRESS	DODAAC /
CAGE
	[***]	[***]	[***]
FOB: Destination 
	[***]

To:
												
	DELIVERY DATE	QUANTITY	SHIP TO ADDRESS	DODAAC /
CAGE
	[***]	[***]	[***]
FOB: Destination 
	[***]

The following Delivery Schedule item for SUBCLIN 3001AB has been changed from:
												
	DELIVERY DATE	QUANTITY	SHIP TO ADDRESS	DODAAC /
CAGE
	[***]	[***]	[***]
FOB: Destination 
	[***]

To:
												
	DELIVERY DATE	QUANTITY	SHIP TO ADDRESS	DODAAC /
CAGE
	[***]	[***]	[***]
FOB: Destination 
	[***]

The following Delivery Schedule item for SUBCLIN 3001AC has been changed from:

W911QY20C0100
(P00007)
Page 14 of 29

												
	DELIVERY DATE	QUANTITY	SHIP TO ADDRESS	DODAAC /
CAGE
	[***]	[***]	[***]
FOB: Destination 
	[***]

To:
												
	DELIVERY DATE	QUANTITY	SHIP TO ADDRESS	DODAAC /
CAGE
	[***]	[***]	[***]
FOB: Destination 
	[***]

The following Delivery Schedule for SUBCLIN 3001 AD has been added:
												
	DELIVERY DATE	QUANTITY	SHIP TO ADDRESS	DODAAC /
CAGE
	[***]	[***]	[***]
FOB: Destination 
	[***]

The following Delivery Schedule item for SUBCLIN 4001AA has been changed from:
												
	DELIVERY DATE	QUANTITY	SHIP TO ADDRESS	DODAAC /
CAGE
	[***]	[***]	[***]
FOB: Destination 
	[***]

To:
												
	DELIVERY DATE	QUANTITY	SHIP TO ADDRESS	DODAAC /
CAGE
	[***]	[***]	[***]
FOB: Destination 
	[***]

The following Delivery’ Schedule item for SUBCLIN 4001AB has been changed from:
												
	DELIVERY DATE	QUANTITY	SHIP TO ADDRESS	DODAAC /
CAGE
	[***]	[***]	[***]
FOB: Destination 
	[***]

To:
												
	DELIVERY DATE	QUANTITY	SHIP TO ADDRESS	DODAAC /
CAGE
	[***]	[***]	[***]
FOB: Destination 
	[***]

W911QY20C0100
(P00007)
Page 15 of 29

The following Delivery Schedule item for SUBCLIN 4001AC has been changed from:
												
	DELIVERY DATE	QUANTITY	SHIP TO ADDRESS	DODAAC /
CAGE
	[***]	[***]	[***]
FOB: Destination 
	[***]

To:
												
	DELIVERY DATE	QUANTITY	SHIP TO ADDRESS	DODAAC /
CAGE
	[***]	[***]	[***]
FOB: Destination 
	[***]

The following Delivery Schedule for SUBCLIN 4001AD has been added:
												
	DELIVERY DATE	QUANTITY	SHIP TO ADDRESS	DODAAC /
CAGE
	[***]	[***]	[***]
FOB: Destination 
	[***]

SECTION G -CONTRACT ADMINISTRATION DATA
Accounting and Appropriation Summary for the Payment Office
As a result of this modification, the total funded amount for this document was increased by $3,300,000,000.00 from $4,845,591,662.60 to $8,145,591,662.60.
SUBCLIN 3001AA:
AK: [***] was increased by $412,500,000.00 from $0.00 to $412,500,000.00
The contract ACRN AK has been added.
The CIN [***] has been added.
The Cost Code [***] has been added.
SUBCLIN 3001AB:
AK: [***] was increased by $412,500,000.00 from $0.00 to $412,500,000.00
The contract ACRN AK has been added.
The CIN [***] has been added.
The Cost Code [***] has been added.
SUBCLIN 3001 AC:
AL: [***] was increased by $495,000,000.00 from $0.00 to $495,000,000.00
The contract ACRN AL has been added.

W911QY20C0100
(P00007)
Page 16 of 29

The CIN [***] has been added.
The Cost Code [***] has been added.
SUBCLIN 3001 AD:
Funding on SUBCLIN 3001AD is initiated as follows:
ACRN: AM
CIN: GFEBS001166190500004
Acctng Data: 0212021202220400000665654255    S.0074658.5.58.1    6100.9000021001
Increase: $330,000,000.00
Total: $330,000,000.00
Cost Code: [***]
SUBCLIN 4001AA:
AK: [***] was increased by $165,000,000.00 from $0.00 to $165,000,000.00
The contract ACRN AK has been added.
The CIN [***] has been added.
The Cost Code [***] has been added.
SUBCLIN 4001AB:
AN: [***] was increased by $462,000,000.00 from $0.00 to $462,000,000.00
The contract ACRN AN has been added.
The CIN [***] has been added.
The Cost Code [***] has been added.
SUBCLIN 4001AC:
AN: [***] was increased by $462,000,000.00 from $0.00 to $462,000,000.00
The contract ACRN AN has been added.
The CIN [***] has been added.
The Cost Code [***] has been added.
SUBCLIN 4001AD:
Funding on SUBCLIN 4001AD is initiated as follows:
ACRN: AM
CIN: [***]
AcctngData: [***]
Increase: $561,000,000.00
Total: $561,000,000.00

W911QY20C0100
(P00007)
Page 17 of 29

Cost Code: [***]
The following have been modified:
G.1GOVERNMENT CONTRACT ADMINISTRATION
In no event shall any understanding or agreement, contract modification, change order, or other matter in deviation from the terms of this contract between the Contractor and a person other than the Contracting Officer be effective or binding upon the Government.  All such actions must be formalized by a proper contractual document executed by the Contracting Officer.
Procuring Contracting Officer:
[***]
Joint COVID-19 Response Division
US Army Contracting Command
6472 Integrity Court (Building 4401)
Aberdeen Proving Ground, MD 21005-3013
Contract Specialist:
[***]
Joint COVID-19 Response Division
US Army Contracting Command
6472 Integrity Court (Building 4401)
Aberdeen Proving Ground, MD 21005-3013
G.2GOVERNMENT TECHNICAL POINT OF CONTACT
[***]
Biologist/Project Officer
200 C Street, SW
Washington, DC 20201
G.3CONTRACTOR’S CONTRACT ADMINISTRATION
[***]
Moderna US, Inc.
200 Technology SQ.
Cambridge, MA 02139-3578
G.4PLACES OF PERFORMANCE
Moderna US, Inc.
200 Technology SQ.
Cambridge, MA 02139-3578
G.5NOTIFICATION OF REVISIONS AND CHANGE
Notification of revision or changes to names or email addresses will be provided by official correspondence from the PCO/ACO or office of the PCO/ACO in lieu of a contract modification.  This does not apply to any such revisions or changes in the event this contract includes a key personnel clause.
G.6PERFORMANCE BASED PAYMENT

W911QY20C0100
(P00007)
Page 18 of 29

Performance-based payments (PBP) are authorized under this contract in accordance with FAR 52.232-32.  The contractor shall bill for the PBP upon achievement of the completion criteria identified in Attachment 0007, Performance-based Payment Milestone Table dated 4 May 2021.  Upon achievement of the completion criteria, the contractor shall bill for the PBP for the base and each option I AW the following schedule:
									
	CLIN	PERIOD	AMOUNT
	0001AA	BASE	$90,210,000
	0001AB	BASE	$132,308,000
	0001AC	BASE	$180,420,000
	0001AD	BASE	$198,462,000
	TOTAL		$601,400,000
			
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]		[***]
			
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]		[***]
			
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]		[***]
			
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]		[***]

Delivery Invoicing: PBPs are a type of contract financing and are recouped by the Government through deductions of payments otherwise due to the contractor for the partial or complete delivery’ of contract items.  The deductions are made by applying a liquidation rate to the price of delivered contract items.  Attachment 0008, Performance- based Payment Milestone Billing Plan, identifies the contractor invoicing schedule for liquidation.  The contractor shall submit all invoices IAW Attachment 0008.
SECTION H -SPECIAL CONTRACT REQUIREMENTS
The following have been modified:
H.1Key Personnel
Any key personnel specified in this contract are considered to be essential to work performance.  At least thirty (30) calendar days prior to the Contractor voluntarily diverting any of the specified individuals to other programs or contracts the Contractor shall notify the Contracting Officer and shall submit a justification for the diversion or replacement and a request to replace the individual.  The request must identify the proposed replacement and provide an explanation of how the replacement’s skills, experience, and credentials meet or exceed the requirements 

W911QY20C0100
(P00007)
Page 19 of 29

of the contract (including, when applicable.  Human Subjects Testing requirements).  If the employee of the Contractor is terminated for cause or separates from the Contractor voluntarily with less than thirty (30) calendar-day notice, the Contractor shall provide the maximum notice practicable under the circumstances.  The Contractor shall not divert, replace, or announce any such change to key personnel without the written consent of the Contracting Officer.  The contract will be modified to add or delete key personnel as necessary to reflect the agreement of the parties.  The following individuals are determined to be key personnel:
						
	Name	Title
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]

H.2Substitution of Key Personnel
The Contractor agrees to assign to the contract those persons whose resumes/CVs were submitted with the proposal who are necessary to fill the requirements of the contract.  No substitutions shall be made except in accordance with this clause.
All requests for substitution must provide a detailed explanation of the circumstance necessitating the proposed substitution, a complete resume for the proposed substitute and any other information requested by the contracting officer to approve or disapprove the proposed substitution.  All proposed substitutes must have qualifications that are equal to or higher than the qualifications of the person to be replaced.  The contracting officer or authorized representative will evaluate such requests and promptly notify the contractor of his approval or disapproval thereof.
H.3Disclosure of Information:
Performance under this contract may require the Contractor to access non-public data and information proprietary to a Government agency, another Government Contractor or of such nature that its dissemination or use other than as specified in the work statement would be adverse to the interests of the Government or others.  Neither the Contractor, nor Contractor personnel, shall divulge nor release data nor information developed or obtained under performance of this contract, except authorized by Government personnel or upon written approval of the CO which the KO will provide in accordance with OWS or other Government policies and/or guidance.  The Contractor shall not use, disclose, or reproduce proprietary data that bears a restrictive legend, other than as specified in this contract, or any information at all regarding this agency.
The Contractor shall comply with all applicable Government requirements for protection of non-public information.  Unauthorized disclosure of nonpublic information is prohibited by the Government’s rules.  Unauthorized disclosure may result in termination of the contract, replacement of a Contractor employee, or other appropriate redress.  Neither the Contractor nor the Contractor’s employees shall disclose or cause to be disseminated, any information concerning the operations of the activity, which could result in, or increase the likelihood of, the possibility of a breach of the activity’s security or interrupt the continuity of its operations.
No information related to data obtained under this contract shall be released or publicized without the prior written consent of the COR, whose approval shall not be unreasonably withheld, conditioned, or delayed, provided that no such consent is required to comply with any law, rule, regulation, court ruling or similar order; for submission to any government entity’ for submission to any securities exchange on which the Contractor’s (or its parent corporation’s) securities may be listed for trading; or to third parties relating to securing, seeking, establishing or maintaining regulatory or other legal approvals or compliance, financing and capital raising activities, or mergers, acquisitions, 

W911QY20C0100
(P00007)
Page 20 of 29

or other business transactions.  The exceptions identified in this paragraph apply to all disclosures under this Section H.3 except to the extent that a disclosure is otherwise prohibited by law.
H.4Publication and Publicity
The contractor shall not release any reports, manuscripts, press releases, or abstracts about the work being performed under this contract without written notice in advance to the Government.
(a) Unless otherwise specified in this contract, the contractor may publish the results of its work under this contract.  The contractor shall promptly send a copy of each submission to the COR for security review prior to submission.  The contractor shall also inform the COR when the abstract article or other publication is published, and furnish a copy of it as finally published.
(b) Unless authorized in writing by the CO. the contractor shall not display the DoD logo including Operating Division or Staff Division logos on any publications.
(c) The contractor shall not reference the products(s) or services(s) awarded under this contract in commercial advertising, as defined in FAR 31.205-1. in any maimer which states or implies DoD approval or endorsement of the product(s) or service(s) provided.
(d) The contractor shall include this clause, including this section (d) in all subcontracts where the subcontractor may propose publishing the results of its work under the subcontract.  The contractor shall acknowledge the support of the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority whenever publicizing the work under this contract in any media by including an acknowledgement substantially’ as follows:
“This project has been funded in whole or in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract Number W911QY-20-C-0100.”
H.5Confidentiality of Information
a.  Confidential information, as used in this article, means non-public information or data of a personal nature about an individual, or proprietary’ information or data submitted by or pertaining to an institution or organization.
b.  The Contracting Officer and the Contractor may, by mutual consent, identify elsewhere in this contract specific information and/or categories of information which the Government will furnish to the Contractor or that the Contractor is expected to generate which is confidential.  Similarly, the Contracting Officer and the Contractor may, by mutual consent, identify such confidential information from time to time during the performance of the contract.  Failure to agree will be settled pursuant to the “Disputes” clause.
c.  If it is established elsewhere in this contract that information to be utilized under this contract, or a portion thereof, is subject to the Privacy Act, the Contractor will follow the rules and procedures of disclosure set forth in the Privacy Act of 1974, 5 U.S.C. 552a, and implementing regulations and policies, with respect to systems of records determined to be subject to the Privacy Act.
d.  Confidential information, as defined in paragraph (a) of this article, shall not be disclosed without the prior written consent of the individual, institution, or organization.
e.  Whenever the Contractor is uncertain with regard to the proper handling of material under the contract, or if the material in question is subject to the Privacy Act or is confidential information subject to the provisions of this article, the Contractor shall obtain a written determination from the Contracting Officer prior to any release, disclosure, dissemination, or publication.

W911QY20C0100
(P00007)
Page 21 of 29

f.  Contracting Officer Determinations will reflect the result of internal coordination with appropriate program and legal officials.
g.  The provisions of paragraph (d) of this article shall not apply to conflicting or overlapping provisions in other Federal, State or local laws.
ALL REQUIREMENTS OF THIS SECTION H.5 MUST BE PASSED TO ALL SUB-CONTRACTOR.
H.6Regulatory Rights
This contract involves supply of a product that requires FDA pre-market approval or clearance before commercial authorization.  Contractor is seeking FDA authorization or clearance for the commercialization of mRNA-1273.  Moderna vaccine for SARS-CoV-2 Coronavirus (the “Technology”).  The Contractor is the Sponsor of the Regulatory Application (an investigational new drug application (IND), investigational device exemption (IDE), emergency use authorization (EUA), new drug application (NDA), biologies license application (BLA), premarket approval application (PMA), or 510(k) pre-market notification filing (510(k)) or another regulatory filing submitted to FDA) for the technology.  As the Sponsor of the Regulatory Application to FDA (as the terms “sponsor” and “applicant” are defined or used in at 21 CFR §§3.2(c), 312.5, 600.3(t), 812.2(b), 812 Subpart C, or 814.20), the Contractor has certain standing before the FDA that entitles it to exclusive communications related to the Regulatory Application.
Accordingly, the Contractor and the Government agree to the following:
a.  DoD Medical Product Priority, PL 115-92 allows the DoD to request, and FDA to provide, assistance to expedite development of products to diagnose, treat, or prevent serious or life-threatening diseases or conditions facing American military personnel.  The contractor recognizes that only the DoD can utilize PL 115-92.  As such, the contractor will work proactively with the Government to leverage this law to its maximum potential under this contract.  The contractor shall submit Public Law 115-92 Sponsor Authorization Letter that will be delivered to the designated OWS POC(s) within [***] of award.
b.  [***].
H.7Performance Based Payment Liquidated under Termination
Performance Based Payments (PBPs) have been authorized as a method of financing under this contract.  In the event the Moderna’s mRNA-1273 CO VID Vaccine is unsuccessful in its bid to obtain EUA or FDA approval, the Government may issue a Termination for Convenience (T4C) in whole or in part, on this contract.  Upon notice of a T4C, the contractor shall submit a termination settlement proposal, IAW FAR 52.249-2, Termination for Convenience of the Government (Fixed-Price).
H.8Public Readiness and Emergency Preparedness (PREP) Act:
In accordance with the Public Readiness and Emergency Preparedness Act (“PREP Act”). Pub. L. No. 109-148, Division C, Section 2, as amended (codified at 42 U.S.C. § 247d-6d and 42 U.S.C. § 247d-6e), as well as the Secretary of HHS’s Declaration Under the Public Readiness and Emergency Preparedness Act for Medical Countermeasures Against CO VID-19. 85 Fed. Reg. 15198 (Mar. 17, 2020, effective Feb. 4, 2020), and amended on April 15, 2020, 85 Fed. Reg. 21012 (together, the “Prep Act Declaration”):
(i) This Agreement is being entered into for purposes of facilitating the manufacture, testing, development, distribution, administration, and use of “Covered Countermeasures” for responding to the CO VID-19 public health emergency, in accordance with Section VI of the PREP Act Declaration;

W911QY20C0100
(P00007)
Page 22 of 29

(ii) Contractor’s performance of this Agreement falls within the scope of the “Recommended Activities” for responding to the CO VID-19 public health emergency, to the extent it is in accordance with Section III of the PREP Act Declaration; and
(iii) Contractor is a “Covered Person” to the extent it is a person defined in Section V of the PREP Act Declaration.
Therefore, in accordance with Sections IV and VII of the PREP Act Declaration as well as the PREP Act (42 U.S.C. § 247d-6d), the Department of Defense contracting via assisted acquisition on behalf of the HHS, expressly acknowledges and agrees that the HHS Declaration cited above, specifically its language providing immunity from suit and liability is applicable to this acquisition as long as Contractors activities fall within the terms and conditions of the PREP Act and the PREP Act Declaration.
The Government may not use, or authorize the use of, any products or materials provided under this contract, unless such use occurs in the United States (or a U.S. territory where U.S. law applies such as embassies, military and NATO installations) and is protected from liability under a declaration issued under the PREP Act, or a successor COVID-19 PREP Act Declaration of equal or greater scope.  Any use where the application of the PREP Act is in question will be discussed with Moderna prior to use and, if the parties disagree on such use, the dispute will be resolved according to the “Disputes Clause” (52.233-1)
The items and technology covered by this Contract are being developed for both civil and military’ applications.
H.9[***].
H.10[***]. 
H.11[***]. 
H.12Transportation to Final Destination
During the course of performance under this contract, the Government may require storage of the filled drug product (FDP) before delivery to the final government location.  In these circumstances, the Government will accept FDP at the contractor facility (Origin).  The contractor; however, shall continue to be responsible for secure delivery of the vaccine to its final destination as identified on this contract.  [***].
H.13Validation of IP/Data
The Parties acknowledge that background intellectual property and technical data assertions have been made and evaluated by the parties.  The parties agree that, should additional information relevant to these assertions become available, the parties will reevaluate said assertions as necessary in the future.
H.14Novation
Upon Moderna, US, Inc.’s registration in the System for Award Management, the Government will, at the Contractor’s request, complete a novation of this Contract to recognize Moderna US. Inc. as a counterparty instead of Moderna TX, Inc. This novation will be completed through a modification executed by the Government that identifies Moderna US. Inc. as the contracting party for all purposes as if it had originally executed the Contract.
H.15Base & Option 1 Delivery Acceleration
In an effort to accelerate production of the mRNA-1273 vaccine, [***] within the Option 1 period via a Modification to the contract.  If these manufacturing slots are successfully utilized, [***] funded above what was projected by Moderna and assumed within the price per dose for the doses of mRNA-1273 vaccine delivered in the Base Period and Option 1.  However, [***], the Government is entitled to an adjustment under the conditions outlined.  The Government and Moderna agree to the following:

W911QY20C0100
(P00007)
Page 23 of 29

1.  If the Government exercises Option 2 (NLT 15 May):
a.  Moderna will reduce the cost of Option 2 by [***] for each successfully accelerated drug product fill under the Base Period [***] and [***] for each successfully accelerated drag product fill under Option 1 [***].
2.  If the Government does not exercise Option 2 (NLT 15 May):
a.  In the event Moderna timely cancels the manufacturing slots and/or is able to otherwise fully utilize the slots originally reserved for production in the Option 2 period.  Moderna agrees to credit the Government [***] for [***] and [***] for [***].  In no case shall the number of drug product manufacturing slots credited exceed the number of successfully accelerated drag product manufacturing fills under the Base Period and Option 1.  It is understood that Moderna will make all good-faith efforts to fill reserved slots or cancel reservations in a timely manner (i.e. within the time period required by the subcontractor).
b.  In the event that Moderna is unable to fill those reserved slots (i.e. due to lack of demand) and cancels slots, Moderna shall be entitled to recoup those reservation cancellation costs from the USG.  The process is outlined as follows:
1.) Moderna shall submit documentation to the USG of the following:
i.) Cancellation notice to the subcontractor,
ii.) The basis of the cancellation, and
iii.) Cancellation fees incurred.
2.) Moderna shall reduce credits to the USG under paragraph 2a) of this clause.  IAW agreed cancellation costs incurred.
3.) Bi-lateral agreement of the final credit shall be included in a modification to the contract.  Net credit shall be deducted from final payments under the contract.
H.16Delivery Schedule, as revised 11 Feb 2021 via modification P00004
[***]

Moderna confirms that it will provide the USG with the first 300M doses manufactured within its US-based supply chain [***], with the exception of doses required for clinical studies.  The delivery schedule assumes that Moderna will work to further maximize fill/finish capacity by working with the FDA to increase fill volumes, [***].  Both parties acknowledge that resulting revisions to future accounting, invoicing, acceptance and delivery of doses subject to the revised label will be implemented via a subsequent modification.
H.17Post-Termination Disposition of Undelivered Product
For the avoidance of doubt, if the USG elects to terminate the exercised CLINs prior to acceptance and delivery in full of the required quantities of mRNA-1273, Moderna will be free to direct any unaccepted/undelivered supplies of mRNA-1273 to customers other than the USG, at its discretion, without further obligation of either party with regard to such unaccepted/undelivered supplies of mRNA-1273.  The contract will be bilaterally modified to decrease the quantities by the agreed upon volume.
H.18[***]. 
In order to facilitate projections and invoicing, the Government shall provide or direct a third party [***] to provide to Moderna (1) actual quantities of Moderna [***] with 8.0mL vials during the reporting period; (2) actual quantities of Moderna [***] with 8.0mL vials during the reporting period; and (3) the number of [***] remaining in inventory 

W911QY20C0100
(P00007)
Page 24 of 29

and available for upcoming shipments.  This information will be provided to Moderna at a frequency of at least twice monthly.
For each 8.0mL fill volume (1600mcg) vial of vaccine shipped with [***].
Both parties acknowledge that the delivery schedule is based [***] 8.0mL fill volume (1600mcg) vial delivered.  In accordance with the agreed approach for invoicing and counting doses toward Moderna’s delivery requirement, [***].  Specifically for purposes of adhering to the scheduled delivery dates set forth in this contract for the Base Period, Option 1 and Option 2, schedule shall be deemed to have been met once doses are released by Moderna and are available for order.
H.19Product [***] (as added via P00007)
Specific to CLINs 3001 and 4001, Moderna will deliver to the Government [***]:
•mRNA-1273 Primary Series (0.2mg/mL, 100pg, 2-dose)
•[***]

All doses delivered in calendar year 2021 will be delivered in multi-dose vials [***].
The Government and Moderna agree that total monthly delivery quantities for each of CLIN 3001 and 4001 will follow the schedule in the table below.  The Government and Moderna also agree on the following points specific to product ordering:
[***]
SECTION J -LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS
The following have been modified:
												
	Document Type	Description	Page #	Date
	Exhibit A	CDRLs	15	11 Feb 2021
	Attachment 0001	Supply Chain Resiliency Plan for CDRL A010	3	23 July 2020
	Attachment 0002	Security’ Plan	7	23 July 2020
	Attachment 0003	Dose Tracking Template Draft Moderna	Excel	15 July 2020
	Attachment 0004	Data Rights	3	7 August 2020
	Attachment 0005	[***]	2	7 August 2020
	Attachment 0006	ModernaTx, Inc. Background Intellectual Property	3	6 August 2020
	Attachment 0007	Performance Base Payment Milestone Schedule	1	14 June 2021
	Attachment 0008	Performance Base Payment Milestone Billing Plan	16	14 June 2021
	Attachment 0009	HRPAS Moderna Letter	1	3 September 2020

(End of Summary of Changes)

Attachment 0008
Performance Based Payment (PBP) Milestone Billing Plan
14 June 2021
Pages 16

[***]

Attachment 0007
Performance Based Payment (PBP) Milestone Schedule
14 June 2021
															
	CLIN	Milestone	Severable / Cumulative	Price	Milestone Completion Verification Method
	0001	Capacity and Raw Material Severable Reservation	Severable	$601,400,000	Moderna shall provide:
1) Written confirmation from the CMO network that sufficient capacity has been reserved; and, 2) Written confirmation of reservation of sufficient raw materials along with a manufacturing schedule.
	1001	[***]
	2001	[***]
	3001	[***]
	4001	[***]

																																				
	AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT	1. CONTRACT ID CODE	PAGE OF PAGES
	1	12
	2. AMENDMENT/MODIFICATION NO.:
P00008
	EFFECTIVE DATE
16-Jun-2021
	4. REQUESTION/PURCHASE REQ. NO.
SEE SCHEDULE
	5. PROJECT NO. (If applicable)
	6. ISSUED BY    CODE
	W58P05	7. ADMINISTERED BY (If other than item6)    CODE
	S2206A
	ACC-APG-COVID RESPONSE-W58P05
6472 INTEGRITY COURT (BUILDING 4401)
ABERDEEN PROVING GROUND MD 21005-3012	DEFENSE CONTRACT MANAGEMENT AGENCY
DCMA BOSTON
495 SUMMER STREET
BOSTON MA 02210-2138	
	8. NAME AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code) 
MODERNA US, INC.
[***]
200 TECHNOLOGY SQ
CAMBRIDGE MA 02139-3578
		9A. AMENDMENT OF SOLICITATION NO.
		9B. DATED (SEE ITEM 11)
	X	10A. MOD. OF CONTRACT/ORDER NO.
W911QY20C0100

	CODE
8PTM0
	FACILITY CODE	X	10B. DATED (SEE ITEM 13)
09-Aug-2020

	11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS
	    The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offer  is extended,  is not extended. Offer mist acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended by one of the following methods: (a) By completing Items 8 and 15, and returning _____ copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers.  FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

	12. ACCOUNTING AND APPROPRIATION DATA (If required)
	13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACT BORDERS.
IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.
		A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.
		B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B).
	X	C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:
See Block 14 Continuation Page

		D. OTHER (Specify type of modification and authority)
	E. IMPORTANT: Contractor  is not, ☒ is required to sign this document and return ___1___ copies to the issuing office.

	14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.) Modification Control Number:  [***]
See Block 14 Continuation Page
Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.

	15 A. NAME AND TITLE OF SIGNER (Type or print)
Stephen Hoge, President
	16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)
[***]
tel: [***]    email:  [***]

	15B. CONTRACTOR/OFFEROR 
/s/ Stephen Hoge
	15C. DATE SIGNED
June 16, 2021
	16B. UNITED STATES OF AMERICA
BY
	16C. DATE SIGNED
June 16, 2021

	(Signature person authorized to sign)	(Signature of Contracting Officer)

SECTION SF 30 BLOCK 14 CONTINUATION PAGE
SUMMARY OF CHANGES
SECTION SF 30 - BLOCK 14 CONTINUATION PAGE
The following have been added by full text:
P00008
OBLIGATION AMOUNT: $0.00
a.    The purpose of this modification (P00008) is to:
-    Add H.20 Donation of Excess Product and Exhibit B (Authority FAR 43.103(a)(3), Mutual Agreement of the Parties)
b.    This modification was requested by the program office to meet the Government’s mission requirements.
c.    The total contract value and total funded amount remain unchanged.
All other terms and conditions remain unchanged.  Please see below for details.
SECTION H - SPECIAL CONTRACT REQUIREMENTS
The following have been modified:
H.1    Key Personnel
Any key personnel specified in this contract are considered to be essential to work performance.  At least thirty (30) calendar days prior to the Contractor voluntarily diverting any of the specified individuals to other programs or contracts the Contractor shall notify the Contracting Officer and shall submit a justification for the diversion or replacement and a request to replace the individual.  The request must identify’ the proposed replacement and provide an explanation of how the replacement’s skills, experience, and credentials meet or exceed the requirements of the contract (including, when applicable, Human Subjects Testing requirements).  If the employee of the Contractor is terminated for cause or separates from the Contractor voluntarily with less than thirty (30) calendar-day notice, the Contractor shall provide the maximum notice practicable under the circumstances.  The Contractor shall not divert, replace, or announce any such change to key personnel without the written consent of the Contracting Officer.  The contract will be modified to add or delete key personnel as necessary to reflect the agreement of the parties.  The following individuals are determined to be key personnel:
						
	Name	Title
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]

H.2    Substitution of Key Personnel
The Contractor agrees to assign to the contract those persons whose resumes/CVs were submitted with the proposal who are necessary to fill the requirements of the contract.  No substitutions shall be made except in accordance with this clause.

All requests for substitution must provide a detailed explanation of the circumstance necessitating the proposed substitution, a complete resume for the proposed substitute and any other information requested by the contracting officer to approve or disapprove the proposed substitution.  All proposed substitutes must have qualifications that are equal to or higher than the qualifications of the person to be replaced.  The contracting officer or authorized representative will evaluate such requests and promptly notify the contractor of his approval or disapproval thereof.
H.3    Disclosure of Information:
Performance under this contract may require the Contractor to access non-public data and information proprietary to a Government agency, another Government Contractor or of such nature that its dissemination or use other than as specified in the work statement would be adverse to the interests of the Government or others.  Neither the Contractor, nor Contractor personnel, shall divulge nor release data nor information developed or obtained under performance of this contract, except authorized by Government personnel or upon written approval of the CO which the KO will provide in accordance with OWS or other Government policies and/or guidance.  The Contractor shall not use, disclose, or reproduce proprietary data that bears a restrictive legend, other than as specified in this contract, or any information at all regarding this agency.
The Contractor shall comply with all applicable Government requirements for protection of non-public information.  Unauthorized disclosure of nonpublic information is prohibited by the Government’s rules.  Unauthorized disclosure may result in termination of the contract, replacement of a Contractor employee, or other appropriate redress.  Neither the Contractor nor the Contractors employees shall disclose or cause to be disseminated, any information concerning the operations of the activity, which could result in, or increase the likelihood of, the possibility of a breach of the activity’s security or interrupt the continuity of its operations.
No information related to data obtained under this contract shall be released or publicized without the prior written consent of the COR, whose approval shall not be unreasonably withheld, conditioned, or delayed, provided that no such consent is required to comply with any law, rule, regulation, court ruling or similar order; for submission to any government entity’ for submission to any securities exchange on which the Contractor’s (or its parent corporation’s) securities may be listed for trading; or to third parties relating to securing, seeking, establishing or maintaining regulatory or other legal approvals or compliance, financing and capital raising activities, or mergers, acquisitions, or other business transactions.  The exceptions identified in this paragraph apply to all disclosures under this Section H.3 except to the extent that a disclosure is otherwise prohibited by law.
H.4    Publication and Publicity
The contractor shall not release any reports, manuscripts, press releases, or abstracts about the work being performed under this contract without written notice in advance to the Government.
a.    Unless otherwise specified in tins contract, the contractor may publish the results of its work under this contract.  The contractor shall promptly send a copy of each submission to the COR for security review prior to submission.  The contractor shall also inform the COR when the abstract article or other publication is published, and furnish a copy of it as finally published.
b.    Unless authorized in writing by the CO, the contractor shall not display the DoD logo including Operating Division or Staff Division logos on any publications.
c.    The contractor shall not reference the products(s) or services(s) awarded under this contract in commercial advertising, as defined in FAR 31.205-1, in any manner which states or implies DoD approval or endorsement of the product(s) or service(s) provided.
d.    The contractor shall include this clause, including this section (d) in all subcontracts where the subcontractor may propose publishing the results of its work under the subcontract.  The contractor shall acknowledge the support of the Department of Health and Human Services, Office of the Assistant Secretary for 

Preparedness and Response, Biomedical Advanced Research and Development Authority whenever publicizing the work under this contract in any media by including an acknowledgement substantially as follows:
“This project has been funded in whole or in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract Number W911QY-20-C-0100.”
H.5    Confidentiality of Information
a.    Confidential information, as used in this article, means non-public information or data of a personal nature about an individual, or proprietary information or data submitted by or pertaining to an institution or organization.
b.    The Contracting Officer and the Contractor may, by mutual consent, identify elsewhere in this contract specific information and/or categories of information which the Government will furnish to the Contractor or that the Contractor is expected to generate which is confidential.  Similarly, the Contracting Officer and the Contractor may, by mutual consent, identify such confidential information from time to time during the performance of the contract.  Failure to agree will be settled pursuant to the “Disputes” clause.
c.    If it is established elsewhere in this contract that information to be utilized under this contract, or a portion thereof, is subject to the Privacy Act, the Contractor will follow the rules and procedures of disclosure set forth in the Privacy Act of 1974, 5 U.S.C. 552a, and implementing regulations and policies, with respect to systems of records determined to be subject to the Privacy Act.
d.    Confidential information, as defined in paragraph (a) of this article, shall not be disclosed without the prior written consent of the individual, institution, or organization.
e.    Whenever the Contractor is uncertain with regard to the proper handling of material under the contract, or if the material in question is subject to the Privacy Act or is confidential information subject to the provisions of this article, the Contractor shall obtain a written determination from the Contracting Officer prior to any release, disclosure, dissemination, or publication.
f.    Contracting Officer Determinations will reflect the result of internal coordination with appropriate program and legal officials.
g.    The provisions of paragraph (d) of this article shall not apply to conflicting or overlapping provisions in other Federal, State or local laws.
ALL REQUIREMENTS OF THIS SECTION H.5 MUST BE PASSED TO ALL SUB-CONTRACTOR.
H.6    Regulatory Rights
This contract involves supply of a product that requires FDA pre-market approval or clearance before commercial authorization.  Contractor is seeking FDA authorization or clearance for the commercialization of mRNA-1273, Moderna vaccine for SARS-CoV-2 Coronavirus (the ‘‘Technology”).  The Contractor is the Sponsor of the Regulatory Application (an investigational new drug application (IND), investigational device exemption (IDE), emergency use authorization (EUA), new drug application (NDA), biologies license application (BLA), premarket approval application (PMA), or 510(k) pre-market notification filing (510(k)) or another regulatory filing submitted to FDA) for the technology.  As the Sponsor of the Regulatory Application to FDA (as the terms “sponsor” and “applicant” are defined or used in at 21 CFR §§3.2(c), 312.5, 600.3(t), 812.2(b), 812 Subpart C, or 814.20), the Contractor has certain standing before the FDA that entitles it to exclusive communications related to the Regulatory Application.
Accordingly, the Contractor and the Government agree to the following:

a.    DoD Medical Product Priority.  PL 115-92 allows the DoD to request, and FDA to provide, assistance to expedite development of products to diagnose, treat, or prevent serious or life-threatening diseases or conditions facing American military personnel.  The contractor recognizes that only the DoD can utilize PL 115-92.  As such, the contractor will work proactively with the Government to leverage this law to its maximum potential under this contract.  The contractor shall submit Public Law 115-92 Sponsor Authorization Letter that will be delivered to the designated OWS POC(s) within [***] of award.
b.    [***].
H.7    Performance Based Payment Liquidated under Termination
Performance Based Payments (PBPs) have been authorized as a method of financing under this contract.  In the event the Moderna’s mRNA-1273 CO VID Vaccine is unsuccessful in its bid to obtain EUA or FDA approval, the Government may issue a Termination for Convenience (T4C) in whole or in part, on this contract.  Upon notice of a T4C, the contractor shall submit a termination settlement proposal, IAW FAR 52.249-2.  Termination for Convenience of the Government (Fixed-Price).
H.8    Public Readiness and Emergency Preparedness (PREP) Act:
In accordance with the Public Readiness and Emergency Preparedness Act (“PREP Act”), Pub. L. No. 109-148. Division C, Section 2, as amended (codified at 42 U.S.C. § 247d-6d and 42 U.S.C. § 247d-6e), as well as the Secretary of HHS’s Declaration Under the Public Readiness and Emergency Preparedness Act for Medical Countermeasures Against CO VID-19, 85 Fed. Reg. 15198 (Mar. 17, 2020, effective Feb. 4, 2020), and amended on April 15, 2020, 85 Fed. Reg. 21012 (together, the “Prep Act Declaration”):
(i)    This Agreement is being entered into for purposes of facilitating the manufacture, testing, development, distribution, administration, and use of “Covered Countermeasures” for responding to the CO VID-19 public health emergency, in accordance with Section VI of the PREP Act Declaration;
(ii)    Contractor’s performance of this Agreement falls within the scope of the “Recommended Activities” for responding to the CO VID-19 public health emergency, to the extent it is in accordance with Section III of the PREP Act Declaration: and
(iii)    Contractor is a “Covered Person” to the extent it is a person defined in Section V of the PREP Act Declaration.
Therefore, in accordance with Sections IV and VII of the PREP Act Declaration as well as the PREP Act (42 U.S.C. § 247d-6d), the Department of Defense contracting via assisted acquisition on behalf of the HHS, expressly acknowledges and agrees that the HHS Declaration cited above, specifically its language providing immunity from suit and liability is applicable to this acquisition as long as Contractors activities fall within the terms and conditions of the PREP Act and the PREP Act Declaration.
The Government may not use, or authorize the use of, any products or materials provided under this contract, unless such use occurs in the United States (or a U.S. territory where U.S. law applies such as embassies, military and NATO installations) and is protected from liability under a declaration issued under the PREP Act, or a successor COVID-19 PREP Act Declaration of equal or greater scope.  Any use where the application of the PREP Act is in question will be discussed with Moderna prior to use and, if the parties disagree on such use, the dispute will be resolved according to the “Disputes Clause” (52.233-1)
The items and technology covered by this Contract are being developed for both civil and military applications.
H.9    [***]. 
H.10    [***]. 

H.11    [***]. 
H.12    Transportation to Final Destination
During the course of performance under this contract, the Government may require storage of the filled drag product (FDP) before delivery to the final government location.  In these circumstances, the Government will accept FDP at the contractor facility (Origin).  The contractor; however, shall continue to be responsible for secure delivery of the vaccine to its final destination as identified on this contract.  [***].
H.13    Validation of IP/Data
The Parties acknowledge that background intellectual property and technical data assertions have been made and evaluated by the parties.  The parties agree that, should additional information relevant to these assertions become available, the parties will reevaluate said assertions as necessary in the future.
H.14    Novation
Upon Moderna, US, Inc.’s registration in the System for Award Management, the Government will, at the Contractor’s request, complete a novation of this Contract to recognize Moderna US, Inc. as a counterparty instead of Moderna TX, Inc. This novation will be completed through a modification executed by the Government that identifies Moderna US, Inc. as the contracting party for all purposes as if it had originally executed the Contract.
H.15    Base & Option 1 Delivery Acceleration
In an effort to accelerate production of the mRNA-1273 vaccine, [***] within the Option 1 period via a Modification to the contract.  If these manufacturing slots are successfully utilized, [***] funded above what was projected by Moderna and assumed within the price per dose for the doses of mRNA-1273 vaccine delivered in the Base Period and Option 1.  However, because the Government is funding the additional slots within the Base and Option 1 periods in order to accelerate production, the Government is entitled to an adjustment under the conditions outlined.  The Government and Moderna agree to the following:
1.    If the Government exercises Option 2 (NLT 15 May):
a.    Moderna will reduce the cost of Option 2 by [***] for each successfully accelerated drug product fill under the Base Period [***] and [***] for each successfully accelerated drug product fill under Option 1 [***].
2.    If the Government does not exercise Option 2 (NLT 15 May):
a.    In the event Moderna timely cancels the manufacturing slots and/or is able to otherwise fully utilize the slots originally reserved for production in the Option 2 period, Moderna agrees to credit the Government [***] for [***] and [***] for [***].  In no case shall the number of drug product manufacturing slots credited exceed the number of successfully accelerated drag product manufacturing fills under the Base Period and Option 1.  It is understood that Moderna will make all good-faith efforts to fdl reserved slots or cancel reservations in a timely manner (i.e. within the time period required by the subcontractor).
b.    In the event that Moderna is unable to fill those reserved slots (i.e. due to lack of demand) and cancels slots, Moderna shall be entitled to recoup those reservation cancellation costs from the USG.  The process is outlined as follows:
1.)    Moderna shall submit documentation to the USG of the following:
i.)    Cancellation notice to the subcontractor,
ii.)    The basis of the cancellation, and
iii.)    Cancellation fees incurred.

2.)    Moderna shall reduce credits to the USG under paragraph 2a) of this clause, IAW agreed cancellation costs incurred.
3.)    Bi-lateral agreement of the final credit shall be included in a modification to the contract.  Net credit shall be deducted from final payments under the contract.
H.16    Delivery Schedule, as revised 11 Feb 2021 via modification P00004
[***]

H.17    Post-Termination Disposition of Undelivered Product
For the avoidance of doubt, if the USG elects to terminate the exercised CLINs prior to acceptance and delivery in full of the required quantities of mRNA-1273, Moderna will be free to direct any unaccepted/undelivered supplies of mRNA-1273 to customers other than the USG, at its discretion, without further obligation of either party with regard to such unaccepted/undelivered supplies of mRNA-1273.  The contract will be bilaterally modified to decrease the quantities by the agreed upon volume.
H.18    [***] 
In order to facilitate projections and invoicing, the Government shall provide or direct a third party [***] to provide to Moderna (1) actual quantities of Moderna [***] with 8.0mL vials during the reporting period; (2) actual quantities of Moderna [***] with 8.0mL vials during the reporting period; and (3) the number of [***] remaining in inventory and available for upcoming shipments.  This information will be provided to Moderna at a frequency of at least twice monthly.
For each 8.0mL fill volume (1600mcg) vial of vaccine shipped with [***].
Both parties acknowledge that the delivery schedule is based on [***] 8.0mL fill volume (1600mcg) vial delivered.  In accordance with the agreed approach for invoicing and counting doses toward Moderna’s delivery requirement, [***].  Specifically for purposes of adhering to the scheduled delivery dates set forth in this contract for the Base Period, Option 1 and Option 2, schedule shall be deemed to have been met once doses are released by Moderna and are available for order.
H.19    Product [***] (as added via P00007)
Specific to CLINs 3001 and 4001, Moderna will deliver to the Government [***]:
•mRNA-1273 Primary Series (0.2mg/mL, l00pg, 2-dose)
•[***]
All doses delivered in calendar year 2021 will be delivered in multi-dose vials [***].
The Government and Moderna agree that total monthly delivery quantities for each of CLIN 3001 and 4001 will follow the schedule in the table below.  The Government and Moderna also agree on the following points specific to product ordering:
[***]
H.20    Donation of Excess Product
a.    If the Government determines that a quantity of doses of mRNA-1273 supplied to the Government under this contract is no longer needed by the Government, the Government may donate such doses to a foreign nation or non-governmental organization (NGO) facilitating donation to a foreign nation, subject to the remainder of this 

Clause H.20.  The Government shall notify Contractor in writing prior to any proposed donation to a foreign nation or NGO, which notice will include [***].
b.    Contractor must verify in writing that all of the required conditions below are met before any such donation is made, [***].
[***]
c.    The Government’s donations will be from supplies of vaccine delivered to and accepted by the Government.  To the extent the Government commits to deliver doses that have not yet been physically delivered to the Government, such donation will not occur until such doses have been delivered to the Government.  The Government will be responsible for delivery of the donated doses to, and coordination of delivery with, the receiving foreign nation or NGO, as applicable.  The Government or the receiving foreign nation or NGO, as applicable, will (i) satisfy all customs shipping requirements for import and export of the product; and (ii) as the exporter, file any required FDA export notifications.  To the extent not already provided to the Government, the Contractor will provide all information necessary to complete any requirements identified in this paragraph in advance of shipment.
d.    When the conditions above are met for any donation, the Parties will [***].
e.     [***].
f.    Shipment of any donated doses under this Article does not constitute a violation of the Defense Production Act.
SECTION J - LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS
The following have been modified:
												
	Document Type	Description	Page #	Date
	Exhibit A	CDRLs	15	11 Feb 2021
	Exhibit B	Donation of Excess Product	1	16 June 2021
	Attachment 0001	Supply Chain Resiliency Plan for CDRL A010	3	23 July 2020
	Attachment 0002	Security Plan	7	23 July 2020
	Attachment 0003	Dose Tracking Template Draft Moderna	Excel	15 July 2020
	Attachment 0004	Data Rights	3	7 August 2020
	Attachment 0005	[***]	2	7 August 2020
	Attachment 0006	ModernaTx, Inc. Background Intellectual Property	3	6 August 2020
	Attachment 0007	Performance Base Payment Milestone Schedule	1	14 June 2021
	Attachment 0008	Performance Base Payment Milestone Billing Plan	16	14 June 2021
	Attachment 0009	HRPAS Moderna Letter	1	3 September 2020

(End of Summary of Changes)

																																							
	AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT	1. CONTRACT ID CODE	PAGE OF PAGES
	1	2
	2. AMENDMENT/MODIFICATION NO.:
P00009
	EFFECTIVE DATE
16-Jun-2021
	4. REQUESTION/PURCHASE REQ. NO.
SEE SCHEDULE
	5. PROJECT NO. (If applicable)
	6. ISSUED BY    CODE
	W58P05	7. ADMINISTERED BY (If other than item 6)    CODE
	S2206A
	ACC-APG-COVID RESPONSE-W58P05
6472 INTEGRITY COURT (BUILDING 4401)
ABERDEEN PROVING GROUND MD 21005-3013
	DCMA BOSTON
495 SUMMER STREET
BOSTON MA 02210-2138
	
	8. NAME AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code) 
MODERNA US, INC.
[***]
200 TECHNOLOGY SQ
CAMBRIDGE MA 02139-3578
		9A. AMENDMENT OF SOLICITATION NO.
		9B. DATED (SEE ITEM 11)
	X	10A. MOD. OF CONTRACT/ORDER NO.
W911QY20C0100

	CODE      8PTM0	FACILITY CODE	X	10B. DATED (SEE ITEM 13)
09-Aug-2020

	11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS
	    The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offer  is extended,  is not extended. Offer mist acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended by one of the following methods: (a) By completing Items 8 and 15, and returning _____ copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

	12. ACCOUNTING AND APPROPRIATION DATA (If required)
	13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACT BORDERS.
IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.
		A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.
		B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B).
	X	C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:
See Continuation Page

		D. OTHER (Specify type of modification and authority)
	E. IMPORTANT: Contractor  is not, ☒ is required to sign this document and return __1___ copies to the issuing office.

	14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.) Modification Control Number:      [***]
See Block 14 Continuation Page
Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.

	15 A. NAME AND TITLE OF SIGNER (Type or print)
Stephen Hoge, President
	16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)
[***]
tel:  [***]    email:  [***]

	15B. CONTRACTOR/OFFEROR 
/s/ Stephen Hoge
	15C. DATE SIGNED
June 16, 2021
	16B. UNITED STATES OF AMERICA
BY
	16C. DATE SIGNED
June 16, 2021

	(Signature person authorized to sign)	(Signature of Contracting Officer)

SECTION SF 30 BLOCK 14 CONTINUATION PAGE
SUMMARY OF CHANGES
SECTION SF 30 - BLOCK 14 CONTINUATION PAGE
The following have been added by full text:
P00009
OBLIGATION AMOUNT: $0.00
a.    The purpose of this modification (P00009) is to:
-    Update Exhibit B as outlined in clause H.20 with donation information for donation to Canada (Authority FAR 43.103(a)(3), Mutual Agreement of the Parties)
b.    This modification was requested by the program office to meet the Government’s mission requirements.
c.    The total contract value and total funded amount remains unchanged.
SECTION J - LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS
The following have been modified:
												
	Document Type	Description	Page #	Date
	Exhibit A	CDRLs	15	11 Feb 2021
	Exhibit B	Donation of Excess Product	1	16 June 2021
	Attachment 0001	Supply Chain Resiliency Plan for CDRL A010	3	23 July 2020
	Attachment 0002	Security Plan	7	23 July 2020
	Attachment 0003	Dose Tracking Template Draft Moderna	Excel	15 July 2020
	Attachment 0004	Data Rights	3	7 August 2020
	Attachment 0005	[***]	2	7 August 2020
	Attachment 0006	ModernaTx, Inc. Background Intellectual Property	3	6 August 2020
	Attachment 0007	Performance Base Payment Milestone Schedule	1	14 June 2021
	Attachment 0008	Performance Base Payment Milestone Billing Plan	16	14 June 2021
	Attachment 0009	HRPAS Moderna Letter	1	3 September 2020

(End of Summary of Changes)

Exhibit B - Donation of Excess
Product As of 16 June 2021
																								
	Country	Mod No	Batch	Exp Date	COVID Vaccine Type	DS Source	Fill Finish Site	Dose Total
	[***]	[***]	[***]	[***]	mRNA-1273
[***]	[***]	[***]	[***]

																																							
	AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT	1. CONTRACT ID CODE	PAGE OF PAGES
	1	2
	2. AMENDMENT/MODIFICATION NO.:
P00010
	EFFECTIVE DATE
17-Jun-2021
	4. REQUESTION/PURCHASE REQ. NO.
SEE SCHEDULE
	5. PROJECT NO. (If applicable)
	6. ISSUED BY    CODE
	W58P05	7. ADMINISTERED BY (If other than item 6)    CODE
	S2206A
	ACC-APG-COVID RESPONSE-W58P05
6472 INTEGRITY COURT (BUILDING 4401)
ABERDEEN PROVING GROUND MD 21005-3013
	DCMA BOSTON
495 SUMMER STREET
BOSTON MA 02210-2138
	
	8. NAME AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code) 
MODERNA US, INC.
[***]
200 TECHNOLOGY SQ
CAMBRIDGE MA 02139-3578
		9A. AMENDMENT OF SOLICITATION NO.
		9B. DATED (SEE ITEM 11)
	X	10A. MOD. OF CONTRACT/ORDER NO.
W911QY20C0100

	CODE	FACILITY CODE	X	10B. DATED (SEE ITEM 13)
09-Aug-2020

	11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS
	    The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offer  is extended,  is not extended. Offer mist acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended by one of the following methods: (a) By completing Items 8 and 15, and returning _____ copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

	12. ACCOUNTING AND APPROPRIATION DATA (If required)
	13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACT BORDERS.
IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.
		A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.
		B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B).
	X	C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:
See Block 14 Continuation Page

		D. OTHER (Specify type of modification and authority)
	E. IMPORTANT: Contractor  is not, ☒ is required to sign this document and return ___1__ copies to the issuing office.

	14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.) Modification Control Number:         [***]
See Block 14 Continuation
Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.

	15 A. NAME AND TITLE OF SIGNER (Type or print)
Stephen Hoge, President
	16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)
[***]
tel:  [***]    email:  [***]

	15B. CONTRACTOR/OFFEROR 
/s/ Stephen Hoge
	15C. DATE SIGNED
June 17, 2021
	16B. UNITED STATES OF AMERICA
BY
	16C. DATE SIGNED
June 17, 2021

	(Signature person authorized to sign)	(Signature of Contracting Officer)

SECTION SF 30 BLOCK 14 CONTINUATION PAGE
SUMMARY OF CHANGES
SECTION SF 30 - BLOCK 14 CONTINUATION PAGE
The following have been added by full text:
P00010
OBLIGATION AMOUNT: $0.00
a.    The purpose of this modification (P00010) is to:
-    Update Exhibit B as outlined in clause H.20 with donation information for donation to Taiwan (Authority FAR 43.103(a)(3), Mutual Agreement of the Parties)
b.    This modification was requested by the program office to meet the Government’s mission requirements.
c.    The total contract value and total funded amount remains unchanged.
SECTION J - LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS
The following have been modified:
												
	Document Type	Description	Page#	Date
	Exhibit A	CDRLs	15	11 Feb 2021
	Exhibit B	Donation of Excess Product	1	17 June 2021
	Attachment 0001	Supply Chain Resiliency Plan for CDRL A010	3	23 July 2020
	Attachment 0002	Security Plan	7	23 July 2020
	Attachment 0003	Dose Tracking Template Draft Moderna	Excel	15 July 2020
	Attachment 0004	Data Rights	3	7 August 2020
	Attachment 0005	[***]	2	7 August 2020
	Attachment 0006	ModernaTx, Inc. Background Intellectual Property	3	6 August 2020
	Attachment 0007	Performance Base Payment Milestone Schedule	1	14 June 2021
	Attachment 0008	Performance Base Payment Milestone Billing Plan	16	14 June 2021
	Attachment 0009	HRPAS Moderna Letter	1	3 September 2020

(End of Summary of Changes)

Exhibit B - Donation of Excess Product
As of 17 June 2021
																								
	Recipient	Mod No	Batch	Exp Date	COVID Vaccine Type	DS Source	Fill Finish Site	Dose Total
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]

																																							
	AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT	1. CONTRACT ID CODE	PAGE OF PAGES
	1	12
	2. AMENDMENT/MODIFICATION NO.:
P00011
	EFFECTIVE DATE
01-Jul-2021
	4. REQUESTION/PURCHASE REQ. NO.
SEE SCHEDULE
	5. PROJECT NO. (If applicable)
	6. ISSUED BY    CODE
	W58P05	7. ADMINISTERED BY (If other than item6)    CODE
	S2206A
	ACC-APG-COVID RESPONSE-W58P05
6472 INTEGRITY COURT (BUILDING 4401)
ABERDEEN PROVING GROUND MA 21005-3013
	DCMA BOSTON
495 SUMMER STREET
BOSTON MA 02210-2138
	
	8. NAME AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code) 
MODERNA US, INC.
[***]
200 TECHNOLOGY SQ
CAMBRIDGE MA 02139-3578
		9A. AMENDMENT OF SOLICITATION NO.
		9B. DATED (SEE ITEM 11)
	X	10A. MOD. OF CONTRACT/ORDER NO.
W911QY20C0100

	CODE     8PTM0	FACILITY CODE	X	10B. DATED (SEE ITEM 13)
09-Aug-2020

	11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS
	    The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offer  is extended,  is not extended. Offer mist acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended by one of the following methods: (a) By completing Items 8 and 15, and returning _____ copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

	12. ACCOUNTING AND APPROPRIATION DATA (If required)
	13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACT BORDERS.
IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.
		A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.
		B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B).
	X	C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:
See Block 14 Continuation Page

		D. OTHER (Specify type of modification and authority)
	E. IMPORTANT: Contractor  is not, ☒ is required to sign this document and return ___1__ copies to the issuing office.

	14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.) Modification Control Number:      [***]
See Block 14 Continuation Page
Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.

	15 A. NAME AND TITLE OF SIGNER (Type or print) 
Stephen Hoge, President
	16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)
[***]
tel:  [***]    email: [***]

	15B. CONTRACTOR/OFFEROR 
/s/ Stephen Hoge
	15C. DATE SIGNED	16B. UNITED STATES OF AMERICA
BY
	16C. DATE SIGNED
07-20-21

	(Signature person authorized to sign)	(Signature of Contracting Officer)

SECTION SF 30 BLOCK 14 CONTINUATION PAGE
SUMMARY OF CHANGES
SECTION SF 30 - BLOCK 14 CONTINUATION PAGE
The following have been added by full text:
P00011
OBLIGATION AMOUNT: $0.00
a.    The purpose of this modification (P00011) is to:
-    Update language in H.16 to remove the requirement to deliver 300M doses prior to sale or export (Authority FAR 43.103(a)(3), Mutual Agreement of the Parties).
-    Update Exhibit B as outlined in clause H.20 with donation information for multiple recipients identified within the past 10 business days (Authority FAR 43.103(a)(3), Mutual Agreement of the Parties).
-    Update language in H.20(d) to reflect current operating procedures (Authority FAR 43.103(a)(3), Mutual Agreement of the Parties).
b.    The modification was requested by the program office to meet the Government’s mission requirements.
c.    The total contract value and total funded amount remains unchanged.
SECTION H - SPECIAL CONTRACT REQUIREMENTS
The following have been modified:
H.1    Key Personnel
Any key personnel specified in this contract are considered to be essential to work performance.  At least thirty (30) calendar days prior to the Contractor voluntarily diverting any of the specified individuals to other programs or contracts the Contractor shall notify the Contracting Officer and shall submit a justification for the diversion or replacement and a request to replace the individual.  The request must identify the proposed replacement and provide an explanation of how the replacement’s skills, experience, and credentials meet or exceed the requirements of the contract (including, when applicable, Human Subjects Testing requirements).  If the employee of the Contractor is terminated for cause or separates from the Contractor voluntarily with less than thirty (30) calendar-day notice, the Contractor shall provide the maximum notice practicable under the circumstances.  The Contractor shall not divert, replace, or announce any such change to key personnel without the written consent of the Contracting Officer.  The contract will be modified to add or delete key personnel as necessary to reflect the agreement of the parties.  The following individuals are determined to be key personnel:
						
	Name	Title
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]

H.2    Substitution of Key Personnel

The Contractor agrees to assign to the contract those persons whose resumes/CVs were submitted with the proposal who are necessary to fill the requirements of the contract.  No substitutions shall be made except in accordance with this clause.
All requests for substitution must provide a detailed explanation of the circumstance necessitating the proposed substitution, a complete resume for the proposed substitute and any other information requested by the contracting officer to approve or disapprove the proposed substitution.  All proposed substitutes must have qualifications that are equal to or higher than the qualifications of the person to be replaced.  The contracting officer or authorized representative will evaluate such requests and promptly notify the contractor of his approval or disapproval thereof.
H.3    Disclosure of Information:
Performance under this contract may require the Contractor to access non-public data and information proprietary to a Government agency, another Government Contractor or of such nature that its dissemination or use other than as specified in the work statement would be adverse to the interests of the Government or others.  Neither the Contractor, nor Contractor personnel, shall divulge nor release data nor information developed or obtained under performance of this contract, except authorized by Government personnel or upon written approval of the CO which the KO will provide in accordance with OWS or other Government policies and/or guidance.  The Contractor shall not use, disclose, or reproduce proprietary data that bears a restrictive legend, other than as specified in this contract, or any information at all regarding this agency.
The Contractor shall comply with all applicable Government requirements for protection of non-public information.  Unauthorized disclosure of nonpublic information is prohibited by the Government’s rules.  Unauthorized disclosure may result in termination of the contract, replacement of a Contractor employee, or other appropriate redress.  Neither the Contractor nor the Contractor’s employees shall disclose or cause to be disseminated, any information concerning the operations of the activity, which could result in, or increase the likelihood of, the possibility of a breach of the activity’s security or interrupt the continuity of its operations.
No information related to data obtained under this contract shall be released or publicized without the prior written consent of the COR, whose approval shall not be unreasonably withheld, conditioned, or delayed, provided that no such consent is required to comply with any law, rule, regulation, court ruling or similar order; for submission to any government entity’ for submission to any securities exchange on which the Contractor’s (or its parent corporation’s) securities may be listed for trading; or to third parties relating to securing, seeking, establishing or maintaining regulatory or other legal approvals or compliance, financing and capital raising activities, or mergers, acquisitions, or other business transactions. The exceptions identified in this paragraph apply to all disclosures under this Section H.3 except to the extent that a disclosure is otherwise prohibited by law.
H.4    Publication and Publicity
The contractor shall not release any reports, manuscripts, press releases, or abstracts about the work being performed under this contract without written notice in advance to the Government.
a.    Unless otherwise specified in this contract, the contractor may publish the results of its work under this contract. The contractor shall promptly send a copy of each submission to the COR for security review prior to submission. The contractor shall also inform the COR when the abstract article or other publication is published, and furnish a copy of it as finally published.
b.    Unless authorized in writing by the CO, the contractor shall not display the DoD logo including Operating Division or Staff Division logos on any publications.
c.    The contractor shall not reference the products(s) or services(s) awarded under this contract in commercial advertising, as defined in FAR 31.205-1, in any manner which states or implies DoD approval or endorsement of the product(s) or service(s) provided.

d.    The contractor shall include this clause, including this section (d) in all subcontracts where the subcontractor may propose publishing the results of its work under the subcontract. The contractor shall acknowledge the support of the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority whenever publicizing the work under this contract in any media by including an acknowledgement substantially as follows:
“This project has been funded in whole or in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract Number W911QY-20-C-0100.”
H.5    Confidentiality of Information
a.    Confidential information, as used in this article, means non-public information or data of a personal nature about an individual, or proprietary information or data submitted by or pertaining to an institution or organization.
b.    The Contracting Officer and the Contractor may, by mutual consent, identify elsewhere in this contract specific information and/or categories of information which the Government will furnish to the Contractor or that the Contractor is expected to generate which is confidential.  Similarly, the Contracting Officer and the Contractor may, by mutual consent, identify such confidential information from time to time during the performance of the contract.  Failure to agree will be settled pursuant to the “Disputes” clause.
c.    If it is established elsewhere in this contract that information to be utilized under this contract, or a portion thereof, is subject to the Privacy Act, the Contractor will follow the rules and procedures of disclosure set forth in the Privacy Act of 1974, 5 U.S.C. 552a, and implementing regulations and policies, with respect to systems of records determined to be subject to the Privacy Act.
d.    Confidential information, as defined in paragraph (a) of this article, shall not be disclosed without the prior written consent of the individual, institution, or organization.
e.    Whenever the Contractor is uncertain with regard to the proper handling of material under the contract, or if the material in question is subject to the Privacy Act or is confidential information subject to the provisions of this article, the Contractor shall obtain a written determination from the Contracting Officer prior to any release, disclosure, dissemination, or publication.
f.    Contracting Officer Determinations will reflect the result of internal coordination with appropriate program and legal officials.
g.    The provisions of paragraph (d) of this article shall not apply to conflicting or overlapping provisions in other Federal, State or local laws.
ALL REQUIREMENTS OF THIS SECTION H.5 MUST BE PASSED TO ALL SUB-CONTRACTOR.
H.6    Regulatory Rights
This contract involves supply of a product that requires FDA pre-market approval or clearance before commercial authorization.  Contractor is seeking FDA authorization or clearance for the commercialization of mRNA-1273, Moderna vaccine for SARS-CoV-2 Coronavirus (the “Technology”).  The Contractor is the Sponsor of the Regulatory Application (an investigational new drug application (IND), investigational device exemption (IDE), emergency use authorization (EUA), new drug application (NDA), biologies license application (BLA), premarket approval application (PMA), or 510(k) pre-market notification filing (510(k)) or another regulatory filing submitted to FDA) for the technology.  As the Sponsor of the Regulatory Application to FDA (as the terms “sponsor” and “applicant” are defined or used in at 21 CFR §§3.2(c), 312.5, 600.3(t), 812.2(b), 812 Subpart C, or 814.20), the Contractor has certain standing before the FDA that entitles it to exclusive communications related to the Regulatory Application.

Accordingly, the Contractor and the Government agree to the following:
a.    DoD Medical Product Priority.  PL 115-92 allows the DoD to request, and FDA to provide, assistance to expedite development of products to diagnose, treat, or prevent serious or life-threatening diseases or conditions facing American military personnel.  The contractor recognizes that only the DoD can utilize PL 115-92.  As such, the contractor will work proactively with the Government to leverage this law to its maximum potential under this contract.  The contractor shall submit Public Law 115-92 Sponsor Authorization Letter that will be delivered to the designated OWS POC(s) within [***] of award.
b.    [***].
H.7    Performance Based Payment Liquidated under Termination
Performance Based Payments (PBPs) have been authorized as a method of financing under this contract.  In the event the Moderna’s mRNA-1273 COVID Vaccine is unsuccessful in its bid to obtain EUA or FDA approval, the Government may issue a Termination for Convenience (T4C) in whole or in part, on this contract.  Upon notice of a T4C, the contractor shall submit a termination settlement proposal, IAW FAR 52.249-2, Termination for Convenience of the Government (Fixed-Price).
H.8    Public Readiness and Emergency Preparedness (PREP) Act:
In accordance with the Public Readiness and Emergency Preparedness Act (“PREP Act”), Pub. L. No. 109-148, Division C, Section 2, as amended (codified at 42 U.S.C. § 247d-6d and 42 U.S.C. § 247d-6e), as well as the Secretary of HHS’s Declaration Under the Public Readiness and Emergency Preparedness Act for Medical Countermeasures Against CO VID-19, 85 Fed. Reg. 15198 (Mar. 17,2020, effective Feb. 4, 2020), and amended on April 15, 2020, 85 Fed. Reg. 21012 (together, the “Prep Act Declaration”):
(i)    This Agreement is being entered into for purposes of facilitating the manufacture, testing, development, distribution, administration, and use of “Covered Countermeasures” for responding to the COVID-19 public health emergency, in accordance with Section VI of the PREP Act Declaration;
(ii)    Contractor’s performance of this Agreement falls within the scope of the “Recommended Activities” for responding to the COVID-19 public health emergency, to the extent it is in accordance with Section III of the PREP Act Declaration; and
(iii)    Contractor is a “Covered Person” to the extent it is a person defined in Section V of the PREP Act Declaration.
Therefore, in accordance with Sections IV and VII of the PREP Act Declaration as well as the PREP Act (42 U.S.C. § 247d-6d), the Department of Defense contracting via assisted acquisition on behalf of the HHS, expressly acknowledges and agrees that the HHS Declaration cited above, specifically its language providing immunity from suit and liability is applicable to this acquisition as long as Contractors activities fall within the terms and conditions of the PREP Act and the PREP Act Declaration.
The Government may not use, or authorize the use of, any products or materials provided under this contract, unless such use occurs in the United States (or a U.S. territory where U.S. law applies such as embassies, military and NATO installations) and is protected from liability under a declaration issued under the PREP Act, or a successor CO VID-19 PREP Act Declaration of equal or greater scope.  Any use where the application of the PREP Act is in question will be discussed with Moderna prior to use and, if the parties disagree on such use, the dispute will be resolved according to the “Disputes Clause” (52.233-1)
The items and technology covered by this Contract are being developed for both civil and military applications.
H.9    [***]. 

H.10    [***]. 
H.11    [***]. 
H.12    Transportation to Final Destination
During the course of performance under this contract, the Government may require storage of the filled drag product (FDP) before delivery to the final government location.  In these circumstances, the Government will accept FDP at the contractor facility (Origin).  The contractor; however, shall continue to be responsible for secure delivery of the vaccine to its final destination as identified on this contract.  [***].
H.13    Validation of IP/Data
The Parties acknowledge that background intellectual property and technical data assertions have been made and evaluated by the parties.  The parties agree that, should additional information relevant to these assertions become available, the parties will reevaluate said assertions as necessary in the future.
H.14    Novation
Upon Moderna, US, Inc.’s registration in the System for Award Management, the Government will, at the Contractor’s request, complete a novation of this Contract to recognize Moderna US, Inc.  as a counterparty instead of Moderna TX, Inc.  This novation will be completed through a modification executed by the Government that identifies Moderna US, Inc. as the contracting party for all purposes as if it had originally executed the Contract.
H.15    Base & Option 1 Delivery Acceleration
In an effort to accelerate production of the mRNA-1273 vaccine, [***] within the Option 1 period via a Modification to the contract.  If these manufacturing slots are successfully utilized, [***] above what was projected by Moderna and assumed within the price per dose for the doses of mRNA-1273 vaccine delivered in the Base Period and Option 1.  However, because the Government is funding the additional slots within the Base and Option 1 periods in order to accelerate production, the Government is entitled to an adjustment under the conditions outlined.  The Government and Moderna agree to the following:
1.    If the Government exercises Option 2 (NLT 15 May):
a.    Moderna will reduce the cost of Option 2 by [***] for each successfully accelerated drug product fill under the Base Period [***]) and [***] for each successfully accelerated drug product fill under Option 1 [***].
2.    If the Government does not exercise Option 2 (NLT 15 May):
a.    In the event Moderna timely cancels the manufacturing slots and/or is able to otherwise fully utilize the slots originally reserved for production in the Option 2 period, Moderna agrees to credit the Government [***] for [***] and [***] for [***].  In no case shall the number of drug product manufacturing slots credited exceed the number of successfully accelerated drug product manufacturing fills under the Base Period and Option 1.  It is understood that Moderna will make all good-faith efforts to fill reserved slots or cancel reservations in a timely manner (i.e.  within the time period required by the subcontractor).
b.    In the event that Moderna is unable to fill those reserved slots (i.e.  due to lack of demand) and cancels slots, Moderna shall be entitled to recoup those reservation cancellation costs from the USG.  The process is outlined as follows:
1.)    Moderna shall submit documentation to the USG of the following:
i.)    Cancellation notice to the subcontractor,

ii.)    The basis of the cancellation, and
iii.)    Cancellation fees incurred.
2.)    Moderna shall reduce credits to the USG under paragraph 2a) of this clause, IAW agreed cancellation costs incurred.
3.)    Bi-lateral agreement of the final credit shall be included in a modification to the contract.  Net credit shall be deducted from final payments under the contract.
H.16    Delivery Schedule, as revised 11 Feb 2021 via modification P00004
[***]
H.17    Post-Termination Disposition of Undelivered Product
For the avoidance of doubt, if the USG elects to terminate the exercised CLINs prior to acceptance and delivery in full of the required quantities of mRNA-1273, Moderna will be free to direct any unaccepted/undelivered supplies of mRNA-1273 to customers other than the USG, at its discretion, without further obligation of either party with regard to such unaccepted/undelivered supplies of mRNA-1273.  The contract will be bilaterally modified to decrease the quantities by the agreed upon volume.
H.18    [***] 
In order to facilitate projections and invoicing, the Government shall provide or direct a third party (e.g., McKesson) to provide to Moderna (1) actual quantities of Moderna [***] with 8.0mL vials during the reporting period; (2) actual quantities of Moderna [***] with 8.0mL vials during the reporting period; and (3) the number of [***] remaining in inventory and available for upcoming shipments.  This information will be provided to Moderna at a frequency of at least twice monthly.
For each 8.0mL fill volume (1600mcg) vial of vaccine shipped with [***].
Both parties acknowledge that the delivery schedule is based on [***] 8.0mL fill volume (1600mcg) vial delivered.  In accordance with the agreed approach for invoicing and counting doses toward Moderna’s delivery requirement, [***].  Specifically for purposes of adhering to the scheduled delivery dates set forth in this contract for the Base Period, Option 1 and Option 2, schedule shall be deemed to have been met once doses are released by Moderna and are available for order.
H.19    Product [***] (as added via P00007)
Specific to CLINs 3001 and 4001, Moderna will deliver to the Government [***]
•mRNA-1273 Primary Series (0.2mg/mL, 100pg, 2-dose)
•[***]
All doses delivered in calendar year 2021 will be delivered in multi-dose vials [***].
The Government and Moderna agree that total monthly delivery quantities for each of CLIN 3001 and 4001 will follow the schedule in the table below.  The Government and Moderna also agree on the following points specific to product ordering:
[***]
H.20    Donation of Excess Product

a.    If the Government determines that a quantity of doses of mRNA-1273 supplied to the Government under this contract is no longer needed by the Government, the Government may donate such doses to a foreign nation or non-governmental organization (NGO) facilitating donation to a foreign nation, subject to the remainder of this Clause H.20.  The Government shall notify Contractor in writing prior to any proposed donation to a foreign nation or NGO, which notice will include [***].
b.    Contractor must verify in writing that all of the required conditions below are met before any such donation is made, [***].
c.    The Government’s donations will be from supplies of vaccine delivered to and accepted by the Government.  To the extent the Government commits to deliver doses that have not yet been physically delivered to the Government such donation will not occur until such doses have been delivered to the Government.  The Government will be responsible for delivery of the donated doses to, and coordination of delivery with, the receiving foreign nation or NGO, as applicable.  The Government or the receiving foreign nation or NGO, as applicable, will (i) satisfy all customs shipping requirements for import and export of the product; and (ii) as the exporter, file any required FDA export notifications.  To the extent not already provided to the Government, the Contractor will provide all information necessary to complete any requirements identified in this paragraph in advance of shipment.
d.    When the conditions above are met for any donation, the Parties will [***].
e.    [***]. 
f.    Shipment of any donated doses under this Article does not constitute a violation of the Defense Production Act.
(End of Summary of Changes)

Exhibit B - Donation of Excess Product
As of 1 July 2021
																											
	Country	Mod No	Batch	Exp Date	COVID Vaccine Type	DS Source	NGO Facilitator (if applicable)	Fill Finish Site	Dose Total
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]		[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]		[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]		[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]		[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]		[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]		[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]	[***]

																											
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]	[***]

																																							
	AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT	1. CONTRACT ID CODE	PAGE OF PAGES
	1	2
	2. AMENDMENT/MODIFICATION NO.:
P00012
	EFFECTIVE DATE
20-Jul-2021
	4. REQUESTION/PURCHASE REQ. NO.
SEE SCHEDULE
	5. PROJECT NO. (If applicable)
	6. ISSUED BY    CODE
	W58P05	7. ADMINISTERED BY (If other than item6)    CODE
	S2206A
	ACC-APG-COVID RESPONSE-W58P05
6472 INTEGRITY COURT (BUILDING 4401)
ABERDEEN PROVING GROUND MA 21005-3013
	DCMA BOSTON
495 SUMMER STREET
BOSTON MA 02210-2138
	
	8. NAME AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code) 
MODERNA US, INC.
[***]
200 TECHNOLOGY SQ
CAMBRIDGE MA 02139-3578
		9A. AMENDMENT OF SOLICITATION NO.
		9B. DATED (SEE ITEM 11)
	X	10A. MOD. OF CONTRACT/ORDER NO.
W911QY20C0100

	CODE     8PTM0	FACILITY CODE	X	10B. DATED (SEE ITEM 13)
09-Aug-2020

	11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS
	    The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offer  is extended,  is not extended. Offer mist acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended by one of the following methods: (a) By completing Items 8 and 15, and returning _____ copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

	12. ACCOUNTING AND APPROPRIATION DATA (If required)
	13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACT BORDERS.
IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.
		A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.
		B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B).
	X	C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:
See Block 14 Continuation Page

		D. OTHER (Specify type of modification and authority)
	E. IMPORTANT: Contractor  is not, ☒ is required to sign this document and return ___1__ copies to the issuing office.

	14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.) Modification Control Number:      [***]
See Block 14 Continuation Page
Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.

	15 A. NAME AND TITLE OF SIGNER (Type or print) 
Stephane Bancel, CEO
	16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)
[***]
tel:  [***]    email: [***]

	15B. CONTRACTOR/OFFEROR 
/s/ Stephane Bancel
	15C. DATE SIGNED	16B. UNITED STATES OF AMERICA
BY
	16C. DATE SIGNED
07-20-21

	(Signature person authorized to sign)	(Signature of Contracting Officer)

SECTION SF 30 BLOCK 14 CONTINUATION PAGE
SUMMARY OF CHANGES
SECTION SF 30 - BLOCK 14 CONTINUATION PAGE
The following have been added by full text:
P00012
OBLIGATION AMOUNT: $0.00
a.    The purpose of this modification (P00012) it to:
- Update Exhibit B as outlined in clause H.20 with donation information for multiple recipients identified with the past 7 business days (Authority FAR 43.103(a)(3), Mutual Agreement of the Parties).
b.    The modification was required by the program office to meet the Government’s mission requirements.
c.    The total contract value and total funded amount remains unchanged.
SECTION J - LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS
The following have been modified:
												
	Document Type	Description	Page#	Date
	Exhibit A	CDRLs	15	11 Feb 2021
	Exhibit B	Donation of Excess Product	3	13 July 2021
	Attachment 0001	Supply Chain Resiliency Plan for CDRL A010	3	23 July 2020
	Attachment 0002	Security Plan	7	23 July 2020
	Attachment 0003	Dose Tracking Template Draft Moderna	Excel	15 July 2020
	Attachment 0004	Data Rights	3	7 August 2020
	Attachment 0005	[***]	2	7 August 2020
	Attachment 0006	ModernaTx, Inc. Background Intellectual Property	3	6 August 2020
	Attachment 0007	Performance Base Payment Milestone Schedule	1	14 June 2021
	Attachment 0008	Performance Base Payment Milestone Billing Plan	16	12 July 2021
	Attachment 0009	HRPAS Moderna Letter	1	3 September 2020

(End of Summary of Changes)

Exhibit B - Donation of Excess Product
As of 13 July 2021
																																	
	Country	Mod No	Batch	Exp Date	COVID Vaccine Type	DS Source	Fill Finish Site	Dose Total
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]

																																	
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273
[***]
	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	mRNA-1273 
[***]
	[***]	[***]	[***]Document

Exhibit 10.2
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED

																																																			
	AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT
	1. CONTRACT ID CODE
	PAGE OF PAGES

	1
	13

	2. AMENDMENT/MODIFICATION NO.
P00008
	3. EFFECTIVE DATE
See Block 16C
	4. REQUISITION/PURCHASE REQ. NO.
OS273940
	5. PROJECT NO.(If applicable)
	6. ISSUED BY
ASPR-BARDA
200 Independence Ave., S.W.
Room 640-G
Washington DC 20201
	CODE	ASPR-BARDA	7. ADMINISTERED BY (If other than item 6)    
US DEPT OF HEALTH & HUMAN SERVICES
ASST SEC OF PREPAREDNESS & RESPONSE
ACQ MANAGEMENT, CONTRACTS, & GRANTS
O'NEILL HOUSE OFFICE BUILDING
Washington DC 20515
	CODE	ASPR-BARDA02
			
	8. NAME AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code)
MODERNAUS, INC.
[***]
200 TECHNOLOGY SQ
CAMBRIDGE MA 02139-3578
		9A. AMENDMENT OF SOLICITATION NO.
		9B. DATED (SEE ITEM 11)
	X	10A. MOD. OF CONTRACT/ORDER NO.
75A50120C00034

	X	10B. DATED (SEE ITEM 13)
04/03/2020

	CODE    1492235
			FACILITY CODE
	11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS

		The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offer     is extended,     is not extended.
Offer mist acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended by one of the following methods: 
(a) By completing Items 8 and 15, and returning ___________ copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted;
or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE
RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION
OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

	12. ACCOUNTING AND APPROPRIATION DATA (If required)
See Schedule    Net Increase:    $236, 364, 615.00

	13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

		A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.

		B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B).

	X	C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:
FAR 52.243- 2 Alternate 1 (APR 1984) Changes - Cost-Reimbursement

		D. OTHER (Specify type of modification and authority)

	E. IMPORTANT: Contractor      is not,     is required to sign this document and return     1     copies to the issuing office.

	14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)
Tax ID Number: 27-0226313
DUNS Number: 069723520
This contract (75A50120C00034 - Moderna COVID-19 Vaccine)was awarded under
BAA-18-100-SOL-00003 - Development of an mRNA Vaccine for SARS-CoV-2.
The purpose of this modification is to support the additional scope of the Clinical
Development Plan (CLIN 0002)which includes increases the P301(Efficacy)(WBS 1.4.3.1);
Clinical(FTEs and digital clinical system)(WBS 1.4);Biologics License Application BLA (WBS
1.5.2) and Pharmacovigilance (supporting EUA) (WBS 1.5.3.1).
The obligated amount of CLIN 0002 is increased from $961,387,795 by $236,364,615 to Continued ...
Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in foil force and effect.

	15A. NAME AND TITLE OF SIGNER (Type or print) 
Stephane Bancel, CEO
	16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)
[***]

	15B. CONTRACTOR/OFFEROR
/s/ Stephane Bancel
        
(Signature of person authorized to sign)
	15C. DATE SIGNED	16B. UNITED STATES OF AMERICA
BY        
(Signature of Contracting Officer)
	16C. DATE SIGNED
04/18/2021

																																				
	CONTINUATION SHEET	Reference No. of Document Being Continued
75A50120C00034/P00008
	PAGE
2
	OF
11

	NAME OF OFFEROR OR CONTRACTOR
MODERNATX, INC. 1492235

	Item No.
(A)	Supplies/Services
(B)	Quantity
(C)	Unit
(D)	Unit Price
(E)	Amount
(F)
	2	$1,197,752,410.
CLIN 0002 is the only CLIN changed by the issuance of this modification. CLIN 0002 remains cost plus fixed fee (CPFF). Fee was not applied to the additional scope.

		Prior Contract Value	Additional Funding	Revised Contract Value
	CLIN 0001	$    3,212,541	$    -	$    3,212,541
	CLIN 0002	$    961,387,795	$    236,364,615	$    1,197,752,410
	CLIN 0003	$    53,000,000	$    -	$    53,000,000
	Total	$    1,017,600,336	$    236,364,615	$    1,253,964,951
	All other contract terms and conditions remain unchanged.
Period of Performance: 04/03/2020 to 08/31/2023
Change Item 2 to read as follows(amount shown is the obligated amount):

	Base CLIN 0002 - Development of mRNA vaccine to BLA	236,364,615.00
	Accounting Info:		
	2020.199COV1.25103 Appr. Yr.: 2020 CAN: 199COV1 Object Class:	25103
	Funded:    $0.00	
	Accounting Info:	
	2020.199C014.25103 Appr. Yr.: 2020 CAN: 199C014 Object Class:	25103
	Funded:    $0.00	
	Accounting Info:	
	2021.199C035.25103 Appr. Yr.: 2021 CAN: 199C035 Object Class:	25103
	Funded:    $0.00	
	Accounting Info:	
	2021.199C035.25103 Appr. Yr.: 2021 CAN: 199C035 Object Class:	25103
	Funded: $236,364,615.00	

Contract #75A50120C00034
Modification P00008

C.  Statement of Work
Updated with Modification P00008
Independently, and not as an agent of the United States Government, the contractor shall furnish all necessary services, qualified professional, technical, and administrative personnel, material, equipment and facilities, not otherwise provided by the Government under the terms of this contract, as needed to perform the tasks set forth below.
mRNA-1273 Vaccine Development (WBS 1.0)
The Contractor, Moderna, Inc. (“Moderna”) shall execute the preclinical, clinical, and chemistry, manufacturing and controls (CMC) activities required to license a vaccine against the SARS-CoV-2 virus (hereafter referred to as “mRNA-1273”).  Building upon early clinical development already underway, this proposal will support the late stage development, including the demonstration of clinical efficacy and generation of a dataset supportive of licensure.  Moderna will additionally evaluate the platform manufacturing capabilities relative to the needs for supply in response to a pandemic.
* Program Management (WBS 1.1) - Updated with Mod P00007
mRNA-1273 Program Management (WBS 1.1.1)
Moderna’s mRNA-1273 program team is composed of a multidisciplinary, highly matrixed, group of functional leads with experience in, and responsibility for, integrating plans and operationalizing strategies across Research, Toxicology, CMC, Regulatory Affairs, Clinical Development, Medical Affairs, Market Access and Launch Readiness in support of vaccine deployment under Emergency Use Authorization and Quality.  Collectively, the team has advanced ten programs to first-in-human studies within five years.  The group will be led by a program lead (PL) who will oversee and coordinate the activities necessary to meet the program objective of licensure.  The PL will be the point of accountability for the development and deployment of mRNA-1273.  [***].  The Sub Principal Investigator will be responsible for ensure sufficient manufacturing capacity and production of mRNA-1273.  A program management office (PMO) will be responsible for managing the cost and schedule constraints of the contract via an integrated master schedule and corresponding budget, identifying and managing program risk, and ensuring contract compliance.  With the input from the mRNA-1273 project team, the PMO will be responsible for coordinating the drafting of and management to an integrated development plan.  Upon execution of the contract, weekly meetings with BARDA will be held to monitor program performance and monthly and annual reports will be will delivered to BARDA for the record.  Moderna will contribute a portion of the subcontractor program management effort to support the contract.
Nonclinical Toxicology (WBS 1.2)
Development and Reproductive Toxicology of mRNA-1273 (WBS 1.2.2.1)
To assess the risk of administering the vaccine to pregnant women, a complete GLP rat developmental and reproductive toxicology (DART) study is planned.  Female Sprague Dawley rats will be dosed at the highest anticipated clinical dose level and include a control arm of phosphate-buffered saline (PBS).  As is typical for DART evaluations for vaccines, the animals will be immunized three times prior to mating and two times during gestation.  Each group will 

have two cohorts (one group will undergo Cesarean section with examination of the uteri and embryos; the other group will have natural delivery and will be terminated at weaning).
Nonclinical (WBS 1.3)
For the purposes of this proposal it is assumed that the VRC continues to support nonclinical activities to develop murine and non-human primate efficacy studies, and animal models to assess the potential of vaccine- enhanced disease.  The scope of work below will execute additional robustness experiments in these developed models.
Assess Disease Enhancement (WBS 1.3.3.1)
The CoV spike protein expressed by the mRNA-1273 vaccine is stabilized in the prefusion conformation which should be optimal for inducing high quality antibody responses with low binding antibody to neutralizing antibody ratios.  mRNA delivery and induction of CD8 T cells and Th1 CD4 T cells will avoid Th2-biased responses.  The SARS-CoV-2 S protein expressed by the mRNA-1273 vaccine is stabilized in the pre-fusion conformation which should be optimal for inducing high functional antibody responses with low binding antibody to neutralizing antibody ratios, as it has been seen in RSV DS-Cav1 clinical trials and 2P-stabilized CoV S animal studies.  In addition, mRNA vaccines induce Th1 skewed response as has been evident in several pre-clinical and clinical vaccine programs at Moderna, including pandemic flu and CMV (PMID 28457665, 29456015).  By expressing pre-fusion SARS-CoV-2 S delivered with mRNA we should induce CD8 T cells and Th1-biased CD4 T cell responses as shown in both human, NHP, and murine studies, thus avoiding a Th2- biased response.
We plan to perform studies in mouse and NHPs to assess the theoretical risk of vaccine induced disease enhancement triggered by CoV infection following vaccination with imRNA-1273.  [***]
[***]

Ralph Baric is also developing a human ACE-2 transgenic mouse model, resulting in viremia and lung pathology upon wild-type SARS-CoV-2 infection.  This model should facilitate evaluation of wild-type SARS- CoV-2 virus and will also be used to evaluation protection from mRNA-1273 vaccination.  This model is however still under development and data are unlikely to become available before June/July 2020.
Finally, Vincent Munster (NIH/NIAID) has developed a Rhesus macaque model of SARS-CoV infection.  After challenge animals get sick but infection is not lethal.  Decreased respiration and irregular breathing, weight loss, fever spike at day 1 and evidence of pneumonia are all observed.  In addition, hematological evidence of disease is seen, as well as viremia and shedding in nose, throat, and rectum up to day 10.  Unlike what is observed clinically a high challenge dose of virus is required, and animals recover without intervention.  Animals will be immunized with limiting doses of mRNA-1273 to allow breakthrough infection and endpoints relevant for disease enhancement will be collected.  Results from these challenge studies may become available by end of June 2020.
2 of 8

Establish a Surrogate of Protection (WBS 1.3.3.2)
The primary endpoint for accelerated approval of a SARS-CoV-2 vaccine would be a neutralization assay.  This endpoint must be supported with a body of pre-clinical work that demonstrates a correlation between neutralizing titers and efficacy and that quantifies a protective serologic threshold titer using the same neutralization assay.  Murine and NHP efficacy models are being developed in parallel to the Phase 1 clinical study.  Building on data from these preliminary models and studies, Moderna will conduct NHP efficacy and murine passive transfer studies to confirm and refine the surrogate of protection.
** Clinical (WBS 1.4) -- Updated with Mod P00008
A Phase 1 study of mRNA-1273 in 120 healthy subjects 18-55 years of age will evaluate the safety and immunogenicity of two injections (28 days apart) at four dose levels (25, 50, 100 and 250 ^g).  The proposed Phase 2 study will enroll n=600 healthy subjects (>18 years) to receive two injections, 28 days apart, of placebo or 50 or 100 ^g mRNA-1273, at 1:1:1, age stratified (18-55 yrs; >55 yrs).
The total safety database from the mRNA-1273 Phase 1 and Phase 2 studies will be approximately 445 adult participants exposed and approximately 245 adult participants at the highest dose level.  The proposed Phase 2 study (synopsis included below) is intended to support entry to subsequent Phase 3 study(ies).  [***].
** Phase 2 Safety and Immunogenicity Study (WBS 1.4.2.1) - Updated with Mod P00007
Immediately following dose selection in the initial Phase 1 study the program will initiate a Phase 2 clinical study.  The P201 study will confirm the safety and immunogenicity results from the open-label Phase 1, again testing a two-dose administration series 28d apart.  Its assumed that 600 participants, randomized 1:1:1 active: placebo, testing a two dose levels of mRNA-1273.  Enrollment will be age-stratified participants 18 year of age and above into two age cohorts.  Primary objectives will include standard clinical safety evaluation with conventional safety and SARS-CoV-2-specific IgG endpoints though a neutralizing antibody assay would be preferred if available.  Secondary objectives will evaluate of the specific humoral response against SARS-CoV-2 by binding and neutralizing antibody (nAb) response.  Safety will be followed through 6 months post-last vaccination and primary immunogenicity endpoint will be measured at D57.  The study will enroll in the US under IND.  The study will assess COVID-19 as exploratory endpoint which may extend the duration of follow-up accordingly.  Clinical trial assessments will include measurement of SARS-CoV-2 S-specific binding antibody and neutralizing activity in sera.  This will provide an indication of vaccine-induced antibody quality and relative potency.  Historically, immune-complex mediated lung pathology has been associated with a high ratio of binding to functional antibody activity.  In addition, vaccine-induced T cell responses will be evaluated by peptide pool stimulation to define the pattern of cytokine production.  [***].  To support the EUA, an interim clinical study synopsis will be drafted based on D57 safety and immunogenicity data.
** Pediatrics (WBS 1.4.2.3 Updated with Mod P00007 and WBS 1.4.2.4)
Moderna will conduct an initial pediatric study plan (PSP) under Pediatric Research Equity Act requirements during the IND phase.  A deferral will be requested for children less than 6 months 
3 of 8

of age at the time of initial BLA approval.  Having demonstrated the mRNA-1273 is safe, tolerated, and effective in adults, Moderna will test the safety and immunogenicity of mRNA-1273 in a pediatric population with an aged-based step-down design.
The P203 study is a Phase 2/3, randomized, observer-blind, placebo controlled, study to evaluate the safety, reactogenicity, and effectiveness of mRNA-1273 SARS-CoV-2 vaccine in 3000 healthy adolescents 12 to < 18 years of age.  Participants will be randomly assigned to receive injections of either 100 ^g of mRNA-1273 vaccine or a placebo control in a 2:1 randomization ratio.  The goal of the study is to seek an indication for use of mRNA 1273 (100 ^g IM, given as 2 injections, 28 days apart) in the 12 to < 18 year age group.  The basis for demonstrating vaccine effectiveness is proposed to be met by serum antibody (Ab) response measured in this adolescent age group.  The approach to inferring vaccine effectiveness will depend on whether or not an accepted serum Ab threshold conferring protection against COVID-19 has been established.  If an Ab threshold of protection has been established, effectiveness will be inferred based on the proportion of adolescent study participants with serum Ab levels (on study Day 57) meeting or exceeding the Ab threshold.  If an Ab threshold of protection has not been established, effectiveness will be inferred based on demonstrating non-inferiority of the geometric mean value of serum nAb from adolescent participants compared to the geometric mean value of serum nAb from adults enrolled in the ongoing clinical endpoint efficacy trial (Study P301).
This adolescent study will monitor all participants for a total of 12 months following the second dose of vaccine or placebo.  Safety assessments will include solicited ARs (7 days post each injection), unsolicited AEs (28 days post each injection), medically attended adverse events (MAAEs), serious adverse events (SAEs), and adverse event of special interest (AESI) (pediatric MIS C) throughout the study period.
The 204 study is a Phase 2/3, randomized, observer-blind, placebo controlled, study to evaluate the safety, reactogenicity, and effectiveness of mRNA-1273 SARS-CoV-2 vaccine in approximately 6,000 healthy children 6 months to < 12 years of age.  Approximately 6,000 participants will be enrolled in a dose-escalation, age de-escalation design testing 50 and 100 ug dose levels across three age groups: 6 to <12 years of age, 2 to <6 years of age and 6 month to <2 years of age.  Safety and Immunogenicity endpoints will follow the P203.  The study will enroll in the US and up to two ex-US countries (e.g. Canada and/or Australia).
** Phase 3 Pivotal Study (WBS 1.4.3.1) - — Updated with Mod P00008
Phase 3 Pivotal Study (WBS 1.4.3.1).  The Phase 3 mRNA-1273-P301 study will confirm the trends observed during the Phase 1 and 2 trials, evaluating safety and efficacy in a larger number of subjects aged 18 and above.  Approximately 30,000 subjects will be enrolled according to 1:1 randomization (active: placebo).  Primary objectives will be 1) to demonstrate the efficacy of mRNA-1273 to prevent COVID-19 and 2) to evaluate the safety and reactogenicity of 2 injections of the mRNA-1273 vaccine given 28 days apart.  Secondary objectives will evaluate: the efficacy of mRNA-1273 to prevent severe COVID-19; the efficacy of mRNA-1273 to prevent virologically confirmed SARS-CoV-2 infection or COVID-19 regardless of symptomatology or severity; VE against a broad definition of COVID-19 disease; VE to prevent 
4 of 8

death due to COVID-19 disease; VE against all-cause mortality; the efficacy of mRNA-1273 to prevent COVID-19 after the first dose of investigational product (IP); the efficacy of mRNA-1273 to prevent COVID-19 in all study participants, regardless of evidence of prior SARS-CoV-2 infection; the efficacy of mRNA-1273 to prevent asymptomatic SARS-CoV-2 infection.
The sample size of this Phase 3 is driven by the total number of cases to demonstrate VE (mRNA-1273 vs.  placebo) to prevent COVID-19.  [***].

[***]
On issuance of the EUA, in agreement with the FDA and OWS, the P301 study will offer vaccine to participants that were randomized to receive placebo and the study will transition to an open label study.  All 30K participants will return for a Participant Decision Visit.  Participants will complete an updated ICF, a sera and NP swab sample will be collected to test for asymptomatic infection, and participants randomized to the placebo arm will be offered vaccine.  After unblinding the sponsor will continue to leverage the clinical trial infrastructure.  Doubling the exposed population will reduce the incidence of rare events potentially detectable with high confidence in the trial to approximately 1/10,000 or 0.01%.
Lot to Lot Consistency (WBS 1.4.3.2)
Based on FDA feedback received on 27 Aug this study is no longer required for licensure.
Post-Authorization Safety and Effectiveness Studies (WBS 1.4.4.1, 1.4.4.2, 1.4.4.3 and 1.4.4.4)
During EUA, Moderna will conduct signal refinement analyses using tokenized real-world data within the United States.  The population complements but does not duplicate the populations under observation in the CDC’s Vaccine Safety DataLink and the FDA’s CMS programs.  This real-world data infrastructure will significantly decrease the time between safety signal identification and evaluation.  Using the tokenized data the sponsor will be able to conduct an early post-authorization general safety study at a point in time approximately 8-12 months after the initiation of the study to provide further reassurance that prespecified adverse events of interest are being addressed during the EUA period.
Further, Moderna is planning to establish an observational pregnancy cohort study, (e.g., with the Vaccines and Medications in Pregnancy Surveillance System (VAMPSS) Mother to Baby cohort).  Unlike a traditional passive pregnancy registry this approach will enable the calculation of incidence rates for adverse pregnancy and birth outcomes.  It will also enable the identification of key confounders and non-medically attended outcomes (e.g., spontaneous abortions) that are incompletely recorded in secondary healthcare records.
With respect to continued evaluation of effectiveness after crossover, early in the EUA period, tokenized real- world data will provide COVID-19 incidence rates within geographic zones surrounding the clinical trial sites as a proxy for rates among unvaccinated individuals.  The Moderna envisions conducting one descriptive analysis involving both trial and geographic incidence rates 3-6 months after EUA and before broad product distribution removes the utility of this early approach.  Simultaneously, a prospective cohort study within a large integrated 
5 of 8

healthcare delivery system (e.g., a Kaiser Permanente region) will be initiated to formally evaluate the vaccine effectiveness (VE) and long-term effectiveness of mRNA-1273 at the patient level with a concurrent comparator group.  Effectiveness outcomes to be evaluated include effectiveness against severe COVID-19, Follow-up time will be two years after the last dose, and interim analyses will be performed based on the number of events of the primary effectiveness outcome to assess durability of protection.  A final analysis including 1-dose VE and 2-dose VE will be evaluated.  Moderna will contribute by funding these EUA studies.  The USG will obtain access to the data.
Medical Affairs (WBS 1.4.6.1) — Updated with Mod P00007
The Medical Affairs group will provide scientific and clinical support for mRNA-1273 through the EUA period.  This will include developing patient and healthcare provider materials to support vaccine deployment under EUA and establishing a non-promotional call center to support vaccine distribution and administration.  Given the importance of vaccine confidence during EUA, special consideration will be given to scientific communication on the mRNA platform, vaccine development in a pandemic, and the safety, immunogenicity and effectiveness data of mRNA-1273.  Moderna will contribute by funding these activities.  The USG will obtain access to the data.
Regulatory (WBS 1.5)
IND Preparation and Filing (WBS 1.5.1.1)
Moderna’s Regulatory Affairs group, in close collaboration with BARDA, will work to draft a comprehensive regulatory master plan to guide the preclinical, CMC and clinical development of mRNA-1273 within the first 90 days of the contract.  An original investigational new drug application (IND) will be filed with the United States Food and Drug Administration (FDA) to support the clinical development of the Moderna product from Phase 2 onwards.
IND Maintenance (WBS 1.5.1.2)
The Moderna-owned IND will be maintained to support the desired clinical development plan.  As needed, meetings will be conducted to receive feedback and gain concurrence on the specifics of the development activities with the FDA.  Moderna will file for Emergency Use Authorization, following the FDA guidance of EUA for COVID-19 vaccines.  A product-specific VRBPAC will be held.
***BLA Submission (WBS 1.5.2.1) - Updated with ModP00008
Moderna will submit a Biologics License Application (BLA) and seek approval for the mRNA-1273 vaccine.
*** The Pharmacovigilance (WBS 1.5.3.1) Updated with Mod P00008
Moderna will conduct standard pharmacovigilance for all active mRNA-1273 clinical studies.
CMC (WBS 1.6)
CTM Manufacture for Phase 2 (WBS 1.6.3.2)
Clinical trial materials for the P201 study will be supplied using the AMP process.  The target yield of each lot is approximately [***] vials; consequently, manufacture of up to five drug product (DP) lots is expected to deliver [***] total vials.  The DP will be a frozen liquid stored at 
6 of 8

[***].  The DP vials will be labeled and packaged by Moderna to support clinical testing in the US.
Process Development for Late Stage Clinical Supply (WBS 1.6.3.3)
mRNA Process Development
Technical Development will confirm and optimize the process parameters for mRNA manufacture.  [***]

[***]
BLA Readiness (WBS 1.6.3.8)
In support of the Biologics License Application (BLA) due to the nature of the proposed timeline, it is likely that Moderna will need to complete some of process validation activities, primarily process characterization, after the completion of process performance qualification and before BLA filing.  Moderna intends to rapidly develop a robust process for clinical manufacturing and PPQ, and then fully describe the acceptable design space for the process prior to BLA filing.  Other activities to support this BLA filing, such as completing raw material qualification activities; if not included in the BLA submission, will require a supplement to the initial BLA.  In the initial BLA filing Moderna will describe its control strategy to cover the gap between initial BLA filing and the BLA supplement.
Process Development for Full Commercial Scale (WBS1.6.4.1)
The following section outlines the process development activities [***].  The goal of this work is to demonstrate the capability to produce mRNA-1273 at a scale that can support clinical demand.

[***]
Controls (Analytical and Validation) (WBS 1.6.5)
Potency Assay Development and Implementation (WBS 1.6.5.1)
[***]
Analytical Method Development and Validation (WBS 1.6.5.2)
Moderna has established a set of analytical methods that are applied to the release and stability testing of intermediates and DP.  These methods are sufficient to assure the identity, strength, quality, purity and potency of the final product, and will have been qualified for use for mRNA-1273 as part of the Phase 2 CTM campaign.  Robustness of product release and stability methods, structural characterization and identification of impurities to further support product specifications, product comparability assessment will continue to support Phase 3 development and licensure.
Characterization Assay Development and Implementation (WBS 1.6.5.3)
A heightened characterization panel of analytical techniques will be used to assess any process modifications and to confirm process reproducibility for both drug substance and drug product during process development and scale up.  As the applicability of the methods used in the heightened panel to elucidate quality attributes of drug substance and drug product is determined, these methods may be elevated to the respective release panel.
7 of 8

Stability Studies (WBS 1.6.5.4)
Throughout the program, many studies will be undertaken [***].  This includes studies using development bench scale material, engineering lot material, and GMP material.  This body of data will be used to apply interim and long-term shelf life to the drug product and process intermediates.
8 of 8

																																										
	AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT
	1. CONTRACT ID CODE	PAGE OF PAGES
	1	3
	2. AMENDMENT/MODIFICATION NO.
P00009
	3. EFFECTIVE DATE
See Block 16C
	4. REQUISITION/PURCHASE REQ. NO.
OS277805
	5. PROJECT NO. (if applicable)

	6. ISSUED BY    CODE	ASPR-BARDA	7. ADMINISTERED BY (if other than Item 6)    CODE
	ASPR-BARDA02
	ASPR-BARDA
200 Independence Ave., S.W.
Room 640-G
Washington DC 20201	US DEPT OF HEALTH & HUMAN SERVICES
ASST SEC OF PREPAREDNESS & RESPONSE
ACQ MANAGEMENT, CONTRACTS, & GRANTS
O’NEILL HOUSE OFFICE BUILDING
Washington DC 20515
	8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code)
	(X)	9A. AMENDMENT OF SOLICITATION NO.
	MODERNATX, INC 1492235
Attn: [***]
MODERNATX, INC.    200 TECHNOLOGY
200 TECHNOLOGY SQ
CAMBRIDGE MA 021393578
	9B. DATED (SEE ITEM 11)

	X	10A. MODIFICATION OF CONTACT/ORDER NO.
75A50120C00034

	CODE
1492235
	FACILITY CODE	10B. DATED (SEE ITEM 13)
04/03/2020

	11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS
	 The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers     is extended.     is not extended.
Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended , by one of the following methods: (a) By completing Items 8 and 15, and returning ___________ copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted ; or (c) By separate letter or electronic communication which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted , such change may be made by letter or electronic communication, provided each letter or electronic communication makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

	12. ACCOUNTING AND APPROPRIATION DATA (if required)
See Schedule    Net Increase:    $144,140,941.00

	13. THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER No. AS DESCRIBED IN ITEM 14.
	CHECK ONE	A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.

	
		B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation data, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).

	X	C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:
FAR 52.243- 2 Alternate 1 (APR 1984) Changes - Cost-Reimbursement

		D. OTHER (Specify type of modification and authority)

	E. IMPORTANT: Contractor     is not     is required to sign this document and return ________________ copies to the issuing office.

	14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)
Tax ID Number: 27-0226313
DUNS Number: 069723520
This contract (75A50120C00034 - Moderna COVID-19 Vaccine)was awarded under
BAA-18-100-SOL-00003 - Development of an mRNA Vaccine for SARS-CoV-2.
The purpose of this modification is to support the additional scope of the Clinical Development Plan (CLIN 0002)for the P204 Pediatrics study (0-<12) WBS 1.4.2.4 in the amount of $144,140,941.
The P204 study is a Phase 2/3 study to evaluate the safety of mRNA-1273 SARS-CoV-2 vaccine in healthy children 6 months to < 12 years of age.
Continued ...
Except as provided herein, all terms and conditions of the document referenced in Item 9 A or 10A, as heretofore changed, remains unchanged and in full force and effect.

	15A. NAME AND TITLE OF SIGNER (Type or print)
 Stephane Bancel, CEO
	16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)
[***]

	15B. CONTRACTOR/OFFEROR
/s/ Stephane Bancel    
(Signature of person authorized to sign)
	15C. DATE SIGNED	16B. UNITED STATES OF AMERICA
    
(Signature of Contracting Officer)
	16C. DATE SIGNED

																											
	CONTINUATION SHEET	REFERENCE NO. OF DOCUMENT BEING CONTINUED
75A50120C00034/P00009
	PAGE OF
	2	3
	NAME OF OFFEROR OR CONTRACTOR
MODERNATX, INC 1492235

	ITEM NO.
(A)
	SUPPLIES/SERVICES
(B)
	QUANTITY
(C)
	UNIT
(D)
	UNIT PRICE
(E)
	AMOUNT
(F)

	2	The obligated amount of CLIN 0002 is increased from $1,197,752,410 by $144,140,941 to $1,341,893,351.
CLIN 0002 is the only CLIN changed by the issuance of this modification. CLIN 0002 remains cost plus fixed fee (CPFF). Fee was not applied to the additional scope.
    Prior Contract Value    Additional Funding    Revised Contract Value
CLIN 0001    $3,212,541    $-    $3,212,541
CLIN 0002    $1,197,752,410    $144,140,941    $1,341,893,351
CLIN 0003    $53,000,000    $-    $53,000,000
Total    $1,253,964,951    $144,140,941    $1,398,105,892
All other contract terms and conditions remain unchanged.
Period of Performance: 04/03/2020 to 08/31/2023
Change Item 2 to read as follows (amount shown is the obligated amount):
Base CLIN 0002 – Development of mRNA vaccine to BLA
Accounting Info:
2020.199cov1.25103 Appr. Yr.: 2020 CAN: 199cov1 Object Class: 25103
Funded: $0.00
Accounting Info:
2020.199co014.25103 Appr. Yr.: 2020 CAN: 199co14 Object Class: 25103
Funded: $0.00
Accounting Info:
2021.199co35.25103 Appr. Yr.: 2021 CAN: 199co035 Object Class: 25103
Funded: $0.00
Accounting Info:
2021.199co35.25103 Appr. Yr.: 2021 CAN: 199co035 Object Class: 25103
Funded: $0.00
Accounting Info:
2021.199co35.25103 Appr. Yr.: 2021 CAN: 199co035 Object Class: 25103
Funded: $144,140,941.00
				144,140,941.00

Statement of Work (SOW) P204 - Modification P00009
P204 Pediatrics (WBS 1.4.2.4)
mRNA-1273-P204 is a Phase 2/3, 2-part, open-label, dose-escalation, age de-escalation, randomized, observer-blind, placebo-controlled, expansion study intended to infer the effectiveness of mRNA-1273 in children aged 6 months to < 12 years. The study population will be divided into 3 age groups (6 to < 12 years, 2 to < 6 years, and 6 months to < 2 years) and up to 3 dose levels (25, 50, and 100 ^g) of mRNA- 1273 will be evaluated.
The study will be conducted in 2 parts. Part 1 of the study will be open label and consist of dose-escalation, age de-escalation in 750 participants (see Table below for the number of participants in each age group) to select the dose for each age group. Part 2 of the study will be placebo-controlled, observer-blind evaluation of the selected dose in 6,000 participants (2,000 participants in each age group). No participants in Part 1 will participate in Part 2 of the study. The total participants in mRNA-1273-P204 study is 6,750 participants.
The study will begin with the oldest age group (6 to < 12 year) and age de-escalate. Each age group will begin with Part 1 and advance to Part 2. The mRNA-1273 investigational vaccine or placebo will be administered as 2 intramuscular (IM) injections, approximately 28 days apart.
The mRNA-1273 dose levels that will be evaluated in each age group in Part 1 and Part 2 of the study are given in the Table below. Only the 6-month to < 2-year age group will receive the 25 ^g dose level.
																		
	Age Group	Part 1	Part 2
	mRNA-1273
25 gg
	mRNA-1273
50 gg	mRNA-1273
100 gg
	Selected Dose Level of
mRNA-1273
From Part 1	Placebo
	6 to < 12 years		Study arm 1
(n=75)	Study arm 2
(n=75)	Study arm 8 (n=1500)	Study arm 9 (n=500)
	2 to < 6 years		Study arm 3
(n=75)	Study arm 4
(n=75)	Study arm 10 (n=1500)	Study arm 11 (n=500)
	6 months to < 2 years	Study arm 5 (n=150)	Study arm 6 (n=150)	Study arm 7 (n=150)	Study arm 12 (n=1500)	Study arm 13 (n=500)

The study will enroll in the US and Canada. The result of mRNA-1273-P204 study is to expand the label indication to 6 months to < 12 years old.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00331-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00331-of-00352.parquet"}]]